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Patients receiving long-term corticosteroid treatment may develop adrenal 
insufficiency (AI) with failure of an adequate cortisol surge during stress, 
potentially resulting in serious illness and death. There is growing concern about 
inhaled corticosteroids, used in the treatment of asthma, causing AI. 
 
The Short Synacthen Test (SST) is a popular diagnostic investigation for AI. It 
requires intravenous cannulation and blood sampling to measure the adequacy 
of the cortisol response. Meta-analytical level evidence supports a lower dose 
SST, using 1 microgram (mcg) rather than the standard 250 mcg. The SST is 
invasive, time-consuming and resource-intensive.  
 
This work aimed to develop a non-invasive alternative to the intravenous 1 mcg 
SST, with Synacthen given nasally and saliva used to measure cortisol response. 
The initial doses of 25 and 100 mcg were derived from extrapolated animal data 
and showed some absorption but were not equivalent to the 1 mcg intravenous 
dose. To aid nasal absorption an increased dose and the addition of a nasal drug 
enhancer, chitosan, were investigated. Bioavailability and cortisol response were 
both heightened but dose escalation improved the absorption of nasal 
Synacthen more than the addition of chitosan. The 500 mcg and the 100 mcg 
with chitosan formulations showed a good and comparable cortisol response to 
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the 1 mcg i.v dose. Nasal administration of the 500 mcg tetracosactide with 
chitosan formulation resulted in the highest bioavailability.  
 
The use of salivary cortisol and cortisone samples to detect the adrenal response 
to Synacthen had a close and reliable relationship with serum samples. Salivary 
cortisone was the more sensitive marker of adrenocortical response at lower 
values. 
 
Nasally administered 500 mcg tetracosactide (Synacthen) with chitosan and 
salivary cortisone sampling at 60, 75 and 90 minutes may provide a useful 
alternative to the low-dose SST and help establish which children with asthma 
are at risk of AI. 
 
 
Word count: 300  
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1 Rationale for the research 
 
The advent of inhaled corticosteroids (ICS) for the treatment of asthma allowed 
their anti-inflammatory actions to be targeted at the lung in the hope that 
reduced doses might minimise the problematic systemic side effects of steroids: 
poor linear growth, reduced bone mineral density and hypothalamic-pituitary-
adrenal axis (HPA) suppression. In the UK, national asthma guidelines published 
within the last two decades (1997), prescribing off-label high doses of ICS, were 
recommended for difficult to control cases (British Thoracic Society 1997). 
However during the last decade there has been increased recognition and 
concern about the possibility of adrenal suppression in children taking high-dose 
ICS (Todd, Acerini et al. 2002). The Commission on Human Medicines and British 
Thoracic Society/Scottish Intercollegiate Guidelines Network have issued 
guidance suggesting children who require prolonged courses of high-dose ICS 
should be provided with a steroid treatment card and consideration given to 
checking their adrenal function (MHRA 2006, BTS/SIGN 2008). What remains 
unclear is what dose of inhaled steroids may potentially cause adrenal 
suppression, whether age, sex, pubertal status and ethnicity play a significant 
role and therefore whom we should be screening and with what screening test. 
There is no national consensus and a questionnaire study of UK tertiary 
paediatric respiratory centres demonstrated considerable variation in practice 
(Brodlie and McKean 2008).  
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Asthma is the most common chronic disease of childhood and worldwide. The 
UK has the highest prevalence of children with asthma (Asthma UK 2013). There 
are an estimated 1.1 million (1 in 11) children with asthma in the UK (Asthma UK 
2013), a large proportion of whom are treated with ICS, therefore the number of 
children who may require evaluation or investigation is significant. Almost 50% 
of respondents to a recently published questionnaire survey of British Paediatric 
Endocrinologists have noted a marked increase in referrals from other clinicians 
for the investigation of potential adrenal suppression in children with asthma 
prescribed ICS (Elder, Sachdev et al. 2012). 
 
Traditionally the investigation of choice to assess adrenal 
insufficiency/suppression in most paediatric units has been the Short Synacthen 
Test (SST). Synacthen is a synthetic analogue of naturally occurring 
adrenocorticotropic hormone (ACTH). Both Synacthen and ACTH act on the 
adrenal gland to stimulate cortisol production. The test requires intravenous (i.v) 
cannulation (or intramuscular (i.m) injection) to administer the Synacthen and 
subsequent blood sampling to quantify the cortisol response. The dose of 
Synacthen used in the SST is a controversial area as some studies have advocated 
that a lower dose (e.g. 1 microgram (mcg)) may be more physiological than the 
licenced 250 mcg.  
 
The SST may be unpleasant for the patient and is labour-intensive, requiring 
skilled personnel and a day-care admission. There is also a paucity of normative 
data for the SST in children with a single paediatric study using 250 mcg of 
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Synacthen, performed over 20 years ago, on relatively small numbers and using 
now out-dated analytical techniques (Lashansky, Saenger et al. 1991). There is no 
normal paediatric reference range data for the low-dose 1 mcg SST (LDSST). It 
remains unclear what the most appropriate cut-offs are for paediatric practice 
(Mushtaq, Shakur et al. 2008) and the questionnaire survey of British Paediatric 
Endocrinologists has shown considerable variation in the definition of adrenal 
insufficiency (Elder, Sachdev et al. 2012).   
 
Cortisol can be readily measured in saliva, providing an alternative to venous 
blood sampling. If the plasma levels required to maximally stimulate the adrenal 
gland can be reached by nasal administration of Synacthen, a non-invasive SST 
would be possible. A non-invasive SST would enable research involving sufficient 
children of different ages, sex and pubertal status to be recruited, allowing 
normative data to be established and subsequently investigate which children 
with asthma are at particular risk of adrenal insufficiency. Ultimately this may 
allow stratification of patients on ICS into risk groups, with their adrenal 
monitoring tailored to their risk, negating unnecessary investigation of low-risk 
patients and allowing close monitoring for high-risk individuals. Additionally if 
this data were available it would enable national consensus guidelines to be 
written improving consistency of practice.  
 
This chapter will outline the physiology of the HPA-axis, its component parts and 
how they interact, adrenal insufficiency and its relationship to corticosteroid use 
(including ICS), how to test the integrity of the HPA-axis, with particular emphasis 
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on the SST, nasal drug administration and the measurement of corticosteroids in 
particular cortisol, in saliva. 
 
 
2 Hypothalamic-Pituitary-Adrenal (HPA) axis 
The HPA-axis is integral both to the maintenance of baseline homeostasis and 
the body’s response to stress. Within the hypothalamus both corticotropin-
releasing hormone (CRH) and arginine vasopressin (AVP) are synthesised and 
then travel in the hypothalamo-pituitary-portal circulation to act on the anterior 
pituitary gland and cause release of adrenocorticotropic hormone (ACTH) which 
in turn acts on the adrenal cortex to stimulate biosynthesis and release of a 
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Figure 1.1: Schematic diagram of the Hypothalamic-Pituitary-Adrenal axis. Green 
arrows depict stimulating inputs and red arrows negative feedback. Kindly illustrated on 




2.1 Corticotropin-releasing hormone (CRH) & arginine vasopressin 
(AVP) 
 
Corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) are 
synthesised in the hypothalamus. Corticotropin-releasing hormone is synthesised 
within the nerve cell bodies of the parvocellular neurosecretory neurons, and 
AVP in the magnocellular division, of the paraventricular nucleus (PVN). They 
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travel via axons to the median eminence where they are released into the 
hypothalamo-pituitary portal system (Majzoub 2006, Miller 2009). Corticotropin-
releasing hormone axons terminate in the anterior pituitary and the majority of 
AVP axons in the posterior pituitary gland (Miller 2009).  
 
The hypothalamus receives input from central (brainstem, amygdala and 
hippocampus) and peripheral (sympathetic and parasympathetic) sources when 
triggers, including stress, food and light are encountered. These stimuli cause the 
synthesis and release of both CRH and AVP (Chrousos, Kino et al. 2009) (figure 
1.1). A number of neurotransmitters have a role in the regulation of CRH: 
acetylcholine, noradrenaline, serotonin and histamine, all stimulate release. 
Gamma-aminobutyric acid (GABA), benzodiazepines and opiates inhibit release 
(Majzoub 2006, Chrousos, Kino et al. 2009). Corticotropin-releasing hormone 
biosynthesis is reduced by gene transcription down-regulation when 
glucocorticoid levels are high (Majzoub 2006). 
 
Corticotropin-releasing hormone is a 41-amino-acid peptide hormone whose 
mechanism of action, when acting via its type-1 receptor (CRH-R1), is stimulation 
of adenylate cyclase to increase cyclic adenosine monophosphate (cAMP) and 
protein kinase A (PKA) and thus promote gene transcription of the precursor 
hormone of adrenocorticotrophic hormone (ACTH). There are two CRH 
receptors, CRH-R1 and CRH-R2. The R2 receptor is further divided into two 
subtypes: CRH-R2α and CRH-R2β. Both CRH receptors are transmembrane G-
protein-coupled cell surface receptors but with different patterns of tissue 
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expression and effecting different functional roles within the stress system. 
Corticotropin-releasing hormone–R1 is expressed in the brain, predominantly in 
the anterior pituitary corticotrophs, similarly CRH-R2α is found in the brain but 
with a wider distribution. Corticotropin-releasing hormone-R2β is expressed in 
the periphery, predominantly the heart and skeletal muscle. Corticotropin-
releasing hormone-R1 mediates the stimulation of the HPA-axis whereas CRH-R2 
may have effect on vasodilatation and the regulation of blood pressure (Majzoub 
2006). 
 
Arginine vasopressin acts on its receptor, V1b (different from AVP receptors in 
other locations e.g. kidney), a seven-transmembrane domain G-protein-coupled 
receptor which stimulates gene expression of the precursor polypeptide, POMC 
(pro-opiomelanocortin), and therefore ACTH biosynthesis by the activation of 
protein kinase C and an increase in intracellular calcium (Melmed 2011). Without 
CRH, AVP has minimal ACTH secretagogue activity, but has a potent synergistic 
role and both CRH and AVP have a positive effect on the production of the other 
releasing hormone (Miller 2009). 
 
2.2 Adrenocorticotrophic Hormone (ACTH) 
Pituitary ACTH is a 39-amino acid peptide hormone and is synthesised in the 
corticotroph cells of the anterior pituitary gland. It is one of the cleavage 
products of the 241-amino acid pro-opiomelanocortin (POMC) (figure 1.2). Pro-
opiomelanocortin is not found exclusively in the brain but the amounts in the 
testes, liver, kidney and placenta are not thought to contribute significantly to 
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circulating ACTH levels (Miller 2009). It acts through its receptor on the adrenal 
cortex to regulate glucocorticoid and adrenal androgen secretion and 
participates in the control of aldosterone production. 
 
Figure 1.2: Schematic diagram of the main cleavage products of POMC. N and C termini 
depicted. Synacthen is also shown but is a synthetic product and not derived from POMC. 
Not all end products are shown. POMC = pro-opiomelanocortin, MSH = melanocyte 
stimulating hormone, β-LPH = β-lipotropic hormone, CLIP = corticotropin-like 
intermediate peptide. Kindly illustrated on the author’s instruction by Steve Jones 
(research Assistant, SCH). 
 
Adrenocorticotrophic hormone is a peptide hormone and is therefore polar, 
water-soluble and unable to cross lipophilic cell membranes. Unlike steroid 
hormones e.g. cortisol, which are synthesised from cholesterol and non-polar, 
and therefore can cross cell membranes to reach intracellular receptors, peptide 
hormones exert their effects by attaching to cell surface receptors. 
Adrenocorticotrophic hormone promotes steroidogenesis by binding to the 
melanocortin-2 receptor (MC2-R), a 7-transmembrane, G-protein-coupled 
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receptor, which causes an increase in cAMP, affecting LDL (low density 
lipoprotein) receptor biosynthesis and LDL cholesterol uptake. Low-density 
lipoprotein cholesterol acts as a substrate for steroid production (figure 1.3). 
Adrenocorticotrophic hormone is also responsible for a small amount of de novo 
steroid synthesis by promoting transcription of HMGCoA reductase, the rate-
limiting stage in cholesterol biosynthesis (Miller 2009). The rapidity of the 
cortisol response to ACTH is in part due to the number of ACTH receptors in the 
adrenal cortex, (each adrenocortical cell contains approximately 3,500 MC2-
receptors), and the role of ACTH (via cAMP) and glucocorticoids in the 
upregulation of MC2-R gene expression. Melanocortin type 2 receptors are also 
found in skin and adipocytes, stimulating lipolysis during times of stress 
(Papadimitriou and Priftis 2009).  
 
Figure 1.3: Schematic flow diagram of adrenal steroid biosynthetic pathways. DHEA = 
dihydroepiandrosterone, HSD = hydroxysteroid dehydrogenase, DOC = 
deoxycorticosterone. Kindly illustrated on the author’s instruction by Steve Jones 
(research Assistant, SCH). 
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There are only small amounts of cortisol stored in the adrenal gland, thus the 
actions of ACTH are to promote steroid synthesis by increasing intracellular 
cholesterol, maintaining levels of free cholesterol and facilitating transport of 
cholesterol onto the inner membrane of the mitochondria, by the CYP11A1 
enzyme, for conversion to steroid hormones (Papadimitriou and Priftis 2009) 
(figure 1.4). These actions all occur within minutes thus soon after an ACTH peak 
a corresponding surge in cortisol is seen. ACTH has a half-life of approximately 
twenty minutes (Keenan, Roelfsema et al. 2004). Adrenocorticotrophic hormone 
has an additional role within the fetal adrenal gland where it stimulates growth 
by its role in the production of local growth factors including insulin-like growth 
factor 2 and epidermal growth factor (Miller 2009) and increases the adrenal 
weight in children and adults by both hyperplasia and hypertrophy 
(Papadimitriou and Priftis 2009). 
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Figure 1.4: Schematic diagram of the intracellular cortisol biosynthesis pathway, with 
molecular structures depicted for cholesterol and cortisol. LDL = low-density lipoprotein, 
MC2-R = melanocortin receptor type 2 (ACTH receptor), StAR = steroidogenic acute 
regulatory protein, DHEA = dihydroepiandrosterone, 3β-HSD = 3β-hydroxysteroid 




Cholesterol is the precursor of all steroid hormones and in steroidogenic tissues 
(i.e. those that contain P450scc1, which catalyses the conversion of cholesterol to 
pregnenalone), it is stored as an ester, in lipid droplets. Adrenocorticotrophic 
hormone acts to further increase the amount of free cholesterol within the cell 
by promoting the activity of cholesterol esterase and inhibiting cholesterol ester 
synthetase. It is free cholesterol that acts as a substrate for mitochondrial 
P450scc and its transporter, StAR (steroidogenic acute regulatory) protein, is 
                                                 
1
 P450scc – “scc” denotes the side chain cleavage of cholesterol 
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2.3 Cortisol (Hydrocortisone) 
The adrenal cortex forms the outer part of the gland and contains three distinct 
zones: the outermost zona glomerulosa, responsible for mineralocorticoid 
production (mainly aldosterone); the zona fasiculata, the main site of 
glucocorticoid synthesis; and the inner most zona reticularis, which produces 
androgens (mainly DHEA, (dehydroepiandrosterone)) (figure 1.1 and 1.4). The 
only steroids produced in appreciable quantities by the adrenal cortex are DHEA, 
cortisol, corticosterone and aldosterone, with cortisol being the dominant 
glucocorticoid (adult secretion is about 10-20 mg/24 hours) (Miller 2009). All 
steroid hormones have the same basic structure as they derive from cholesterol 
(figure 1.3). Cortisol biosynthesis and secretion are predominantly under the 
control of ACTH, however adrenal steroidogenesis is complex with many 
influencing regulatory factors, including other hormones, growth factors, 
cytokines (TNF-α (tissue necrosis factor) and leptin) and neurotransmitters 
(Papadimitriou and Priftis 2009).  
 
Cortisol, like all glucocorticoids, acts through the glucocorticoid receptor (GR), 
which is expressed by every nucleated cell in the body. Unlike the CRH (CRH-R1) 
and ACTH (MC2-R) receptors, which are both transmembrane G-protein-coupled 
receptors exerting their effect via the adenylate cyclase-cAMP-PKA pathway, GRs 
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are cytosolic receptors, which function as ligand-dependent transcription factors, 
whose forms are very different depending on the presence or absence of ligand 
(glucocorticoids). When no ligand is bound the GR is found as a complex of 
proteins in the cytoplasm however on binding ligand it dissociates, moves into 
the nucleus, where there is interaction with transcription factors such nuclear 
factor-κB (NF-κB) or direct binding to the glucocorticoid response elements (GRE) 
of the promoter region of target genes that up- or down-regulates their 
expression (Chrousos, Kino et al. 2009, Papadimitriou and Priftis 2009).  
 
Glucocorticoids themselves are pleiotropic and central to life-maintaining and -
sustaining processes. Their effects are both immunological and metabolic. They 
are potent immunosuppressors that down-regulate pro-inflammatory proteins 
and up-regulate the expression of anti-inflammatory proteins. The metabolic 
effects of cortisol are numerous but all serve to increase available energy 
sources. Glucocorticoids act to maintain or increase blood glucose by stimulating 
gluconeogenesis. They enhance expression of enzymes in the gluconeogenic 
pathway and counteract the effects of insulin, inhibiting glucose uptake in 
adipose tissue and muscle. Additionally glucocorticoids promote lipolysis and 
protein breakdown releasing substrates for gluconeogenesis. 
 
The enzyme 11--HSD (11--hydroxysteroid-dehydrogenase) converts cortisol to 
a more inactive form, cortisone, and thus determines the level of cortisol activity 
in different tissues (vide infra chapter 1, section 2.3.2).  
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The majority of cortisol is bound (total cortisol) and has a half-life of 
approximately 50 minutes. The remaining 5% is free and has a half-life of only 2 
minutes (Keenan, Roelfsema et al. 2004). The vast majority of cortisol is 
metabolised by the liver to more soluble forms before urinary excretion. Only 1% 
is excreted, unchanged, in the urine (Daidoh, Morita et al. 1995, Miller 2009). 
 
2.3.1 Cortisol Binding Globulin (CBG) 
 
Approximately 95% of cortisol in plasma is bound, the majority (90%) to its 
specific carrier protein, corticosteroid-binding globulin (CBG) and the remaining 
5% to generic binding proteins such as albumin and 1-acid glycoprotein 
(Perogamvros, Keevil et al. 2010). The carriers differ in their binding capacity and 
affinity for cortisol: CBG has a very high affinity but low binding capacity, albumin 
has the opposite characteristics and 1-acid glycoprotein falls in-between. 
Traditionally it was believed that only the unbound steroid (free cortisol) is 
biologically active, this is now thought over-simplistic. Whilst serum free cortisol 
defines most of the biological activity the bound fraction is not rendered 
biologically inactive but rather retains some, albeit significantly reduced, potency 
(Miller 2009). It appears that the effect of binding cortisol allows a reasonably 
equal distribution throughout tissues and thus reduces the deleterious effects 
that large peaks and troughs in cortisol might otherwise have (Miller 2009).   
 
Cortisol Binding Globulin is synthesised in the liver and is regulated by 
oestrogens. Certain states increase CBG levels, most commonly hyper-
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oestrogenism e.g. pregnancy and women on the combined oral contraceptive 
pill, or hyperthyroidism and hereditary CBG excess. The reverse is also the case in 
hypo-oestrogenic states e.g. hypothyroidism, hypoproteinaemic conditions and 
familial CBG deficiency. In conditions where CBG levels are high the unbound 
portion of cortisol is thought to remain at similar levels to a normal CBG state 
whilst the total serum cortisol levels are increased. This can lead to confusion 
clinically, where total serum cortisol is routinely measured rather than the 




After secretion from the zona fasiculata within the adrenal cortex, cortisol is 
converted to the much less biologically potent cortisone in the peripheral tissues, 
by the enzyme 11-hydroxysteroid dehydrogenase (11-HSD). Two isoforms of 
11-HSD exist. 11-hydroxysteroid dehydrogenase-1 which catalyses both 
oxidase activity (conversion of cortisol to cortisone) and the reverse reductase 
activity and is found in glucocorticoid-responsive tissues such as the lung and 
liver. 11-hydroxysteroid dehydrogenase-2 only catalyses oxidation and is 
expressed in mineralocorticoid-responsive tissues. The role of 11-HSD-2 is 
protective by reducing the potent effects of cortisol in tissues where 
mineralocorticoid activity needs to predominate, such as the kidney (Miller 
2009). Cortisol Binding Globulin has a lower affinity for cortisone compared with 
cortisol, probably because the protective role of CBG in moderating the 
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potentially adverse effects of large amounts of circulating free serum cortisol is 
not required (Wood 2009).  
 
2.4 Negative feedback system 
Regulation of the HPA-axis is via a classical endocrine feedback system with 
cortisol having a suppressive effect on both the hypothalamus and the anterior 
pituitary and similarly ACTH on CRH and AVP (figure 1.1). The negative feedback 
system serves to protect the body from the harmful catabolic, lipogenic, anti-
reproductive and immunosuppressive effects of excessive exposure to 
glucocorticoids (Chrousos, Kino et al. 2009).  
 
There are two glucocorticoid receptors in the central nervous system: 
glucocorticoid receptor type I (mineralocorticoid receptor, MR) and 
glucocorticoid receptor type II (GR). The mineralocorticoid receptor responds to 
low levels of glucocorticoids and stimulates production whereas GR is activated 
both when cortisol levels are low and when concentrations are high, suppressing 
further production and is therefore the sole effector of negative feedback 
(Chrousos, Kino et al. 2009).  
 
The mechanism of feedback differs depending on whether the stress exposure is 
acute or chronic. Acute negative feedback disables the release of ACTH and CRH 
from their respective secretory granules and occurs within minutes. The chronic 
exposure negative feedback for ACTH and CRH/AVP is mediated by the direct 
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inhibitory action of glucocorticoids on POMC gene transcription in the anterior 
pituitary gland and mRNA synthesis and in the hypothalamus respectively (Miller 
2009, Papadimitriou and Priftis 2009). 
 
2.5 The secretory patterns of components of the HPA-axis 
Each of the main components of the HPA-axis (CRH, AVP, ACTH and cortisol) is 
secreted in a pulsatile, circadian manner. A circadian rhythm not only repeats 
itself every 24-hours (diurnal) but is endogenous (sustained even in the absence 
of the usual external cues (e.g. light, food)) and yet entrainable e.g. adjustment 
following travel to a different time-zone (Papadimitriou and Priftis 2009). 
Circadian rhythm is orchestrated from the suprachiasmatic nucleus in the 
hypothalamus, and causes CRH release (Debono, Ghobadi et al. 2009). This 
diurnal pattern of secretion is influenced by a number of factors including light, 
activity, food and stress and the intrinsic rhythmicity of both the adrenal gland 
and hypothalamus (Miller 2009). Stressors, such as significant illness or major 
surgery, stimulate an increase in the amplitude of AVP and CRH, their 
synchronisation and a reduction in the time lag between their release and their 
effect on ACTH (Chrousos, Kino et al. 2009). The action of CRH on the anterior 
pituitary gland and ACTH on the adrenal cortex is amplified many thousands of 
times such that a few pg/ml of ACTH results in serum cortisol release of mcg/dl 
(Oelkers 1996). 
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The use of more sensitive assays to measure CRH, ACTH and cortisol has shown 
the HPA-axis to be active throughout the 24-hour period, with episodic pulses of 
its components released every 30-120 minutes. Corticotropin-releasing hormone 
and AVP pulse amplitude is characteristically at its height at 04.00, with ACTH 
peaking between 04.00 and 06.00 and the resultant cortisol surge seen at 08.00. 
In both children and adults the frequency and amplitude of the HPA-axis 
components pulses increase during peak secretion seen in the early morning and 
similarly reduce during the quiescent period of approximately 5 hours in the 
night (23.00 to 04.00) (Wallace, Crowne et al. 1991, Miller 2009).  
 
Estimations of the number of peaks in 24 hours vary between 10 and 40 
dependent on the sampling interval used and the sensitivity and specificity of the 
assays employed (Gallagher, Yoshida et al. 1973, Horrocks, Jones et al. 1990, 
Veldhuis, Iranmanesh et al. 1990). Some episodes of ACTH secretion are not 
succeeded by cortisol bursts, generally because the ACTH peaks are so closely 
temporally related as to result in a single, sustained elevation of cortisol 
secretion (Gallagher, Yoshida et al. 1973). Between half and three quarters of the 
total cortisol peaks occur between midnight and 09.00, with increasing higher 
concentrations of ACTH and cortisol per peak and increasing pulse frequency 
seen to crescendo until maximum levels are reached approximately an hour 
before awakening (Krieger, Allen et al. 1971) (Keenan, Roelfsema et al. 2004).  
 
It is unclear whether circadian rhythm is different between the sexes. One study 
reported more pulses (18 versus 10), higher mean peak amplitude, greater mean 
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level and a larger area under the curve over 24 hours in males but no difference 
in cortisol leading the authors to surmise that the adrenal cortex may be more 
sensitive to the effects of ACTH in the female (Horrocks, Jones et al. 1990). Other 
studies have found circadian rhythm not to be affected by age or sex in adults 
(Krieger, Allen et al. 1971, Keenan, Roelfsema et al. 2004). In children there are 
on average 24-34 peaks of both ACTH and cortisol in a 24-hour period and no 
significant differences with respect to gender or pubertal status (Wallace, 
Crowne et al. 1991). Circadian rhythm is absent in newborn babies and starts to 
establish itself during infancy but may not fully mature until three years of age or 
older (Miller 2009).  
 
2.5.1 Cortisol awakening response (CAR) 
 
It was observed over 40 years ago that cortisol reaches its acrophase2 between 
30 and 120 minutes after waking (Krieger, Allen et al. 1971). More recently a 
sharp increase in cortisol, prior to the acrophase and maximal 30 minutes after 
waking, known as Cortisol Awakening Response (CAR), has been demonstrated 
(Pruessner, Wolf et al. 1997).  
 
There is a large inter-individual variation in early morning cortisol values, usually 
sampled between 08.00 and 09.00, which may cause overlap and clinical 
confusion with samples taken from patients with low cortisol conditions. This 
may in part be due to the sharp decline in cortisol levels seen following the 
                                                 
2
 Acrophase – the time at which the peak of a rhythm occurs 
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acrophase and the variability in individuals’ time of waking. The cortisol 
awakening response is more individually specific as it has been reliably shown to 
increase cortisol values by 38-75% within the first 30 minutes following waking in 
both sexes and appears not to be affected by age (Wust, Wolf et al. 2000). The 
response seems unaffected by the quality or length of sleep or activity following 
waking (Pruessner, Wolf et al. 1997) but does seem to be altered by stress and 
time of waking (Fries, Dettenborn et al. 2009, Clow, Hucklebridge et al. 2010). 
Recently CAR has been shown to be present in toddlers and young children 
(Baumler, Kirschbaum et al. 2013). 
 
2.6 The Stress System 
A significant stressor is one that threatens an individual’s life and therefore 
likelihood of successful reproduction and gene propagation. The response to a 
stressor is tripartite: behavioural (e.g. fear, increased vigilance, anorexia), 
autonomic, mediated by the sympathetic nervous system, (e.g. increase in pulse 
and respiratory rate, bronchodilation, increase cerebral and musculoskeletal 
blood flow and maintenance of normoglycaemia) and hormonal, mediated 
through the HPA-axis, which releases the energy reserves necessary to fuel the 
stress response (Majzoub 2006).  
 
The HPA-axis has a number of different neurological inputs, both central 
(hypothalamus and brainstem) and peripheral, which enable it, in conjunction 
with the sympathetic nervous system, to play the central role in controlling the 
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biological responses to stress. Following an acute stressor these higher centre 
inputs cause greater synchronicity and amplitude of CRH and AVP and thus 
increase their release from the PVN in the hypothalamus. In addition 
secretagogues of CRH, AVP or ACTH such as magnicellular AVP and angiotensin II 
are released (Chrousos 1995). Furthermore in stressors such as febrile illness, 
inflammation and cytokines stimulate cortisol production by increasing CRH (IL-1 
(interleukin) and IL-6 mediated) and ACTH (IL-2 and tumour necrosis factor 
mediated) (Chrousos 1995).  
 
In addition to catecholamines, cortisol is the final common pathway of these 
complex interactions and triggers the “flight, fight and fright” response. This 
enables rapid release and transport of energy sources to vital organs: heart, 
brain and muscles and, by an increase in blood pressure, cardiac output and 
respiratory rate, optimum delivery of oxygen and nutrients is achieved. The end 
result is a body primed for maximum activity with increased concentration and 
cognition, faster motor reflexes, a higher pain threshold and less appetite for 
food and reproduction. The stress system is not quiescent during rest and 
remains responsive to circadian rhythms and other neurosensory inputs. Cortisol 
is both responsible for priming these mechanisms and tempering them to 
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3 Adrenal insufficiency (AI) 
 
3.1 Definition and causes of AI 
Adrenocortical failure may be primary or secondary and can present acutely or 
chronically. It results in hypocortisolism, which may be non-specifically or overtly 
symptomatic or sub-clinical. Primary adrenal failure occurs when there is 
destruction of the adrenal gland itself e.g. by autoimmune antibodies, 
haemorrhage or tumour or a disturbance in its ability to manufacture steroids 
e.g. congenital adrenal hyperplasia (CAH). Secondary failure describes a 
disruption of the hypothalamic or pituitary component of the HPA-axis, and 
tertiary hypothalamic failure leading to reduction in steroidogenesis. Previously 
in all parts of the world tuberculosis was the commonest cause of AI and it 
remains an important cause in developing world, however in the developed 
world autoimmune adrenalitis (Addison’s Disease, first described by Thomas 
Addison in 1855) accounts for 80-90% of the adult cases (Arlt and Allolio 2003). 
Many of the causes of AI have their onset in adulthood, making the genetic 
causes, CAH, and withdrawal from glucocorticoids relatively more common in 
childhood. Reported experience over 20 years in Montreal, Canada, showed that 
72% of the 103 children with primary AI had CAH, 13% autoimmune AI and 
remaining 15% were either unexplained or had one of the rarer causes such as 
Triple A, Zellweger syndrome or adrenoleucodystrophy (Perry, Kecha et al. 2005). 
Some examples of causes of primary and secondary AI are given in table 1.1. 
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Table 1.1: Causes of Adrenal Insufficiency (Oelkers 1996, Arlt and Allolio 2003, Miller 
2009).  
Primary AI Secondary AI 
Autoimmune adrenalitis 

















Congenital adrenal hyperplasia,  
Smith-Lemli-Opitz syndrome 
Congenital lipoid hypoplasia 







Post CNS irradiation 
Idiopathic intracranial hypertension 










3.2 Incidence and prevalence of AI 
Incidence and prevalence figures may be difficult to interpret due to the covert 
and insidious nature of the clinical presentation of AI. Prevalence figures vary but 
it is thought 150-280 per million are affected by secondary AI and 93-140 per 
million people by primary AI, with an incidence in white populations of 4.7-6.2 
per million (Arlt and Allolio 2003). Although not stated it is likely these figures 
based on adult estimates. Both primary and secondary AI occur more commonly 
in women, with primary diagnoses peaking in the fourth decade and secondary in 
the sixth (Arlt and Allolio 2003). Iatrogenic AI from corticosteroid use is the 
commonest cause of secondary AI, although due to its transient aetiology its 
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prevalence may be lower than other causes. Incidence and prevalence figures 
are lacking in the paediatric population but CAH, as the commonest form of 
primary AI, has an incidence of 1 in 10, 000 to 18,000 (White and Speiser 2000). 
A British Paediatric Surveillance Unit (BPSU) survey has been recently conducted 
to ascertain the prevalence of AI in children and its report is awaited. 
 
 
3.3 Symptoms and presentation of AI 
Diagnosing AI is challenging for clinicians due to the numerous and non-specific 
nature of the symptoms, causing a delay in diagnosis and most patients seeking 
multiple opinions with half only being diagnosed following an episode of adrenal 
crisis (Arlt 2008). The symptoms are predominantly due to the glucocorticoid 
deficiency, but others may be because of mineralocorticoid deficiency 
(symptoms attributable to electrolyte disturbance) or adrenal androgen 
deficiency (lack of adrenarche or pubarche in children or loss of pubic and 
axillary hair in women), or derangement in POMC cleavage products (skin colour 
changes secondary to excess melanocortin) (Arlt and Allolio 2003).   
 
Chronic symptoms of AI include fatigue, weakness, arthralgia, anorexia, 
abdominal pain and the patient may feel nauseous or vomit. Adults and older 
children may experience weight loss with younger children failing to thrive. If the 
pathogenesis includes mineralocorticoid deficiency (e.g. the genetic mutation in 
CAH is expressed in the cells of the zona glomerulosa) those affected may 
experience postural hypotension and symptoms associated with hyponatraemia 
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and hyperkalaemia (Arlt 2008). More insidious signs include pale skin in 
secondary AI and hyperpigmentation in primary AI due the lack of negative 
feedback driving an increase in POMC and its cleavage products (figure 1.2) 
which stimulate the melanocortin receptors in the skin (Arlt and Allolio 2003).  
 
Acute adrenal crisis carries an appreciable mortality and may occur when 
undiagnosed, or undertreated chronic insufficiency is further exacerbated by 
stress such as trauma, surgery or infection. Adrenal crisis usually presents with 
the patient hypotensive, in hypovolaemic shock, with severe abdominal pain and 
vomiting. Children, especially young ones, are more likely to present with 
hypoglycaemia and consequent seizures or coma (Shulman, Palmert et al. 2007).  
 
3.4 AI secondary to corticosteroid use 
In 1952, a decade after the medical landmark discovery of cortisone as a 
treatment for inflammatory conditions, the first case of adrenal crisis and death 
in a patient on glucocorticoid therapy undergoing surgery was described (Fraser, 
Preuss et al. 1952) and thereafter a spate of such cases were published (Lewis, 
Robinson et al. 1953, Salassa, Bennett et al. 1953) and recommendations as to 
how these patients should be investigated and managed followed (Bayliss 1958, 
Sampson, Brooke et al. 1962). It is now widely acknowledged that patients on 
long-term corticosteroids require increased steroid cover at times of stress, such 
as major surgery and significant febrile illness, and a gradual tapering of the dose 
if the medication is to be stopped. Although permanent adrenal failure 
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secondary to prolonged corticosteroid usage may occur the effects on the HPA-
axis can usually be reversed and normal HPA-axis activity restored over many 
months or possibly years with carefully managed tapering of long-term 
glucocorticoid therapy (Stewart 2003).  
 
3.4.1 Pathophysiology of AI secondary to corticosteroid usage 
 
Exogenous glucocorticoid use may cause hypothalamic and pituitary suppression 
only, with normally functioning adrenal glands; complete HPA-axis suppression 
with adrenal atrophy; or not cause HPA-axis suppression at all. Adrenal 
suppression secondary to exogenous corticosteroid use causes reduction in CRH 
and ACTH with eventual atrophy of the adrenal cortex (figure 1.5). Whilst 
exogenous steroids are being administered on a regular basis this atrophy is of 
no clinical consequence however if there is an abrupt cessation to the exogenous 
steroid supply or a requirement for a significant increase in glucocorticoids in 
times of stress, then the adrenal insufficiency may become clinically manifest, as 
adrenal crisis.  
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Figure 1.5: Schematic diagram of the HPA-axis with the consequences of exogenous 
steroids on the adrenal gland and the sites of action of two tests of adrenal function 
shown (blue arrows). Kindly illustrated on the author’s instruction by Steve Jones, 
research assistant SCH. 
 
It is thought that corticosteroids cause secondary AI by a number of mechanisms. 
The lack of cortisol production in the adrenal gland leads to adrenal atrophy but 
also to a reduction in the expression of adrenal ACTH receptors. 
Adrenocorticotropic hormone has been shown to up-regulate its own receptor 
and thus down-regulation is thought to occur in times of ACTH deficiency 
(Lebrethon, Naville et al. 1994). Pituitary corticotroph cells atrophy when 
chronically exposed to exogenous glucocorticoids and POMC gene transcription 
is suppressed, thus ACTH levels reduce and the ability to synthesise ACTH 
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diminishes. There is also an effect on CRH with reduced synthesis and storage 
and fewer receptors in the pituitary gland (Miller 2009).  
 
3.4.2 Predicting AI in patients on corticosteroids 
 
The risk of HPA-axis suppression is in part dose-dependent but a number of 
different factors influence the risk for an individual. Different exogenous steroid 
preparations alter the risk of AI with systemic corticosteroids and those with the 
highest potency posing the greatest risk. Of the commonly prescribed 
glucocorticoids hydrocortisone has the least suppressive effect, prednisolone is 
moderately suppressive and dexamethasone has the most suppressive effect 
(table 1.2). Other contributors to the overall risk include how many times a day 
they are taken and evening prescriptions of long acting preparations, as this 
further suppresses the endogenous early morning ACTH surge (Krasner 1999). 
Parenteral and enteral preparations have been described as causing AI with 
routes of delivery as innocuous sounding as dermal, inhaled and intranasal all 
having been reported. Duration of corticosteroid therapy and cumulative dose 
do not appear to be reliable predictors of AI as there appears to be considerable 
individual variation with some individuals developing AI on relatively short 
courses and small doses others seeming more resistant (Mackenzie and Wales 
1991). This may be due to individual protein binding and pharmacokinetics of 
glucocorticoid clearance (Krasner 1999). 
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Table 1.2: Corticosteroid equivalent potencies quoted in BNFc 2013 (Paediatric 








Prednisolone 4 5 mg 18-36 
Dexamethasone or 
betamethasone 
25-50 750 mcg 36-54 
Hydrocortisone 1 20 mg 8-12 
Methylprednisolone or 
triamcinolone 
5 4 mg 18-36 
 
 
A 4-week course of corticosteroids (0.2mg/kg oral dexamethasone) in children 
with leukaemia caused HPA-axis suppression in all at the end of the course and 
for 2 months after discontinuation in 3 out of 10 patients (Felner, Thompson et 
al. 2000). Generally it is believed that in most adult individuals doses of more 
than 7.5 mg prednisolone equivalent or more, for greater than four weeks is 
likely to cause AI (Arlt and Allolio 2003). 
 
3.4.3 Inhaled corticosteroids (ICS) and adrenal insufficiency 
 
In the UK asthma is the most common chronic disease of childhood and has a 
prevalence of 17-23% (NICE 2007). Since their introduction in 1972 inhaled 
corticosteroids (ICS) have become the mainstay of preventative treatment and 
70% of asthmatic children are prescribed them (Office for National Statisitcs 
1998). They are first line treatment in anything but the most mild asthma 
(BTS/SIGN 2008). ICS have not only improved asthma symptoms with fewer side 
effects compared with oral preparations, but have also significantly reduced 
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hospital admissions and deaths (Blais, Ernst et al. 1998, Lanes, Garcia Rodriguez 
et al. 2002). However, at higher doses, side effects may become apparent, 
especially in atopic children who may be receiving intranasal steroids for rhinitis, 
topical steroids for eczema and courses of oral steroids during acute 
exacerbations of their asthma.  
 
Possible HPA-axis suppression with ICS has concerned doctors for 40 years. Early 
studies in children showed low doses, beclomethasone (BDP) up to 400 mcg daily 
or equivalent, to be safe but impairment of normal HPA-axis response to 
provocation testing at higher doses (Vaz, Senior et al. 1982, Law, Marchant et al. 
1986). The current regimen of maintenance with ICS and short courses of oral 
steroids during acute exacerbations was first recommended in the 1970s 
following the deaths of three children from adrenal failure who had had oral 
steroids stopped (Mellis and Phelan 1977). Although there is intra-individual 
variation in sensitivity to steroids it is the use of high-dose ICS which naturally 
causes the most concern and guidelines recommend prescribing the lowest 
effective dose of ICS (BTS/SIGN 2008). A survey of British GPs showed 4.5% of all 
children are prescribed ICS. Of those on ICS, 10% of 5-11 year olds and 5.6% of 
the under 5s were prescribed doses above the recommended maximum for age 
(table 1.3) and over double the recommended maximum dose in 4.9% and 3.9% 
respectively (Thomas, Turner et al. 2006).  
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Table 1.3: Maximum licensed dose of ICS in children quoted in BNFc 2013 (Paediatric 
Formulary Committee 2013). 
 Maximum dose Age 
Beclomethasone dipropionate/ 
Budesonide 
400 mcg bd 
1 mg bd 
5-12 years 
12-18 years 
Fluticasone propionate 200 mcg bd 
500 mcg bd 
5-12 years 
12-18 years 
Mometasone furoate 400 mcg bd 12-18 years 
 
Cases of AI or crisis on high dose ICS began to be reported in the 1990s but the 
issue was further compounded by the introduction in 1993 of fluticasone 
proprionate (FP) (Wong and Black 1992, Zwaan, Odink et al. 1992). Fluticasone is 
an ICS with approximately twice the potency of either budesonide or 
beclomethasone but with a high therapeutic index (a large difference between 
the therapeutic and toxic dose of a drug). The high therapeutic index encouraged 
clinicians to prescribe off-licence doses in difficult to control asthma causing a 
number of cases of AI and a death, attributable to fluticasone (Todd, Dunlop et 
al. 1996, Patel, Wales et al. 2001, Drake, Howells et al. 2002, Macdessi, Van 
Asperen et al. 2003). These cases prompted the authors of one series to conduct 
a national questionnaire survey of all paediatricians and adult endocrinologists in 
the UK requesting cases of adrenal crisis in asthmatic patients on ICS. They 
identified 33 patients, 28 of whom were children, one of whom had died. The 
majority of those identified were on doses above licence, yet recommended in 
national guidelines, and 94% were on fluticasone (Todd, Acerini et al. 2002). This 
prompted several bodies to revise their ICS dosage guidance and recommend 
management by a specialist, specific written advice to be given to the 
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patient/family, steroid treatment cards be issued and consideration given to 
periodic testing of the adrenal gland (MHRA 2006, BTS/SIGN 2008, MHRA/CSM 
2008).  
 
Following this heightened awareness there have been numerous attempts to 
delineate the prevalence of AI in asthmatic children on high dose ICS. This has 
been beleaguered by a lack of consensus about what test to use and difficulty in 
knowing what diagnostic threshold to adopt. A summary of some of the studies 
is shown in table 1.4.  
 
Table 1.4: Summary of prevalence studies of adrenal suppression in children with 
asthma treated with ICS  (FP = fluticasone propionate, BDP = beclomethasone 
dipropionate, LDSST = low-dose SST, SSST = standard SST (250 mcg)) 
 
Study Method Outcome 
Blair et al 
(Blair, Lancaster et 
al. 2013). 
Prospective study of 246 children on 
any ICS for >3 months who all 
underwent a LDSST. 
Peak cortisol was <500 nmol/L in 
37.5% and <350 nmol/L in 4.5%. 
Paton et al 
(Paton, Jardine et 
al. 2006) 
Children recorded as receiving more 
than 500 mcg FP daily underwent 
LDSST. 
192 children met the criteria and had 
LDSST. 
2.8% had flat adrenal responses 
(peak cortisol <500 nmol/L, 
increment of <200nmol/L and 
basal am cortisol <200 nmol/L). 
39.6% had impaired responses 
(peak cortisol <500 nmol/L). 
Sim et al 
(Sim, Griffiths et 
al. 2003) 
Cross-sectional prevalence study. 
Children with asthma prescribed more 
than 1000 mcg FP daily for more than 
six months. 
50 children met criteria and had SSST 
performed if morning serum cortisol < 
400 nmol/L. 
72% had low (<400nmol/l) 
morning serum cortisol levels. 
17% were found to have AI (12% 
of the initial cohort) on SSST 
(peak cortisol <550 nmol/L, <2x 
increase from baseline). 
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Eid et al 
(Eid, Morton et al. 
2002) 
Observational study. 
62 children with asthma on FP followed 
for 2 years. 
Morning cortisol performed after 
approximately 8 months. 
36% of children had abnormal 
early morning cortisol (<150 
nmol/L), 17% on low dose FP and 
43% taking more than 880 mcg 
daily. 
Fitzgerald et al 
(Fitzgerald, Van 
Asperen et al. 
1998) 
Randomised, double-blind cross-over 
study comparing budesonide (1500 
mcg) and fluticasone (750 mcg) daily 
for 12 weeks. 
24 hour urinary free cortisol at 8+12 
weeks and LDSST at 12 weeks. 
68% had abnormal results 
(baseline cortisol <200 nmol/L 
and peak <500 nmol/L) on LDSST, 
but no difference between the 
groups. 
Ninan et al 
(Ninan, Reid et al. 
1993) 
Children prescribed ICS doses of more 
than 400g underwent an am cortisol 
and SSST. 
49 children on budesonide. 
28 children on BDP. 
23 controls (non-asthmatic children 
under investigation for short stature). 
Mean basal (normal > 200 
nmol/L) and stimulated cortisols 
(normal >430 nmol/L) lower in 
children on ICS compared with 
controls. 
33% budesonide and 25% BDP 
groups had suboptimal basal 
cortisol response. 
8% and 10% respectively had 
abnormal results on SSST. 
 
A systematic review and meta-analysis of placebo-controlled randomised dose-
response studies of more than 4 weeks duration in adults examined the data in 
732 patients and reported AI in 3.9%, with the odds of abnormality increasing by 
1.38 for a 500 mcg/day increase in fluticasone (Masoli, Weatherall et al. 2006). 
No such study exists in children although some have attempted to identify a dose 
at which children are at significant increased risk and a cohort study by Vaz et al 
demonstrated 100% absolute risk of HPA-axis suppression in children with 
asthma taking doses of beclomethasone between 250-600 mcg/m2/day for 6-42 
months (Vaz, Senior et al. 1982).  
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A large prospective study of adrenocortical function in children on ICS recently 
published reported a dose related suppressive effect, which was more evident in 
males than females. Basal cortisol levels were seen to increase with age (10 
nmol/L with each year of life) and peak cortisol, quantified following stimulation 
with 1 mcg Synacthen, was lower in boys and as age increased (mean decrease of 
6 nmol/L per year of life) (Blair, Lancaster et al. 2013), similar to that found in a 
study following administration of 250 mcg Synacthen (Lashansky, Saenger et al. 
1991). 
 
Adrenal insufficiency with ICS other than fluticasone occurs (Ozbek, Turktas et al. 
2006, Raux Demay MC 2006) but fluticasone appears to have higher dose-related 
AI than other ICS. This is not entirely due to its greater potency as most studies 
compare therapeutically equivalent doses and is therefore likely to be due to 
pharmacokinetic properties of fluticasone (Lipworth 1999). Additionally whilst AI 
with ICS is thought to be a dose related class effect there are idiosyncrasies 
(delivery device, formulation, adherence, aspects of the patients’ disease and 
genetic factors), causing individuals to be affected to different extents making 
patient specific prediction of systemic side effects very difficult (Anthracopoulos, 
Priftis et al. 2008). In children some have found impaired cortisol responses to be 
more pronounced in children on higher doses of ICS (Nickson, Wilson et al. 2008, 
Blair, Lancaster et al. 2013), others have reported no correlation between daily 
dose of ICS and results of a low-dose Short Synacthen Test (LDSST) (Broide, 
Soferman et al. 1995). Adrenal insufficiency occurs with all the ICS routinely used 
in the treatment of childhood asthma but prevalence rates and severity vary 
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depending on the drug, dose, adrenal function test, diagnostic cut-offs employed 
and the study methodology.  
 
 
4 Tests of adrenocortical function 
 
There are a number of different diagnostic tests of adrenocortical function, each 
attempting to emulate “natural” stress enabling physicians to assess whether or 
not an individual is able to withstand a stressful event or whether corticosteroid 
replacement is required. There is a fine balance between adequate test 
sensitivity and specificity, with none of the available tests classifying all patients 
correctly. The lack of a safe, easy and reliable test of adrenocortical function 
contributes to a number of controversies: who to test, with which test, at what 
dose, what times to sample and what diagnostic cut offs to use.  
 
4.1 A summary of the different tests 
Investigating the HPA-axis usually requires dynamic testing because of the 
pulsatile nature of CRH, ACTH and cortisol secretion and thus a high false positive 
rate when using unprovoked tests. Some physicians measure random cortisol but 
the peaks and troughs of normal circadian rhythm renders low values difficult to 
interpret. A very low early morning cortisol (<100 nmol/L) or one that is 
reassuringly high (>500 nmol/L) may be of help but there is diagnostic 
uncertainty about values in between. An early morning cortisol was performed in 
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a study of 32 children with symptoms of AI. In order to achieve 100% sensitivity 
in children with a normal response to both a low-dose (LDSST) and standard dose 
SST (SSST) a cut-off of 500 nmol/L was required, but at the expense of specificity 
which was only 33%, indicating that an early morning cortisol is helpful if high 
but low values need to be further investigated with a dynamic test (Agwu, 
Spoudeas et al. 1999). More recently the relationship between time of waking 
and the upsurge in cortisol has been investigated and cortisol awakening 
response (CAR) has been suggested as a replacement for 8am cortisol. This may 
be especially pertinent in children who may have very varied and early times of 
awakening (Baumler, Kirschbaum et al. 2013).  
 
 Similarly early morning paired ACTH and cortisol can be difficult to interpret. It is 
popular in adult practice, where primary adrenal disease is more common, and 
the combination of high ACTH with low cortisol may be diagnostic and has even 
been shown to be more sensitive than SST (Blevins, Shankroff et al. 1994). This is 
less commonly the case in paediatric practice, where secondary causes of AI 
predominate.  
 
Serum cortisol profiling (measuring cortisol at 15-30 minute intervals) is time and 
resource expensive and often impractical in children, as are some of the less 
invasive alternatives which may be difficult to perform in children and therefore 
unreliable. Although 24-hour urinary free cortisol has been shown to correlate 
with the results of the LDSST, it may not discriminate normal from abnormal 
clearly enough in conditions of hypocortisolaemia (Broide, Soferman et al. 1995) 
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and is dependent on accurate urine collection, thus generally felt to be 
impractical in children.  
 
The dynamic tests include the CRH test, overnight metyrapone test (OMT), 
Insulin Tolerance Test (ITT) and the Short Synacthen Test (SST). The CRH test is 
rarely performed in children, as it produces unpleasant side effects; is thought by 
some to produce sub-maximal cortisol responses and is not well standardised 
between centres (Orth, Jackson et al. 1983, Oelkers 1996). However it has been 
shown to correlate closely with the ITT (Schlaghecke, Kornely et al. 1992) and has 
a role in investigation of some pathologies. Metyrapone inhibits the conversion 
of 11-deoxycortisol to cortisol by blocking adrenal 11β-hydroxylase and normal 
HPA-axis feedback mechanisms result in a high 11-deoxycortisol the morning 
after administration. Although thought of as one of the gold standard tests by 
some metyrapone can precipitate adrenal crisis, is unpleasant to take and can be 
difficult to source, as can 11-deoxycortisol assays and is therefore rarely used in 
paediatric practice.  
 
The gold standard for investigation of the HPA response to stress is the ITT, 
which evaluates the cortisol response to hypoglycaemia, causing central 
activation and therefore examining the entire axis (figure 1.2). It gained credence 
when it was seen to correlate closely with the adrenal response seen in times of 
surgical stress (Plumpton and Besser 1969). The standard cut-off is a cortisol 
peak of 500 nmol/L (Grinspoon and Biller 1994), although some advocate 550 
nmol/L (Arlt 2008) as cases of clinical AI have been missed. Although the it is still 
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performed in adults and a few paediatric centres, most have rejected it as 
unpleasant and dangerous as it has been responsible for a number of deaths 
(Shah, Stanhope et al. 1992). No test of adrenal function is perfect and, despite 
being considered a standard, healthy controls have been known to fail both the 
OMT and ITT and their adrenal crisis predictive accuracy has not been 
established (Kazlauskaite, Evans et al. 2008). The average inter-subject variability 
in peak cortisol for the ITT has been reported as 8-12%, although others have 
found it to be as much as 42% (Vestergaard, Hoeck et al. 1997, Pfeifer, Kanc et al. 
2001). 
 
The standard and most widely used investigation of adrenocortical function in 
paediatric practice is the SST. This involves i.v (or i.m) administration of the ACTH 
analogue, Synacthen, and the subsequent measurement of plasma cortisol 
levels, usually at 0, 30 and 60 minutes. Most physicians look both for an 
incremental rise from baseline (usually more than 200mol/l) and a peak cortisol 
of more than 500nmol/L or 550nmol/L or 580nmol/L, although some advocate 
higher levels (Grinspoon and Biller 1994, Bangar and Clayton 1998, Abdu, Elhadd 
et al. 1999, Arlt 2008). In children two mainstream paediatric endocrinology 
textbooks advocate sampling at 0 and 60 minutes, following 250 mcg i.v 
Synacthen, and consider a cortisol response of over 830 nmol/l in the pre-
pubertal and 690 nmol/l in pubertal children as normal (Miller, Achermann et al. 
2008, Miller 2009). More recently, as cortisol assay specificity has improved, 
there has been a call to reduce the diagnostic cut-off and determine local 
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reference ranges to avoid excess false positive results (Blair, Lancaster et al. 
2013, Chitale, Musonda et al. 2013, Elder, Somerset et al. 2013).  
 
Although, as a foreign protein, Synacthen is potentially anaphylactogenic it rarely 
causes any adverse reactions (vide infra, chapter 1, section 4.2.2) and is therefore 
widely regarded as a safe and reliable way to assess adrenal function.  
 
In primary AI the adrenal cortex is already maximally stimulated and as such the 
administration of an exogenous ACTH analogue does not usually provoke a 
further rise in glucocorticoid production. In secondary AI the adrenal gland is 
usually atrophic and unable to synthesis and release adequate cortisol (figure 
1.5). Appropriate application of these tests is important; an SST performed too 
early for the assessment of acute onset secondary AI, e.g. in the first post-
operative week after pituitary damage or resection, will not have allowed 
sufficient time for diminished endogenous ACTH to have reduced the 
responsiveness of the zona fasiculata (Thaler and Blevins 1998, Nieman 2003). It 
is thought that 8-12 days of reduced ACTH action on the adrenal gland is enough 
to detect changes in responsiveness of the cortex (Hjortrup, Kehlet et al. 1983, 
Kehlet, Lindholm et al. 1984). 
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4.2 Tetracosactide (Tetracosactrin, Synacthen Cosyntropin) 
4.2.1 Chemistry, pharmacology and mechanism of action of Synacthen 
 
Synacthen is a linear 24-amino acid peptide with a free amino group at the N-
terminus and a free carboxyl group at the C-terminus. The counter ion3 acetate is 
bound in ionic form to the basic groups of the peptide molecule. All amino acid 




L-arginyl-L-arginyl-L-prolyl-L-valyl-L-lysyl-L-valyl-L-tyrosyl-L-proline, acetate salt 
 
Abbreviated chemical name: 
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-
Val-Lys-Val-Tyr-Pro-OH, acetate salt 
 
The 1-24 amino acid component of endogenous ACTH(1-39) confers the same 
biological activity on Synacthen but does not contain the remaining 
immunologically active 15 amino acids of endogenous human ACTH. Its biological 
activity is associated with the N-terminal 1-18 amino acid sequence and the 
immunogenic portion of the protein resides in the N25-33 positions, the 
sequences involved in species differences. Anaphylactic reactions to porcine, 
bovine, ovine and human ACTH were fairly common until the advent of synthetic 
ACTH and the removal of the immunogenic portion of the molecule in the early 
                                                 
3
 Counter ion is the accompanying ion e.g. acetate in order to allow maintenance of electric 
neutrality. 
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1960s. The C-terminal amino acid sequence 19-39 additionally affects the half-
life, with native ACTH having the longest, accounting for the different half-lives 
for the ACTH analogues (Alia, Villabona et al. 2006). Its synthetic manufacture 
also allowed precise amounts to be administered by weight and studies 
investigating the required amount for minimal biological activity and maximal 
secretion of cortisol from the adrenal gland following administration of ACTH.  
 
Two forms of Synacthen are marketed, an i.v form for diagnostic purposes and a 
depot i.m form for therapeutic purposes and occasional diagnostic use. Following 
i.v administration Synacthen exhibits triphasic pharmacokinetics. The first phase 
is rapid elimination from plasma and distribution to the adrenal glands and 
kidneys (half-life approximately 7 minutes). It then undergoes a process of 
metabolism into free amino acids by endopeptidases and aminopeptidases (half-
life approximately 37 minutes) and is finally excreted in the urine (half life 
approximately 3 hours). Almost all (95-100%) of the i.v dose is excreted within 24 
hours. Synacthen has a volume of distribution of 0.4 L/kg and a log p value4 of -
7.9 (Alliance Pharmaceuticals 2011).  
 
As would be expected Synacthen’s mechanism of action mimics that of ACTH(1-
39), binding to its receptor on the plasma membrane of adrenocortical cells and 
activating adenylate cyclase to increase cAMP levels thus promoting the 
synthesis of corticosteroids from cholesterol (Alliance Pharmaceuticals 2011). 
 
                                                 
4
  Log p value describes the partition coefficient, a measure of lipophilia 
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4.2.2 Synacthen safety 
Synacthen can rarely cause serious allergic reactions including anaphylaxis. 
Contraindications include allergic conditions (including asthma), psychosis, 
peptic ulcer, Cushing’s syndrome and primary AI. Safety information was 
sourced from the company with the marketing authorisation for Synacthen in 
the UK, Alliance Pharmaceuticals Ltd (Wiltshire, UK), and shows serious 
reactions to be extremely rare.  
 
In the UK from 1965 (release of Synacthen onto the market) to 2008 (43 years) 
there have been a total of 440 reactions to Synacthen reported to the 
Committee on Safety of Medicines via the yellow card system: 233 Adverse Drug 
Reactions (ADRs) and 15 fatalities, 7 from anaphylaxis or anaphylactoid 
reactions (Gunnenberg, Astley et al. 1999, Drug Analysis Print 2008).  
 
The last Periodic Safety Update Report (PSUR), a worldwide perspective on the 
safety of a medicinal product, for Synacthen covers the 35 years (from 
Synacthen’s launch) to 31st May 2000 during which it was estimated that 
approximately 25 thousand million ampoules of Synacthen/Synacthen Depot 
had been distributed worldwide. There were 418 reported cases worldwide of 
anaphylaxis or anaphylactoid reactions to Synacthen, of which 208 were in 
asthmatic patients (Novartis 2000). 
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4.3 Comparison of ITT and SST 
Each test of the HPA-axis has those who would advocate its use and those who 
would not. The ITT has the advantage of mimicking the stress response and 
therefore with a normal result one can perhaps say with more confidence that a 
patient will respond appropriately when physiologically stressed. The SST gives 
information about the incremental rise and peak cortisol achieved when 
synthetic ACTH acts on the adrenal gland and is as such only a surrogate marker 
of how an individual may respond to stress.  
 
A number of studies have shown the SST to correlate closely with the ITT 
(Stewart, Seckl et al. 1988, Abdu, Elhadd et al. 1999), notably in a study of 200 
consecutive adult patients with proven or suspected HPA-axis disorders. The 30-
minute cortisol level from the SST and peak cortisol in the ITT were significantly 
correlated (r=0.83) (Lindholm and Kehlet 1987). Others have found a close 
correlation in both healthy subjects and those with established HPA-axis disease, 
although some discrepancies occur dependent on the serum cortisol cut-offs 
employed (Stewart, Seckl et al. 1988, Hurel, Thompson et al. 1996). Abdu et al 
compared the standard (250 mcg) SST (SSST), LDSST and ITT in 64 adult patients 
with suspected or confirmed pituitary disease. They found the cortisol peaks in 
all tests to be highly correlated (r=0.83 to 0.89) and calculated the sensitivities 
and specificities of the tests with cortisol cut offs of 500 and 600 nmol/L (vide 
infra, chapter 1, section 4.4, table 1.5) (Abdu, Elhadd et al. 1999). There are a 
number of reported cases of individuals passing one test while failing the other 
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(Borst, Michenfelder et al. 1982, Cunningham, Moore et al. 1983, Stewart, Seckl 
et al. 1988, Ambrosi, Barbetta et al. 1998, Abdu, Elhadd et al. 1999).  
 
Surveys of the SST in 1988 and 1994 reported 25% and 69% of adult 
endocrinologists using it respectively (Stewart, Seckl et al. 1988, Davies and 
Howlett 1996). It is more popular amongst UK paediatricians, with 100% usage, 
as it was felt by most, whilst acknowledging its flaws, to be the most appropriate 
investigation of adrenal function, safer and more pleasant than alternatives 
(Elder, Sachdev et al. 2012).  
 
4.4 Comparison of the SSST (standard dose SST) and LDSST (low 
dose SST) 
The relationship between the administration of ACTH and maximal cortisol 
response was first described as a test of adrenal function in 1963, using porcine 
ACTH (Ney, Nicholson et al. 1963). In 1965 Wood et al described the use of 
ACTH(1-24) in a rapid test of adrenal sufficiency (Wood, Franklan et al. 1965). 
The standard SST administers 250 mcg, an empirical equivalent to 25 IU of 
purified porcine ACTH historical utilised (Daidoh, Morita et al. 1995). Although 
250 mcg is more than adequate to assess the maximum secretory capacity of the 
adrenal gland, it may induce ongoing ACTH receptor stimulation and 
glucocorticoid synthesis, and as such its ability to detect subclinical 
hypoadrenalism has been questioned (Alia, Villabona et al. 2006).  
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Despite two of the early studies showing the effectiveness of a low dose of ACTH 
(Landon, James et al. 1967, Leclercq, Bruno et al. 1972) it was not until the early 
1990s that interest shifted to enhancing the potential sensitivity of the SSST by 
using a lower dose of Synacthen. It had been widely recognised that 250 mcg 
represented a supraphysiological, pharmacological dose and that lower, more 
physiological, doses were capable of maximally stimulating the adrenal gland 
(Graybeal and Fang 1985). Dickstein et al were the first to describe a LDSST. They 
reported that 5 mcg Synacthen was sufficient to achieve maximal adrenal 
secretion in adults and found no difference in cortisol levels obtained at 30 and 
60 minutes for the 250 mcg and 5 mcg tests. The results with 1 mcg were the 
same at 30 minutes but significantly lower at 60 minutes leading them to 
conclude that the 1 mcg test offers a more sensitive alternative (Dickstein, 
Shechner et al. 1991).  
 
Numerous studies have demonstrated in normal healthy adults that the cortisol 
response at 30 minutes is not significantly different between the SSST and the 
LDSST, but that the cortisol rises further by 60 minutes in the SSST, where it falls 
in the LDSST (Dickstein, Shechner et al. 1991, Krishnan, Miller et al. 1993, Daidoh, 
Morita et al. 1995, Mayenknecht, Diederich et al. 1998, Nye, Grice et al. 1999, 
Alia, Villabona et al. 2006). Crowley et al studied the dose-response relationship 
between Synacthen and cortisol at different low doses of Synacthen and 
concluded that 500 ng/1.73m2 was sufficient to elicit a rise in cortisol of more 
than 200 nmol/L (Crowley, Hindmarsh et al. 1991). Further studies have 
confirmed that 1 mcg of Synacthen is sufficient to produce a maximal, but not 
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supraphysiological, cortisol response (Daidoh, Morita et al. 1995, Darmon, 
Dadoun et al. 1999, Nye, Grice et al. 1999) and others have confirmed its 
reproducibility (Bridges, Hindmarsh et al. 1998, Park, Park et al. 1999, Gupta, 
Cheetham et al. 2009). 
 
Demonstration of the discriminatory ability of the tests in patients with AI is 
important when validating their clinical usefulness, as physicians want to avoid 
false negatives and reduce false positives where possible. Advocates of the 
LDSST are concerned that the SSST may falsely reassure by over-stimulating 
partially atrophied adrenal glands, where the reduced serum ACTH levels 
associated with AI may be sufficient to enable the adrenal cortex to respond to 
supraphysiological amounts of ACTH, but this does not mimic the physiological 
stress situation (Streeten 1999). A study of 32 symptomatic children, mostly with 
hypothalamic-pituitary damage from irradiation, compared their responses to 
SSST and LDSSTT. There were eight discrepancies, all “failing” the LDSST but 
“passing” the SSST, three of whom reported amelioration of their AI symptoms 
on commencing glucocorticoid replacement (Agwu, Spoudeas et al. 1999). A 
number of other studies, mainly in adults, have concluded that the LDSST is more 
sensitive compared with the SSST, detecting subtle degrees of AI missed by the 
supraphysiological dosing in the SSST (Broide, Soferman et al. 1995, Rasmuson, 
Olsson et al. 1996, Gonzalez-Gonzalez, De la Garza-Hernandez et al. 1998, Abdu, 
Elhadd et al. 1999, Agwu, Spoudeas et al. 1999, Tordjman, Jaffe et al. 2000).  
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The corollary is argued by other authors believing that the increased sensitivity 
may reflect false positive cases (Oelkers 1998, Stewart and Clark 1999, Mushtaq, 
Shakur et al. 2008) and some advocate a reduction in cortisol cut off (350 
nmol/L) in children undergoing a LDSST on ICS (Blair, Lancaster et al. 2013). A 
follow up study of 148 patients with low-normal or borderline results helped 
allay fears that the SSST lacked sensitivity as only two subsequently developed AI 
(Agha, Tomlinson et al. 2006).  
 
The relative sensitivities and specificities of the two doses have been compared 
(table 1.5). In one study both tests were reported to have excellent sensitivity 
(100%), but the specificity of the LDSST to be greater (93.3% compared to 90%) 
(Abdu, Elhadd et al. 1999). In another study the sensitivity of the SSST was seen 
to improve with higher 30 minute cortisol cut-offs: 18.8% at 500 nmol/L, 75% at 
605 nmol/L and 93.7% at 830 nmol/L (Tordjman, Jaffe et al. 2000) (table 1.5). A 
meta-analysis examined 346 subjects undergoing the SSST and 589 undergoing 
the LDSST. It was reported that a cortisol of less than 440 nmol/L was predictive 
of AI for both tests and a cortisol value of over 833 nmol/L for the SSST and 600 
nmol/L for the LDSST was highly predictive of a normal HPA-axis (Kazlauskaite, 
Evans et al. 2008). These data have resulted in some advocating a higher 
diagnostic cut off for the SSST (Hurel, Thompson et al. 1996, Abdu, Elhadd et al. 
1999, Tordjman, Jaffe et al. 2000, Kazlauskaite, Evans et al. 2008). 
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Table 1.5: Sensitivities and specificities of the SSST and LDSST, using ITT or OMT as gold 
standard, reported by Abdu et al. N=42 and Tordjman et al. N= (Abdu, Elhadd et al. 
1999; (Tordjman, Jaffe et al. 2000) 
 Sensitivity* Specificity* Sensitivity** Specificity** 
SSST 
(cortisol cut off 500 nmol/L) 
100% 90% 18.8% 92.2% 
SSST 
(cortisol cut off 600 nmol/L) 
100% 77% 75% 78.1% 
LDSST 
(cortisol cut off 500 nmol/L) 
100% 93.3% 94.7% 90% 
LDSST 
(cortisol cut off 600 nmol/L) 
100% 80% - - 
*Abdu et al (Abdu, Elhadd et al. 1999) ** Tordjman et al (Tordjman, Jaffe et al. 2000) 
 
Since its introduction there has been much debate as to whether the LDSST 
represents a viable alternative to both the SSST and ITT. Over the last decade 
three meta-analyses have been published examining the studies that compare 
the SSST and LDSST (Dorin, Qualls et al. 2003, Kazlauskaite, Evans et al. 2008, 
Magnotti and Shimshi 2008). All three looked at English language studies 
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Table 1.6: Summary of meta-analyses comparing SST and LDSST (Dorin, Qualls et al. 
2003, Kazlauskaite, Evans et al. 2008, Magnotti and Shimshi 2008) 
 
No of studies 
included 
Exclusion criteria Inclusion criteria 
Dorin et al 2003 
(Dorin, Qualls et 
al. 2003) 
29 1. Normal controls 
 
1. Primary/secondary AI 
2.  5 patients 
3. ITT/OMT control for 
secondary AI 
Kazlauskaite et al 
2008 
(Kazlauskaite, 
Evans et al. 2008) 
13 1. Normal controls 
2. Critically ill patients 
1. Primary/secondary AI 
2.  10 patients 
3. ITT/OMT for comparison 
Magnotti et al  
2008 (Magnotti 
and Shimshi 2008) 
7 None 1. Primary/secondary AI 
 
The controversy about which test is best is partly ameliorated by the conclusions 
of these meta-analyses. All three agree that there is no superiority of the SSST 
over the LDSST, and two reported the LDSST to be a better test (Kazlauskaite, 
Evans et al. 2008, Magnotti and Shimshi 2008). Dorin et al found no significant 
differences in the operating characteristic of the two tests but concluded that, 
due to low sensitivity of the SSTs, for secondary AI a test with hypothalamic 
stimulation (ITT or OMT) may be superior (Dorin, Qualls et al. 2003). There 
continue to be several strong proponents of central dynamic tests in adulthood 
(ITT and OMT) and of the SSST over the LDSST but it appears the evidence is 
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4.4.1 ACTH and cortisol dose response 
 
There are a number of different ways to examine the most appropriate dose of 
Synacthen for assessment of the physiological responsiveness of the adrenal 
gland to stress. One is to compare the plasma ACTH level produced when 
stressed (hypoglycaemia during the ITT) with that produced in the SSST and 
LDSST. The few studies that have measured the plasma ACTH achieved with 
different doses of Synacthen and ITT found the ACTH level following high doses 
of Synacthen (1 mcg/kg, 250 mcg) to be significantly higher than with the 
hypoglycaemic insult of the ITT. The Synacthen dose that most closely mimicked 
the ITT cortisol response was between 1 and 5 mcg (Graybeal and Fang 1985, 
Darmon, Dadoun et al. 1999, Nye, Grice et al. 1999). The ACTH level required to 
near-maximally stimulate the adrenal gland has been quantified as between 60-
80 pg/ml, slightly higher than a typical morning ACTH level (Oelkers, Boelke et al. 
1988, Darmon, Dadoun et al. 1999). This is considerably lower than plasma levels 
achieved following administration of 250 mcg Synacthen, which generates levels 
of between 5800-60,000 pg/ml. In the same studies the levels achieved following 
1 mcg Synacthen administration varied between 13-1900 pg/ml and are closer to 
those doses required to maximally stimulate the gland (Mayenknecht, Diederich 
et al. 1998, Darmon, Dadoun et al. 1999). The variability seen between studies is 
likely to be in part due to the employment of different assays, not primarily 
designed for the detection of Synacthen. 
 
In the only pharmacokinetic study to date examining the relationship between 
Synacthen and cortisol Alia et al reported the responses to both SSST and LDSST 
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in ten normal subjects (five men). Plasma Synacthen levels were higher in SSST 
(maximum plasma concentration 1144 nmol/L SSST compared with 960 nmol/L 
LDSST) but took longer to be achieved (time to maximum plasma concentration 
75 versus 52.5 minutes) and elimination of Synacthen was significantly slower in 
the LDSST. They confirmed identical rates of cortisol production between the 
two tests (Alia, Villabona et al. 2006).  
 
4.4.2 Timing of cortisol sampling 
 
Most studies comparing the SSST and LDSST have demonstrated a similar cortisol 
response at 30 minutes but divergence thereafter, with increasing cortisol values 
in the SSST and diminishing serum levels in the LDSST (Dickstein, Shechner et al. 
1991, Krishnan, Miller et al. 1993, Daidoh, Morita et al. 1995, Mayenknecht, 
Diederich et al. 1998, Nye, Grice et al. 1999, Alia, Villabona et al. 2006, Elder, 
Somerset et al. 2013). Although there is variability, the recommended sampling 
times are 0, 30 and 60 minutes for the SSST (Arlt and Allolio 2003). Sampling 
times for the LDSST tend to be more frequent, including earlier samples, and 
more variable (Elder, Sachdev et al. 2012). Most studies have identified the 
cortisol peak between 15 and 30 minutes (Crowley, Hindmarsh et al. 1991, 
Daidoh, Morita et al. 1995, Nye, Grice et al. 1999). Park et al examined the peak 
cortisol attained following 1 mcg Synacthen in 60 subjects (a mixture of healthy 
volunteers (N=8, 40 tests) and adrenal patients (N=5, 20 tests)). The peak was 
seen at 20 minutes in 65% and 23% at 30 minutes. They reported 100% 
sensitivity and specificity with sampling at 20 and 30 minutes (Park, Park et al. 
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1999). In other studies the peak cortisol following a LDSST would have been 
missed using just these times and testing at 0, 15, 25 and 35 minutes has been 
suggested (Paton, Jardine et al. 2006, Blair, Lancaster et al. 2013).  
 
4.5 Age and sex variability of SST 
When interpreting the results of children’s SSTs the question of whether age, sex 
or pubertal status have a role in the diagnostic cut offs employed needs to be 
considered. Lashansky et al examined the responses of children to the SSST by 
sex, age and puberty groupings (<1 year 8 girls (F), 13 boys (M), 1-5 years 8F 
14M, 6-12 years 7F 8M, Tanner stage 2-3 11F 10M, Tanner stage 4-5 8F 13M). 
They found no differences by age group in basal cortisol levels or between males 
and females but peak cortisol fell with increasing age in boys and similarly in pre-
pubertal girls. They reported greater differences in some of the other products of 
ACTH stimulation (DHEA, androstenedione, 17-hydroxy progesterone and 17-
hydroxy progestogen) and state that age and sex specific normal ranges are 
required, which may be used to aid diagnosis of genetic causes of primary 
adrenal insufficiency (Lashansky, Saenger et al. 1991). Currently there is no 
similar work for the LDSST. 
 
4.6 Current limitations of SST 
Although the SST is widely used, especially in paediatric practice, it is not without 
its limitations. All current versions of the SST require cannulation, i.v or i.m 
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Synacthen and multiple blood samples. It is unpleasant for the child and labour-
intensive, requiring skilled personnel and a brief admission. There is a lack of 
consensus amongst adult physicians and paediatricians about cortisol timings, 
acceptable cut-offs for cortisol response and the most suitable dose of 
Synacthen. There is also marked variability in making up the LDSST and a paucity 
of normative data in children (Barth, Seth et al. 1995, Elder, Sachdev et al. 2012, 
Blair, Lancaster et al. 2013). 
 
As for any endocrine investigation assay variability must be considered when 
interpreting results. A study of the SST using four different cortisol 
immunoassays reported significant differences in the absolute values of the 5th 
and 95th percentiles between the four methods (Clark, Neylon et al. 1998). In 
another study three different assay methods were used and significant 
differences were observed (Nye, Grice et al. 1999). Other authors have followed 
suit and all call for assay specific normal ranges to be determined for both sexes 
(Wood 1998, Stewart and Clark 1999, Chitale, Musonda et al. 2013, Elder, 







Charlotte Elder  08024835 PhD Thesis     
 80 
5 Nasal drugs 
 
5.1 Non-invasive alternatives to i.v administration 
Intravenous administration allows consistent pharmacokinetics to be achieved 
and avoids barriers to absorption such as first pass metabolism, but is not 
without its complications. Cannulation may be painful and a difficult practical 
procedure, especially in children, requiring repeated attempts. It is therefore 
resource-intensive as usually trained professionals need to undertake the 
procedure in a hospital setting. Other adverse effects may occur such as 
displacement of the cannula causing drugs meant for i.v use being accidentally 
administered in the subcutaneous tissues causing pain, swelling and with certain 
drugs tissue damage and long term scarring. All these issues are particularly 
pertinent in children, where even oral drug delivery may not be straightforward.  
 
Attempts to minimise the distress to a child when they are unwell or need to 
undergo a procedure are undertaken both for the short term good and because 
painful experiences have been shown to heighten the perception of pain during 
future encounters (Taddio, Katz et al. 1997).  It is to this end that for many years 
alternative routes of administration, for many different types of drugs, have 
been trialled. Routes such as i.m and subcutaneous injection may be as painful as 
i.v and rectal administration is undesirable in older children and adolescents. 
Many drugs cannot be given orally due to poor absorption, slow onset of action, 
degradation by the acid environment of the stomach, first pass metabolism or 
patient factors e.g. vomiting. Alternative transmucosal routes such as buccal, 
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sublingual, inhalational and intranasal bypass the enteral system and can be 
effective providing the taste is palatable and pharmacokinetics appropriate. A 
study comparing intranasal, sublingual and rectal administration of midazolam 
found all to be acceptable in the 47 children tested, although sublingual was the 
most effective and well tolerated (Geldner, Hubmann et al. 1997).  
 
5.2 The nasal route of administration 
The intranasal route of drug delivery has many advantages. It requires minimal 
training to administer drugs in a rapid and tolerable way. There is generally good 
absorption due to the richly vascular nasal mucosa and thereby high 
bioavailability, with avoidance of first pass metabolism, and a rapid onset of 
action. Anatomical proximity to the central nervous system makes it ideal for 
drugs with central sites of action. 
 
The side effects of intranasal drugs are few and are generally attributable to the 
drug itself rather than the method of delivery. The commonest adverse effects in 
children are nasal irritation and crying although these are generally short-lived 
(McGlone, Ranasinghe et al. 1998, Ljungman, Kreuger et al. 2000, Davis and Illum 
2003). 
 
5.2.1 Volume restriction due to nasal anatomy 
 
The nasal mucosa (squamous epithelium transitioning to columnar, 
pseudostratified, ciliated respiratory epithelium more proximally) is highly 
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vascularised. It covers a small area (the main chamber is about 5 to 8 cm long in 
an adult) yet its surface area is considerably increased, to 150-200 cm2, by the 
turbinates (inferior, middle and superior). This means nasal drugs must be 
administered in small volumes, high concentrations and ideally to both nares in 
an atomised spray to maximise absorption (Goldman 2006). Volumes of 0.2-0.3 
ml per nostril are most suitable and volumes upwards of 1 ml will saturate the 
nasal mucosa and much of the drug will be lost by dripping back down the nasal 
cavity or down the back of the pharynx (Wolfe and Braude 2010). 
 
5.2.2 Mechanism of absorption 
 
Ideal characteristics of a nasally administered drug include low molecular weight, 
lipophilic rather than polar molecules and drugs acting on the central nervous 
system (Davis and Illum 2003). Drugs with a smaller molecular size have a greater 
likelihood of effective absorption from the nasal mucosa e.g. morphine 
(molecular weight (MW) 285 g/mol). Drugs with molecular weights of less than 
1000 g/mol do not require the addition of an adjuvant for effective absorption 
(McMartin, Hutchinson et al. 1987). Some of the most widely used classes of 
nasal drugs are opiates and benzodiazepines as they have many of the ideal 
properties and achieve high cerebrospinal fluid levels for their central action. 
They are effectively administered intranasally for rapid onset of action in cases of 
seizure control, analgesia and anxiolysis (Wolfe and Braude 2010). 
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Peptide hormones, like Synacthen (MW 2934 g/mol), generally have low 
bioavailability by the nasal route, however there is a precedent to administering 
them. Nasal desmopressin (MW 1069 g/mol), has only 10% the effect of i.v at the 
same dose, nasal calcitonin (MW 3455 g/mol), insulin (MW 5808 g/mol) and 
gonadotrophin releasing hormone analogues a 1-3% bioavailability (Davis and 
Illum 2003). Larger peptide molecules are only absorbed in small amounts due to 
the endocytotic transport required (Jadhav, Gambhire et al. 2007). These factors 
and rapid removal via the mucociliary clearance system may be overcome by the 
addition of drug enhancers capable of modifying the transmembrane transport 
of drugs (Davis and Illum 2003). 
 
The poor membrane permeability seen with large polar peptides usually 
precludes them from using transcellular transport mechanisms, exploiting simple 
concentration gradients, or transfer by specific receptors or vesicular transport. 
There are two transport mechanisms used by larger peptides: paracellular 
transport, whereby the molecules pass through the tight junctions between cells 
and endocytotic transport by which the cell engulfs the molecule using vesicle 
carriers (Jadhav, Gambhire et al. 2007). Although the most sizable barrier to 
nasal drug delivery is absorption, mucociliary clearance and enzymatic 
degradation can additionally affect optimal drug plasma levels. 
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5.2.3 Mucociliary clearance (MCC) 
Within the nasal mucosa reside seromucosal glands comprising of mucus cells, 
which secrete a thick sticky mucus, and serous cells, which secrete a more 
watery fluid. There are thought to be 100,000 seromucous glands in the adult 
human nose, producing 1.5 to 2 litres of mucous daily (Ugwoke, Agu et al. 2005). 
One of the protective functions of the nasal mucus is mucociliary clearance 
(MCC), the process of mucus entrapment of potentially noxious particles 
followed by removal from the nasal cavity to the gastrointestinal tract by ciliary 
action. Average mucociliary transit time in a healthy adult is approximately 15 
minutes, not leaving sufficient time for some drugs to be absorbed (Turker, Onur 
et al. 2004). Nasal formulations that prolong MCC are more likely to give 
adequate time for paracellular transport, which is passive and therefore slow.   
 
5.3 Nasal Synacthen 
Synacthen administered orally is inactivated in the gastrointestinal tract by 
proteolytic enzymes and therefore it is given either i.v or i.m. A number of 
historical studies have examined the potential of nasally administered ACTH 
analogues as a replacement for depot i.m ACTH, which was studied as a regular 
therapy in a variety of inflammatory conditions, as an alternative to 
corticosteroid treatment.  
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5.3.1 History of intranasal ACTH 
It was first demonstrated that ACTH could be usefully absorbed through the 
nasal mucosa in 1952 (Smith, Dickson et al. 1952). McKendry, Schwarz and Hall 
performed a control study in nine study volunteers two years later using a 
purified ACTH(1-39) intranasal formulation “rhinacton”, which was observed to 
cause a rise in the eosinophil count and urinary 17-ketosteroid (surrogate 
markers used in the absence of a cortisol assay). There were no significant side 
effects reported. They went on to describe 17 clinical cases in which Rhinacton 
had been used and all but 3 patients demonstrated improvement. Of particular 
interest was the only paediatric case, a 3-year old boy with nephrotic syndrome 
who had previously responded well to i.m ACTH. He received 40 IU (international 
units) of intranasal ACTH twice daily for 8 days and once again remitted 
(McKendry, Schwarz et al. 1954). Although of historical interest, these studies are 
hard to interpret due to their lack of statistical analysis and use of surrogate 
markers as endpoints. 
 
By the 1960s significantly more was known about the ACTH molecule. Its amino 
acid sequence had been elucidated and its biological activity was known to reside 
in its N-terminus. Work on intranasal ACTH from the late 1960s onwards focused 
on investigating the properties of modified forms with a view to enhancing its 
clinical applicability. A number of groups have examined the superior plasma 
levels and duration of action of analogues such as ACTH(1-18) and ACTH(1-17) 
over ACTH(1-24), desirable properties in a therapeutic setting but not for the 
purpose of a one off diagnostic test (Felber, Aubert et al. 1969, Keenan, 
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Thompson et al. 1971, Baumann, Walser et al. 1976, Adelmann, Graef et al. 
1984). The short duration of the corticotrophic activity of ACTH(1-24) has limited 
its therapeutic use and may explain the paucity of research.  
 
The first record of intranasal Synacthen (ACTH(1-24)) was in 1969 when two 
doses (0.25mg and 1.5mg) were insufflated nasally in six healthy volunteers and 
flurogenic corticosteroids measured for five hours afterwards. Both doses 
resulted in a significant adrenal response at 60 minutes but the effect was 
maintained for longer in the higher dose. They concluded that this had both 
diagnostic and therapeutic potential, but no further investigation appears to 
have taken place for several decades (Keenan and Chamberlain 1969). 
 
The late 1970s saw renewed interest in intranasal administration as this route 
was already being used for a number of other drugs. Jeffcoate et al, during an 
extensive study, principally comparing ACTH(1-18) with ACTH(1-24), gave 11 
healthy volunteers either 1 mg or 5 mg of intranasal ACTH(1-24). There was no 
significant difference between the two doses, although the individual variation in 
corticosteroid response was reduced with the higher dose. A peak concentration 
of ACTH was obtained at 30 minutes and returned to baseline at approximately 2 
hours. The corresponding corticosteroid response peaked at 2 hours and was 
almost back at baseline at 8 hours. Levels of ACTH(1-24) were lower and less well 
sustained compared with ACTH(1-18) despite this the rise in corticosteroids was 
almost equivalent. The plasma levels of ACTH were shown to be lower when 
compared with both the i.v and subcutaneous routes. Of note, three subjects 
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had undetectable levels of ACTH(1-18) yet still mounted a comparable plasma 
steroid response with those with higher plasma titres. (Jeffcoate, Phenekos et al. 
1977). This may have been attributable to the ACTH assay employed or indicate 
that relatively small doses of ACTH may be required to generate a suitable 
adrenal response.  
 
The different pharmacological properties of the shorter ACTH analogues and 
ACTH(1-24) are thought to be due to proteolytic enzyme activity within the 
circulation rapidly destroying the steroidogenic potency of ACTH(1-24), but not 
the shorter analogues. This was demonstrated in vivo by a clear dissociation 
between the bioactive and immunoreactive levels of ACTH(1-24) (Jeffcoate, 
Phenekos et al. 1977).  
 
In this millennium a Japanese group looked more closely at the effect of 
intranasal ACTH(1-24) on adrenocortical hormones (Hiroi, Ichijo et al. 2002) and 
catecholamine secretion (Hiroi, Ichijo et al. 2004) and went on to successfully 
treat an adult patient with isolated ACTH deficiency (Hiroi, Ichijo et al. 2004). 
Using 250 mcg ACTH(1-24) both i.v and intranasally (i.n), with saline as a control, 
they demonstrated that cortisol, aldosterone, DHEA, adrenaline and 
noradrenaline all rose significantly but DHEA-S (DHEA-sulphate) and dopamine 
did not. The levels of cortisol and aldosterone were lower following i.n 
administration than with i.v. As seen in the Jeffcoate et al study the cortisol rise 
peaked at 30 minutes and returned to baseline by 2 hours (Hiroi, Ichijo et al. 
2002, Yoshida-Hiroi, Tsuchida et al. 2005).  
Charlotte Elder  08024835 PhD Thesis     
 88 
 
A pertinent animal study examined nasal absorption in rats and reported that 
bioavailability was low compared with i.m administration (4.4% compared with 
24%) and time to reach peak concentrations (Tmax) was 10-15 minutes using the 
i.n route compared with 4 minutes i.m. Two different enhancers were trialled 
and both significantly changed the pharmacodynamics. Sodium glycocholate 
decreased the Tmax and absorption was increased threefold, but this effect was 
relatively short lived. Bacitracin increased the bioavailability of i.n to i.m levels 
(Wuthrich, Martenet et al. 1994). 
 
These studies looked at the use of intranasal ACTH from the perspective of 
discovering an analogue with the pharmacological properties to allow its long-
term use in chronic conditions. These are not the same properties required for 
the SST, where only a single dose is needed, and there are no studies to date 
looking at the use of nasal Synacthen either in the childhood population or as a 
one-off diagnostic test. Previous research, though limited, has shown nasal 
Synacthen to be well tolerated and there have been no significant safety 
concerns reported. 
 
5.4 Nasal drug enhancers 
Nasal absorption enhancers may alter the physiochemical properties of a drug 
e.g. alter the drug solubility, or exert their effects on the nasal mucosal 
membrane (Turker, Onur et al. 2004). The addition of formulation additives to 
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enhance drug absorption offers the opportunity for improved bioavailability 
without changing the physiochemical properties of the drug and is therefore 
more commonly employed (Davis and Illum 2003).  
 
5.4.1 Ideal properties of a nasal drug enhancer 
A nasal drug enhancer should ideally improve bioavailability but without side 
effects or change to the drug mechanism of action. It should therefore be 
pharmacologically inert and non-allergenic, tasteless, odourless and have a 
transient and reversible effect. It should transport the drug molecule from the 
apical to basolateral surface of the cell without harming or disrupting the 
membrane, should improve the mean residence time of the drug (increase the 
time the drug is in contact with the mucosal surface for maximum absorption) 
and preferably not be absorbed (although if it is it should be easily and safely 
metabolised and excreted). The mechanism of action of the promoter should be 
understood and preferably be enhancing an existing process. Few absorption 
promoters fulfil all these attributes, although chitosan (vide infra section 5.4.3) 
appears to satisfy them with the additional advantage of being readily available 
and inexpensive (Davis and Illum 2003).  
 
 
5.4.2 Types of nasal drug enhancer 
 
There are a number of different nasal drug enhancers that have been 
investigated in animal models and some in humans. The main classes of which 
are briefly outlined below (Davis and Illum 2003, Turker, Onur et al. 2004). 
Charlotte Elder  08024835 PhD Thesis     
 90 
 Microspheres – e.g. starch or dextran  
o form a gel-like layer when water is absorbed increasing the drug 
residence time in the nasal mucosa. 
  Liposomes  
o Phospholipid vesicles composed of lipid bilayer and thus act as 
drug carriers across the nasal mucosa. 
 Gels e.g. chitin or chitosan  
o act to slow MCC thereby increasing drug residence time in the 
nasal mucosa and may facilitate paracellular transport. 
 Cyclodextrins  
o appear to both affect paracellular transport and have a 
solubilising effect on some proteins e.g. insulin. 
 Fusidic acid derivatives e.g. tauro-24, 25-dihydrofusidate (STDHF)  
o act as enzyme inhibitors to slow degradation and increase time for 
absorption. 
 Phospholipids - e.g. phosphatidylcholines  
o reside in cell membranes and therefore facilitate cell entry of 
polar drug molecules.  
 Bile salts and surfactants – e.g. sodium glycocholate  
o disrupt paracellular and transcellular pathways but in doing so are 
irritant and can cause mucosal damage. 
 
 




The term chitosan describes a series of chitosan polymers with differing 
molecular weighs and degrees of deacetylation. Chitosan is a polysaccharide 
comprising copolymers of glucosamine and N-acetyl-glucosamine and is found in 
fungi but is more commonly derived by partial deacetylation of chitin from 
crustacea (i.e. crab and shrimp shells as a by-product of seafood processing) 
(Davis and Illum 2003). 
 
Commercially, chitosan is made by alkaline N-deacetylation of chitin derived from 
crustacea, due to their abundance. Chitin is a linear polysaccharide consisting of 
ß-(1→4)-linked 2-acetamido-2-dexoy-D-glucopyranose (GlcNAc) and 2-amino-2-
deoxy-D-glucopyranose (GlcN), chitosan consists nearly entirely of GlcNAc. The 
heterogeneous deacetylation process, combined with removal of insoluble 
compound, results in a chitosan product that possesses a random distribution of 
GlcNAc and GlcN units along the polymer chain. Chitosan is unusual in that it is 
positively charged at neutral and acidic pH. It is a cationic biopolymer and forms 
salts with inorganic and organic acids. The dissolution of the soluble 
polysaccharide results in a positive charge allowing it to demonstrate its 
bioadhesive, film-forming and gelation properties. Due to its high molecular 
weight chitosan is not systemically absorbed to any significant degree, greatly 
minimising its risk of systemic toxicity (Personal communication, Peter Watts, 
Archimedes Development Ltd). As a group of compounds chitosan may exhibit a 
range of molecular weights and different salt forms: glutamate (the most 
common), chloride and lactate. Chitosan displays considerable versatility such 
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that by altering the degree of deacetylation and the pH or ionic strength of the 
formulation the solubility and pKa (acid dissociation constant) can be changed 
(Davis and Illum 2003). The functional properties of chitosan are primarily 
determined by the degree of deacetylation and molecular weight. 
 
These properties render it of interest for several applications. Chitosan is 
extensively used in industry as a clarification agent in beverages (fruit juice and 
beer), a fungicide for the protection of crops and coating apples, a food 
constituent (especially in Japan), and a nutritional supplement and in the 
cosmetic, dental and ophthalmic industries. Chitosan is used as a dietary 
supplement in preparations for weight loss, obesity and hypercholesterolaemia 
(Illum, Farraj et al. 1994). Biomedically, chitosan is used in bandages and wound 
dressings and is being explored for applications in tissue engineering (Muzzarelli 
2009). Pharmaceutical applications of chitosan which are under investigation 
include an excipient in tablets, controlled release formulations and gels, an agent 
for gene delivery, an enhancer of transmucosal drug absorption, and a vaccine 
adjuvant for nasal vaccine delivery (Saranya, Moorthi et al. 2011, Jabbal-Gill, 
Watts et al. 2012).  
 
5.4.3.1 Mechanisms of action 
 
Chitosan differs from other enhancers by not exerting an active change on the 
nasal mucosal membrane, not being absorbed and not being a surfactant-
derived material. The nasal mucosa does not absorb hydrophilic compounds, 
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which generally cannot diffuse across the lipid bilayer, that are larger than the 
intercellular tight junctions (zona occludens, ZO). It is thought that polar 
compounds pass through when chitosan facilitates the bioadhesion to and 
transient (30 to 45 minutes) opening of the membrane’s tight junctions (Ilium 
1998, Dodane, Khan et al. 1999). A model cell membrane has allowed 
investigation of this process and it appears the chitosan’s positive charge enables 
it to alter the cytoskeleton protein, F-actin, from a filamentous to a globular 
structure and decrease the ZO-1 proteins, both vital to the opening mechanism 
of the tight junctions. This alteration is believed to effect ion transport activating 
intracellular secondary messenger systems and triggering a cascade of events 
culminating in increased tight junction permeability (Dodane, Khan et al. 1999, 
Davis and Illum 2003). Additionally there appears from human in vitro studies 
that chitosan also slows mucociliary clearance by three to six fold, using its 
mucoadhesive properties (Soane, Frier et al. 1999). 
 
5.4.3.2 Chitosan glutamate (PROTASAN™ UP G 213) 
 
Chitosan glutamate is chitosan which has been converted into the glutamate salt 
form by dissolving chitosan in glutamic acid. Glutamic acid is present at a 
stoichiometric5 amount to the number of GlcN units. Chitosan glutamate has 
been demonstrated in numerous pre-clinical and clinical studies (phase I-II) to 
enhance the intranasal delivery characteristics of a wide range of drug 
compounds and as an excipient in intranasal vaccine formulations. The 
                                                 
5
 Stoichiometric – quantitative relationship between products and reaction in a chemical 
substance 
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PROTASAN grades of chitosan manufactured by FMC BioPolymer (Philadelphia, 
PA, USA) are characterized by the molecular weight (also measured as viscosity) 
and the ratio of glucosamine to N-acetyl glucosamine (degree of deacetylation). 
A chitosan glutamate product having a high viscosity and a medium degree of 
deacetylation would be described by the product name PROTASAN UP G 213 
(Personal communication, Peter Watts, Archimedes Development Ltd). 
 
Chitosan glutamate (PROTASAN™ UP G 213) was not, at the time of writing, 
licensed for use in any pharmaceutical products in Europe. However, it had been 
extensively evaluated in pre-clinical studies and in human clinical trials in Europe 
and USA. Intranasal chitosan glutamate-containing products evaluated in 
humans have included influenza vaccine (Read, Naylor et al. 2005), norovirus 





6 Salivary steroids 
 
The delivery of nasal Synacthen for diagnostic purposes is novel, as is the 
addition of a nasal drug enhancer, however the second part of a non-invasive 
SST, the measurement of salivary cortisol, is better established. Salivary cortisol 
has been shown to have excellent correlation with serum levels (Vining, 
McGinley et al. 1983) and only the biologically active part of the molecule is 
measured, thus reducing some variability. Salivary sampling is painless, therefore 
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less stressful, and relatively inexpensive, as it does not require a hospital setting 
(Wood 2009). Steroids are not appreciably metabolised in saliva, unlike 
compounds excreted by the kidney, causing some to advocate salivary steroid 
hormone analysis over that of urine determination (Groschl 2008). Much of the 
literature pertaining to salivary cortisol comes from the psychological sciences 
but increasingly it is being recognised as having a role in clinical endocrinology, 
particularly in the diagnosis of Cushing’s syndrome where it is now 
recommended as a first-line diagnostic test (Nieman, Biller et al. 2008). Although 
it is yet to assume widespread adoption in the assessment of hypercortisolism, in 
part due to the laboratory set up required (Wood 2009), it is in the assessment of 
hypocortisolism where a paucity of research exists and its clinical application is, 
as yet, untested.   
 
6.1 Transfer, metabolism and detection of hormones in saliva 
6.1.1 Transfer of steroids into saliva 
 
The parotid, sublingual and submaxillary glands all produce saliva, although the 
character differs between the glands due the relative abundance of serous or 
mucinous acinar cells. The parotid glands produce a watery saliva; sublingual a 
mucousy secretion and submaxillary a combination of the two. Sodium is actively 
pumped into the acinar end of the glands with water following by osmosis 
through the tight junctions of the acinar cells. Sodium is then pumped back into 
the plasma, as saliva travels down the duct, resulting in a hypotonic solution but 
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a variable sodium concentration as the ductal pumps are flow rate-dependent 
(Wood 2009).  
 
The salivary acinar cell membrane is a lipid layer and lipophilic molecules such as 
unconjugated steroids diffuse into the saliva much more readily than hydrophilic 
molecules like peptides (figure 1.6). The majority of steroids are protein bound in 
serum, with a relatively small, biologically active, free fraction. It is only the free, 
unconjugated steroids that enter the saliva by diffusion. The alternative passage 
into the saliva for small, non-protein bound, polar steroids is ultrafiltration, 
whereby molecules with a weight of less than 1900 g/mol are able to pass with 
water through the acinar tight junctions (Wood 2009). This is the only entry 
route for conjugated steroids e.g. DHEA and they are found in very small 
fractions of their unbound serum concentrations (1%), which falls further at high 
salivary flow rates. Unconjugated steroids, like cortisol, are present in saliva at 
equivalent levels to their free fraction in serum (10%) and are unaffected by 
salivary flow rates (Vining, McGinley et al. 1983).  
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Figure 1.6: Schematic diagram of salivary gland showing transport of molecules into 
and out of saliva. Kindly drawn on the instructions of author by Steve Jones, research 
assistant, SCH. 
 
6.1.2 Metabolism of steroids in saliva 
 
The correlation between serum free steroids and salivary values is generally 
close, however salivary gland metabolism may account for some of the variance. 
Progesterone, oestrogen, testosterone and androstenedione have all been 
shown to be metabolised to a greater or lesser extent in saliva but cortisol and its 
relationship with cortisone is the best-known example. The enzyme which 
converts cortisol to cortisone, 11-hydroxysteroid dehydrogenase type 2, (11-
HSD-2), is present in salivary glands and is responsible for the large difference in 
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the proportion of salivary cortisol: cortisone compared with that in serum 
(salivary 1:4, serum 8:1 respectively) (Wood 2009).  
 
 
6.1.3 Analytical methods for quantification of salivary steroids 
Immunological methods for determination of salivary hormones have the 
advantages of requiring small sample sizes, being easy to use and sensitive, 
however their specificity has prompted an increasing popularity of 
chromatographic methods; high pressure liquid chromatography (HPLC) or liquid 
chromatography with tandem mass spectrometric (LC-MS/MS) detection (Baid, 
Sinaii et al. 2007). Immunoassays, despite their flaws, are still widely employed, 
most commonly enzyme immunoassays, luminescence and fluorescence assays. 
Clinical chemists warn of the problems if appropriate extraction and 
prepurification are not carried out in the preparation phase, techniques which 
enhance the reliability of the chromatographic techniques (Turpeinen and 
Hamalainen 2013). Liquid chromatography with tandem mass spectrometry 
overcomes many of the problems of immunoassay and allows the analysis of a 
complete profile of salivary steroids in one sample (Groschl 2008). At the time of 
writing there is no established External Quality Assurance Scheme for salivary 
steroids but it is hoped that one will be introduced as their popularity and clinical 
applications grow (Inder, Dimeski et al. 2012). 
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6.1.4 Saliva collection methods and storage. 
 
Oral saliva is a mixture of secretions from the three main pairs of salivary glands, 
the minor glands, desquamated epithelial cells, food debris, microorganisms and 
possible blood from minor oral abrasions. Invasive collection methods exist: 
suction and cannulation of the ducts, but most look to saliva to access 
information about blood levels of molecules by a non-invasive method. 
Published methods include spitting or drooling (active or passive) into a 
specialised tube, chewing absorbent cotton or polyester and placing cotton 
wads, pads or eyespears (similar to a specialised cotton wool bud but with 
absorbent filter paper tip) between the lower buccal membrane and cheek or 
under the tongue until saturated. The methods involving cotton wool rolls/wads 
require salivary extraction by centrifugation and concerns have previously been 
raised regarding the spuriously high levels of salivary cortisol measured when 
using the cotton or polyester swabs (Shirtcliff, Granger et al. 2001, Kidd, Midgley 
et al. 2009). Blood, not visible to the naked eye, can be present for 30-minutes 
after tooth brushing and therefore it is recommended that saliva samples should 
not be collected within 30 minutes of eating, drinking, chewing flavoured gum, 
brushing teeth or using dental floss (Wood 2009). 
 
Different patient groups present different challenges when trying to obtain 
saliva; from the social unacceptability of spitting for the elderly (Nguyen and 
Wong 2006), to the small size of the mouth in premature infants (Ng, Drury et al. 
2013) and the non-compliance of toddlers. A study using marshmallows 
demonstrated improved procedural adherence in young children, without 
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cortisol assay interference (Clements, Parker et al. 2007). Detection methods 
requiring small volumes of saliva can help overcome the problem of obtaining 
adequate volumes for analysis. Lingual citric acid can increase the amount of 
saliva produced five to ten fold but has been shown to interfere with 
immunoassays (Gallagher, Leitch et al. 2006).  
 
Patient preference, ease of collection, volumes of saliva collected and effect on 
biochemical analysis have all been studied and findings have been varied, on 
balance favouring absorbent cotton methods (Strazdins, Meyerkort et al. 2005, 
Groschl, Kohler et al. 2008). Work carried out in the Department of 
Endocrinology at SCH found the drool technique to be preferred to the chewing 
of absorbent cotton by both study participants and researchers due to the larger 
volumes of saliva collected and the closer correlation with serum cortisol 
(Nickson, Wilson et al. 2008).  
 
Salivary steroids are generally stable and withstand time at room temperature 
and frozen storage (Clements and Parker 1998). Bacterial growth can cause 
deterioration in sample quality if stored at room temperature for a week without 
prior centrifugation (Groschl, Wagner et al. 2001). In the study carried out in the 
Department of Endocrinology at SCH samples were centrifuged and frozen 
(N=10) or centrifuged and refrigerated (N=10) or returned to the lab by 2nd class 
post then centrifuged and frozen (N=10). After one week samples were thawed 
and analysed. No significant effect on cortisol concentration was seen with any 
storage method (Nickson, Wilson et al. 2008). Recommended storage for salivary 
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samples is a month at 4°C and three months at -20 °C, although longer times 
have been shown to be tolerated for centrifuged samples. Freezing is necessary 
for long term storage (Wood 2009).  
 
6.2 Salivary cortisol 
Lipophilic, unconjugated steroids, such as free, non-protein bound cortisol, pass 
relatively easily from capillaries to the acinar cells of the salivary glands along a 
concentration gradient by a method of passive diffusion (figure 1.6). Salivary 
cortisol therefore reflects the unbound, free and biologically active fraction of 
total serum cortisol, however, due to metabolism within the glands, salivary 
cortisol concentrations are about half of the corresponding serum free cortisol 
value (Wood 2009). Passive diffusion results in a stable relationship between 
serum and salivary cortisol, uninfluenced by salivary flow rate (Wood 2009).  
 
Measuring serum free cortisol requires numerous steps, complex laboratory 
techniques and considerable time, making it impractical (Perogamvros, Keevil et 
al. 2010). The disadvantages of measuring serum total cortisol include: reflecting 
less than 5% of the biological activity of cortisol; changes in levels and binding 
affinity of CBG in different situations altering the free and biologically active 
fractions but not the total, and an underestimation of the free cortisol seen in 
stress when CBG becomes saturated (Perogamvros, Keevil et al. 2010). 
Measuring salivary cortisol avoids these biochemical pitfalls and as a non-
invasive, pain-free alternative would enable diagnosis and monitoring to occur in 
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the community setting. Additionally it has been shown that, due to the passive 
diffusion, the salivary concentration of cortisol will reflect that of the serum 
within minutes making it an ideal method to measure adrenal reserve and 
responsiveness (Vining, McGinley et al. 1983).   
 
6.2.1 Relationship of serum and salivary cortisol 
Cortisol is the best studied of the salivary steroids and appears to have most 
clinical applicability due to its reliable relationship with serum total and free 
cortisol levels. Published correlations have demonstrated r values of between 
0.85 and 0.97 (Riad-fahmy, Read et al. 1982, Vining, McGinley et al. 1983, 
Luthold, Marcondes et al. 1985, Gozansky, Lynn et al. 2005, Gallagher, Leitch et 
al. 2006, Perogamvros, Owen et al. 2010). It is important to note however that 
correlations are not a measure of relationship and that as these studies are 
measuring related compounds they would be expected to demonstrate a high 
degree of correlation. The relationship between total serum cortisol and salivary 
cortisol has been described as biphasic, with a slow initial phase until Cortisol 
Binding Globulin (CBG) binding capacity is exceeded (approximately 500 to 600 
nmol/L) followed by more rapid rises in salivary cortisol with increasing total 
serum cortisol concentrations (Vining, McGinley et al. 1983). Others have 
described this relationship as exponential (Gozansky, Lynn et al. 2005; 
Perogamvros, Owen et al. 2010). In conditions where CBG levels are high, e.g. 
pregnant women or those on the oral contraceptive pill, there is a prolonged first 
phase until CBG saturation (Vining, McGinley et al. 1983). This relationship has 
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been tested temporally and shown that salivary and serum cortisol correlate 
closely throughout the circadian rhythm (Dorn, Lucke et al. 2007). When free 
serum cortisol is plotted against salivary cortisol a linear relationship is observed, 
with strong a correlation coefficient from 0.89-0.97 (Vining, McGinley et al. 
1983); Gozansky, Lynn et al. 2005).  
 
Estimates of the percentage of total serum cortisol represented by salivary 
cortisol vary and need to be individually determined for each assay (Inder, 
Dimeski et al. 2012). Perogamvros and colleagues quote 1.66% using LC/MS-MS, 
which is in keeping with previous work carried out at SCH on an immunoassay 
(1.65%) (Nickson, Wilson et al. 2008, Perogamvros, Owen et al. 2010).  
 
6.2.2 Salivary Cortisone 
Salivary cortisone: cortisol ratios are between 16 and 64 times greater than 
serum total cortisone: cortisol ratios (Wood 2009). This is the result of two 
processes: 11-HSD-2 within the salivary glands enables the one way oxidative 
conversion of cortisol to cortisone (to protect the glands form the glucocorticoid 
actions of cortisol) and CBG has a lower affinity for cortisone (the association 
constant is 10 fold higher for cortisol) and as such more free cortisone is 
available to diffuse into the saliva (Wood 2009). Salivary cortisone levels are 
considerably higher than salivary cortisol and it may therefore be the preferable 
biomarker (Perogamvros, Keevil et al. 2010, Blair, Lancaster et al. 2013). Salivary 
cortisone has been shown to closely mimic the levels of free serum cortisol and 
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be independent of CBG levels (Perogamvros, Keevil et al. 2010), however it is not 
a metric used routinely as yet in clinical practice but is an area of research 
interest (Raff and Findling 2010). 
 
6.3 Salivary cortisol in the detection of adrenal insufficiency 
A single morning cortisol sample, whether serum or salivary, has been found to 
exhibit poor sensitivity and specificity for the reliable detection of AI (sensitivity 
33% for both and specificity 34% for serum, 20% for salivary) (Restituto, Galofre 
et al. 2008), however others, albeit with smaller numbers (48 versus 189) found 
it to have 100% sensitivity and 97% specificity (Patel, Shaw et al. 2004).  
 
Those who have studied the use of salivary cortisol as the biochemical endpoint 
in dynamic tests of adrenocortical function have advocated it as an appropriate 
and useful alternative to serum cortisol, with many preferring it for its 
dissociation with CBG. It has been investigated in a number of different 
diagnostic cohorts, normal volunteers, adults and children and by using the ITT, 
CRH and Synacthen at 250, 25 and 1 mcg and been found to correlate well with 
serum cortisol (Laudat, Cerdas et al. 1988, Contreras, Arregger et al. 2004, 
Gozansky, Lynn et al. 2005, Marcus-Perlman, Tordjman et al. 2006, Arafah, 
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6.3.1 The use of salivary cortisol in the assessment of children on ICS 
 
Basal cortisol as a marker for adrenal suppression in children on ICS has been 
investigated and reported to be significantly lower than controls. The reduction 
is dose related, however there is considerable overlap with controls and thus is 
not felt to discriminate adequately enough to be employed as a diagnostic test 
(Nickson, Wilson et al. 2008, Bakkeheim, Mowinckel et al. 2010). A recent large 
study reported the results of three consecutive early morning salivary cortisol 
and cortisone measurements in 269 children on five different types of ICS. They 
found good negative predictive values for both salivary cortisol (98.8%) and 
cortisone (99.2%) but poor positive predictive values (9.5% and 30.1% 
respectively) (Blair, Lancaster et al. 2013).  
 
The utilisation of salivary cortisol in dynamic tests of adrenocortical function in 
children with asthma on beclomethasone diproprionate compared to controls 
was described 30 years ago but has not been repeated since. Early morning 
salivary cortisol was higher in children with asthma, which authors attributed to 
the stress response of a lowered peak expiratory flow rate. The cortisol response 
to 250 mcg Synacthen showed a similar pattern in serum and saliva and were not 








Asthma is common and there are increasing requests to investigate the adrenal 
reserve of children on ICS because of the risk of AI. Most of the cases of AI in 
children prescribed high-dose ICS are sub-clinical, arguably better detected by 
the LDSST. There are unresolved questions as to the contributory role, if any, of 
dose, age, sex and pubertal status on AI in children on high-dose ICS. Currently 
the LDSST is the most commonly used diagnostic test amongst paediatric 
endocrinologists in UK, yet there is a lack of consensus as to who should be 
investigated, with which test, at what dose, when to sample and which 
diagnostic criteria to employ. Research in this area is limited by the invasive 
nature of the current tests. Synacthen is safely absorbed by the nasal mucosa 
and cortisol can be readily detected in salivary samples. Salivary cortisol has a 
predictable relationship with serum cortisol and salivary cortisone. It reflects the 
free portion of serum cortisol, is stable at room temperature and is unaffected 
by CBG levels and salivary flow rate. This research project aims to validate a non-
invasive LDSST test with nasally administered Synacthen and salivary 
cortisol/cortisone for future use both as a diagnostic test in a number of clinical 
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Whilst reviewing the literature during the set up phase of the first clinical study 
undertaken for this thesis (NeSST Study, chapter 4) it became evident that 
practice varies between centres and recommendations are often not adhered to, 
yet little data exists as to what is being done. It was with these deficiencies in 
mind that a number of small projects were devised to ascertain the following:  
 current usage of the low and standard dose SSTs in specialist paediatric 
endocrine practice in the UK;  
 local adherence to recommendations of the assessment of adrenocortical 
function in children on high-dose ICS; 
 local rates of abnormal SSTs in children on high-dose ICS 
 local GPs’ and paediatricans’ knowledge and prescription practises of 
high-dose ICS in children.  
These projects were conceived and supervised by the author, but conducted in 
the main by medical colleagues within the department of endocrinology at 
Sheffield Children’s Hospital.  
 
1 British Society of Paediatric Endocrinology and 
Diabetes (BSPED) survey 
 
There are a number of areas of debate and variation in practice in the use and 
interpretation of the SST to diagnose AI in children. A questionnaire survey of 
paediatric endocrinologists practicing in UK and Eire was conducted to evaluate 
its current usage and variability in practice. With an increase in the use of the 
LDSST, yet only the 250mcg/ml commercial preparation available, respondents 
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were additionally asked how they made up the low-dose Synacthen. The results 
of this survey were published in 2012 (Elder, Sachdev et al. 2012).  
 
1.1 Methods 
A seven-question survey (appendix 1) was emailed to all British Society of 
Paediatric Endocrinology and Diabetes (BSPED) members (257) in 2009 with a 
response requested from a representative of each centre (92 UK and Eire 
centres). This was followed up, one month later, by an emailed request to 
members of departments who had not yet responded.  
 
The questions sought information on whether the centre currently used the SST 
and if so what dose was favoured; how the low-dose, if used, was made up; the 
timings of cortisol sampling and criterion for a normal response. Additionally 
there was a question pertaining to the centre’s experience of request rates for 
SSTs in light of the concern over AI in children prescribed HDICS and whether 
they had experience of detecting AI in such children. 
 
1.2 Results 
Questionnaire replies were received from 39 of the 92 centres with practicing 
paediatric endocrinologists in the UK and Eire (42% response rate). Responses 
were fairly evenly split between secondary and tertiary care centres: 46% (18/39) 
from District General Hospitals and 54% (21/39) from tertiary centres. All 
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responding centres employed a form of the SST (100%): 82% (32/39) used a 
LDSST, 87% (34/39) the SSST, 69% (27/39) used both and 18% (7/39) and 13% 
(5/39) used exclusively the SSST or the LDSST respectively. The LDSST was the 
preferred choice when monitoring patients with asthma on high-dose ICS. The 
majority of LDSST tests were performed using a 1 mcg dose of Synacthen, 44% 
(14/32), and of the remaining 56% (18/32) seven different doses based on age, 
weight and body surface area (BSA) were used (figure 2.1).  
 
Figure 2.1: Variation in dose employed in the LDSST by different British and Irish 
paediatric endocrinology units (reproduced with permission). 
 
There was variation in the timings of cortisol sampling. Although all units 
sampled at 0 and 30 minutes and 69% (22/32) of LDSST and 82% (27/33) of SSST 
at 60 minutes, there were a number of additional samples taken both in the 
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LDSST and SSST (figure 2.2). The number of samples taken was greater for the 
LDSST compared with the SSST (mean number of samples per test 4.4 and 3.8 
respectively). 
 
Figure 2.2: Sampling frequency and timing of British and Irish paediatric endocrinology 
units employing the LDSST (reproduced with permission). 
 
The diagnostic cut-offs used by different centres for a normal SST also varied 
(figure 2.3). Peak cortisol was used on its own as the diagnostic criterion in 36% 
(14/39), the combination of peak cortisol and rise from baseline was used in 38% 
(15/39) and 18% (7/39) used peak or rise from baseline but did not require both 
for a normal result. No centre used rise from baseline as the sole criterion. The 
remaining 8% (3/39) of centres employed either different criteria depending on 
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time of day the test was performed, age related cut-offs or used the baseline 
cortisol value as a component in their decision making.  
 
 
Figure 2.3: Diagnostic criteria used by British and Irish paediatric endocrinology units 
for a normal the LDSST (reproduced with permission). 
 
Regarding the value required for a normal peak cortisol, 54% (21/39) of 
responding centres looked for a peak of 500 nmol/l and 44% (17/39) used 550 
nmol/l, with one centre employing different criteria based on age. Rise from 
baseline was defined as more than 200 nmol/l in 67% (26/39), 8% (3/39) used a 
doubling of the baseline value and one centre used a combination of the two. Of 
the remaining nine centres, eight did not provide the information and one used 
an incremental rise of 150 nmol/l. 
  
Marked variability was observed between units in how they reported making up 
their LDSST, with 14 different methods provided by 23/32 (72%) centres. The 
most popular method, used by five centres, involved mixing 0.1 ml Synacthen (25 
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mcg) with 50 ml of 0.9% saline resulting in a concentration of 500 ng/ml, of 
which 1 ml was given. Single dilution methods, of which eight were described, 
were used by 74% (17/23) of responding centres. Double or triple dilutions 
accounted for six of the methods and were used by 26% (6/23) of centres. The 
diluent volume varied from 10 mls to 1 litre. The volume of Synacthen used 
varied from 0.1 ml to the whole 1 ml vial of 250 mcg/ml; 0.5 ml or less was used 
in five of the different methods described.  
 
The final question examined the respondents’ knowledge of the current 
recommendations with regards to monitoring children with asthma on high-dose 
ICS, whether there had been an appreciable increase in the number of SST 
requested or performed and a chance to comment on their experience of 
detecting AI in these children. Only one respondent was unaware of the current 
recommendations and 44% (17/39) of centres reported an increase in requests 
for SSTs since their publication. Adrenal insufficiency had been detected in 
children on high-dose ICS by 67% (26/39) of responding centres and two 
children’s hospitals reported detection rates of between 40% and 50%.  
 
1.3 Discussion 
Whilst acknowledging that a response rate of 42% resulted in a survey of fewer 
than half of UK and Eire centres offering paediatric endocrinology services it was 
believed to be representative and a good response rate for a questionnaire 
survey. This survey demonstrated considerable variability in almost all aspects of 
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the SST: the dose, the timings of cortisol sampling, the diagnostic criterion and 
cut-offs for AI and the way in which the LDSST was made up. All responding 
centres employed a form of the SST, however, despite meta-analysis level 
evidence, 18% did not use a LDSST at all. The variability perhaps in part reflects 
the paucity of normative data in children and has been noted previously in a UK-
wide survey of clinical biochemistry laboratories. That survey reported a lack of 
consensus with regard to method of Synacthen administration (78% of 
respondents administering Synacthen i.m), timing of cortisol sampling and 
acceptable cut-offs for cortisol response (Barth, Seth et al. 1995). Additionally 
none of the 191 centres adhered to published guidance for interpretation of 
cortisol responses to Synacthen (Moore, Aitken et al. 1985). In this BSPED 
members survey the reference source of each centres’ cortisol sampling times 
and diagnostic cut-offs was unknown but no centre adhered to the suggested 
test in two of the main paediatric endocrinology textbooks: namely 0 and 60 
minute sample, following 250 mcg i.v Synacthen, and a cortisol response of over 
830 nmol/l in the pre-pubertal and 690 nmol/l in pubertal children for a normal 
result (Miller, Achermann et al. 2008, Miller 2009). A 30-minute sample is 
mentioned but the chapters state that best-available evidence is for 60 minute 
sampling only. The only mention of the LDSST is in relation to the assessment of 
adrenal recovery from suppression secondary to corticosteroid usage but with no 
specification of what constitutes a normal response (Miller, Achermann et al. 
2008, Miller 2009). Some of the variation noted in this survey may have been 
due to local protocols written collaboratively with laboratory colleagues, 
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although the diagnostic cut-offs were the aspect of the test with some of the 
least variance between centres.  
 
The 14 different methods for making up the LDSST may be causing a marked 
variation in doses of Synacthen given. Synacthen is an inherently unstable drug, 
which rapidly degrades in natural light and when not refrigerated. Previous 
published work has shown Synacthen to bind to plastic, causing significant losses 
proportionate to the length of the plastic device used for administration 
(Murphy, Livesey et al. 1998, Wade, Baid et al. 2010). Inaccuracies increase with 
serial dilutions and the use of larger volume diluents. Diluting Synacthen using 
ward rather than accurate laboratory equipment and in uncontrolled conditions, 
with inter-individual differences in mixing strategies, is unlikely to create the 
desired equilibrium and thus cause variation in the doses being administered. 
The resultant effect may be of a greater range of cortisol responses and potential 
false negative results.  
 
 
2 Short Synacthen Tests performed in children with 
asthma on high-dose ICS 
 
This project audited how closely Sheffield Children’s Hospital (SCH) complied 
with the recommended guidelines for LDSST in children taking high-dose ICS, 
including the issuing of steroid treatment cards (MHRA 2006, BTS/SIGN 2008, 
MHRA/CSM 2008). In addition the local incidence of AI in children on HDICS was 
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sought and compared to published figures. This work was presented as a poster 
at the annual BSPED meeting in 2009, held in Reading, UK. 
 
2.1 Methods 
A retrospective review over two time periods: pre-recommendation introduction 
(January 2004 to December 2005) and post- recommendation introduction 
(January 2007 to December 2008) was carried out of children prescribed high-
dose ICS. Eighty-five cases were identified, from which 38 cases were prescribed 
high-dose ICS before the recommendations were published and 47 cases after. 
The criteria of a peak cortisol of >500 nmol/l or an incremental rise of >200 
nmol/l were selected for a normal LDSST.  
 
2.2 Results 
There were 14 requests for LDSST in children on HDICS between 2007 and 2008 
compared to 1 between 2004 and 2005, an increase from 2.6% to 30% of 
patients on HDICS. Using the criteria stated 5/14 (35%) of LDSST were abnormal, 
80% of whom were prescribed higher than the recommended dose of ICS. All 
children receiving high-dose ICS with AI were receiving corticosteroid 
replacement but there was no documentation of steroid treatment card 
provision or written advice to carers in the patient notes. 
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2.3 Discussion 
The published recommendations have led to an increase in the monitoring of 
children with asthma on high-dose ICS. The incidence of AI in the local 
population of children on high-dose ICS was similar to that reported elsewhere 
(Ninan, Reid et al. 1993, Eid, Morton et al. 2002, Paton, Jardine et al. 2006, Blair, 
Lancaster et al. 2013). It was unclear whether children and families were not 
receiving adequate advice and steroid treatment cards or whether 
documentation was poor. 
 
 
3 High-dose ICS and AI at Sheffield Children’s 
Hospital 
 
A project looking to establish practice within the respiratory department at SCH 
with respect to the issuing of steroid treatment cards to children prescribed 
doses of ICS higher than those recommended in the British National Formulary 
for Children (BNFc) 2009 was undertaken (Paediatric Formulary Committee 
2009). Additionally knowledge of the link between high-dose ICS and AI amongst 
medical staff was investigated. This work was presented as a poster at the annual 
European Society of Pediatric Endocrinology meeting in 2010, held in Prague, 
Czech Republic. 
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3.1 Method 
A retrospective audit was carried out between April and June 2009 in which 
cases of children prescribed higher than recommended doses of ICS were 
identified from the respiratory clinic database. Reviewing the patient notes and 
telephoning families ascertained information pertaining to steroid treatment 
cards and advice. In addition knowledge amongst paediatric and Emergency 
Department medical staff within the Trust was assessed by a 3-question, 
anonymous questionnaire survey ascertaining seniority, awareness of guidance 
and what dose of different ICS constitutes “high-dose”. 
 
3.2 Results 
Within the database 19 patients were identified, 15 of whom were contactable 
by telephone. The majority (11/19) were children less than 12 years of age, 
prescribed  >400 mcg fluticasone propionate daily. Steroid treatment cards had 
been issued to 40% of patients and 47% of families felt they had been made 
aware of the risks of high-dose ICS. A LDSST had been performed in 16%, all of 
which were normal (n=3).  
 
Of the 65 questionnaires distributed 19 were returned, a 29% response rate. The 
majority, 13/19, were completed by junior doctors (Foundation year 1 (FY1), GP 
trainees and Senior House Officers (ST1-ST3)). Registrars and consultants 
accounted for only 6/19 responses. The seniority of the doctor affected 
awareness of the published recommendations, with 8% of junior and 67% of 
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middle grade doctors reporting they had heard of them. There was also difficulty 
identifying what constitutes high dose of ICS, especially amongst the most junior 
medical staff (table 2.1). 
 
Table 2.1: ICS corrected identified as “high-dose” by medical staff stratified by 
seniority. 
Age group 
% correct responses given 
by junior doctors (FY1-
ST3). N=13 
% correct responses given 
by middle grade and senior 
doctors (>ST3). N=6 
0-4 year olds 74% 93% 
5-11 year olds 60% 78% 
12-16 year olds 68% 71% 
 
3.3 Discussion 
The results were discussed with respiratory colleagues who were concerned 
about reducing adherence in an already possibly poorly adherent population by 
“steroidophobia” and had therefore been reluctant to issue steroid treatment 
cards other than to children on very high doses. Additionally there was a 
reluctance to perform SSTs in this group because of a belief that most children, 
despite very high doses of ICS, do not have AI and that the SSTs lack the 
necessary sensitivity and specificity to predict clinically relevant AI, a view shared 
by others (Blair, Lancaster et al. 2013). 
 
Some confusion and lack of knowledge about what constitutes “high dose” may 
have been due to inconsistencies with the published recommendations. The 
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BNFc used terms for “standard” and “high” doses in their prescribing guidelines 
but the Medicines and Healthcare products Regulatory Agency (MHRA) 
recommendations quote maximum licenced doses, which are different to those 
given in the BNFc (BTS/SIGN 2008, MHRA/CSM 2008, Paediatric Formulary 
Committee 2009). The British Thoracic Society (BTS) states that suppression may 
occur at doses >400 mcg BDP/day or equivalent but does not age stratify 
(BTS/SIGN 2008, MHRA/CSM 2008, Paediatric Formulary Committee 2009).  
 
 
4 Assessment of GP asthma services and 
prescription of high-dose ICS 
 
Previously it had been reported that the prescription of high-dose and off-licence 
ICS was occurring in primary care (Thomas, Turner et al. 2006), and was not in 
keeping with published recommendations (BTS/SIGN 2008, MHRA/CSM 2008). 
Local GPs were therefore surveyed to quantify the number of children with 
asthma in their practice, their awareness of the risk of AI in children on high-dose 
ICS and their criteria for referral to specialist secondary/tertiary services. 
 
4.1 Method 
An 11-question questionnaire (appendix 2) was sent to 350 Sheffield GPs 
requesting information on their awareness of AI in children prescribed high-dose 
ICS, the doses prescribed and monitoring of children on high-dose ICS, whether 
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their practice had a designated asthma lead and their referral policy to 
secondary care. A 5-question questionnaire was sent to 92 GP practice managers 
for information on total number of children coded as having asthma and those 
prescribed high-dose ICS.  
 
4.2 Results 
There was a 15% response rate from both GPs and practice managers. In the 14 
responding practices that supplied information there were 1461 children with 
asthma, 92.5% of who were over 5 years of age. When asked about prescribing 
practice 51% prescribed high-dose budesonide, 42% high-dose fluticasone and 
8% high-dose beclomethasone. The referral of children with asthma to secondary 
care was generally prompted by persistent poor control, polypharmacy or 
multiple admissions and was generally (74%) to a respiratory paediatrician. In 
contrast to the junior hospital doctors, 96% of GPs responded that they were 
aware of the association between high-dose ICS and AI. 
 
4.3 Discussion 
GPs appear to have good knowledge of the link AI and high-dose ICS and refer 
appropriately. However there was a low response rate to the questionnaire and 
it is unknown whether the respondents were knowledgeable, interested in 
asthma and adhering to good practice. Additionally it is unknown whether the 
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There is considerable variation in practice within the UK and Eire as to how the 
SST is employed. A commercially produced 1 mcg Synacthen formulation would 
avoid the different dilution strategies and doses reported in the national survey. 
The adherence to and knowledge of national recommendations for children with 
asthma on high-dose ICS is poor, more evident in junior hospital doctors than 
GPs. Research enabling risk stratification of children at risk of AI due to high-dose 
ICS would enable more uniform recommendations, national consensus 
guidelines and less variance in practice. 
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To enable the pharmacokinetic analysis necessary to compare the bioavailability 
of nasal and i.v Synacthen an estimation of the plasma levels of Synacthen was 
required. Few previous researchers have measured Synacthen and there is no 
commercially available assay. Options to modify an existing ACTH assay were 
therefore investigated, an assay chosen and validation of that assay to measure 
plasma Synacthen performed. This chapter details the trial of numerous 
methodological variations and, despite acknowledged imperfections in the assay 
performance, eventual success when the assay was validated and considered fit 
for purpose.  
 
1 History of measuring plasma Synacthen 
 
Most of the studies to date looking at the optimal dose of Synacthen or 
alternative routes of administration have not measured plasma Synacthen 
directly, opting instead to compare a known quantity of intravenously injected 
Synacthen with the resultant cortisol response (Dickstein, Shechner et al. 1991, 
Dickstein, Spigel et al. 1997, Tordjman, Jaffe et al. 2000, Hiroi, Ichijo et al. 2002).  
 
In the small number of studies where plasma Synacthen levels have been 
quantified almost all groups have employed ACTH radioimmunoassays (RIA) for 
their sensitivity but also their relative lack of specificity, as they detect only the 
N-terminus of the ACTH molecule, shared by both ACTH and Synacthen. 
Quantification has been by a number of different methods, employing different 
anti-sera and using extraction or non-extraction techniques. Some researchers 
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have chosen to measure ACTH assuming the majority of what is detected 
following Synacthen injection is ACTH(1-24) rather than endogenous ACTH(1-39) 
(Mayenknecht, Diederich et al. 1998). Others have used ACTH RIAs which are 
thought to 100% cross-react with Synacthen (Wade, Baid et al. 2010). Some have 
used dexamethasone to suppress endogenous ACTH secretion, with the 
inference that when endogenous ACTH is suppressed anything detected is 
plasma Synacthen (Wuthrich, Martenet et al. 1994).  
 
The first reported measurement of Synacthen was in the 1970s when a number 
of groups employed the method first described by Orth et al, with Synacthen 
used to make up the assay kit standards and for the preparation of the 
radiolabelled iodinated hormone (ACTH 125I) (Orth, Nicholso.We et al. 1973, 
Jeffcoate, Phenekos et al. 1977). In the 1980s rabbit anti-sera directed against 
the ACTH(5-18) portion of the molecule began to be used and some commercial 
production started (Nicholson, Davis et al. 1984, Dickstein, Shechner et al. 1991, 
Darmon, Dadoun et al. 1999, Nye, Grice et al. 1999). Later that decade a C18 
Sep-pak extraction method was described to overcome the interference noted 
when using the rabbit antiserum, it was quoted as giving 80-90% recovery of the 
radiolabelled ACTH (Krishnan, Ritchie et al. 1988). A more recent publication 
described an extraction method and ACTH RIA with manufacturer-quoted 100% 
cross-reactivity with Synacthen. A chemiluminescent immunoassay measuring 
ACTH(1-39) was additionally employed and the endogenous ACTH assumed to be 
the difference between the two results. This group did not generate their own 
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control material, but did calculate coefficients of variation (CV) for ACTH(1-24) 
(Alia, Villabona et al. 2006). 
 
In a departure from traditional RIA methods, two groups have reported the 
results of Synacthen detection using liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) techniques. This has been investigated, both in urine 
and plasma, as a research tool for use in athletes misusing Synacthen as a 
performance-enhancing drug (Thevis, Bredehoft et al. 2006, Thomas, Kohler et 





Immunoassay describes any test in which the analyte of interest, usually a 
protein, is detected by use of a specific antibody. Once the antigen (analyte) and 
antibody have bound a method of detection (label) is attached. The label 
determines the type of immunoassay. A label may emit radiation (RIA); fluoresce 
under light (fluorescent immunoassay, FIA); cause a chemical reaction, which 
produces light (chemiluminescent immunoassay, CIA); be a DNA probe or emit 
light in response to an electrical current (electrochemiluminescence). Previously 
popular were enzyme labels which would chemiluminesce or cause a colour 
change or (enzyme-linked immunosorbent assays, ELISAs). Immunoassays may 
be competitive or non-competitive, one-site or two-site (sandwich); liquid or 
solid-phase and may have multiple steps in which reagents are added and 
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washed off (separation immunoassays) or be simple homogenous immunoassays 
(Christopoulos and Diamandis 1996).  
 
Immunoassays began being used in analytical laboratory medicine in the 1960s 
with the development of RIAs to detect a number of compounds including 
hormones, immunoglobulins and drugs. The first RIA to measure ACTH was 
described by Berson and Yalow in 1968 (Berson and Yalow 1968). Yalow went on 
to win a Nobel Prize for their work in 1977. More recently automated ELISAs, 
CIAs and FIAs, none of which require the handling and disposal of radioactive 
materials, have largely superseded RIAs. However RIAs still have a role detecting 
analytes that exist in very small amounts, like hormones, with high levels of 
sensitivity or small antigens with space for only one antibody binding site.  
 
2.1 Radioimmunoassays (RIAs) 
RIAs require a compound to act as an antigen and bind to a specific and 
complimentary antibody. RIA is inherently sensitive and the affinity of the 
antibody for the antigen confers its specificity. RIA requires the preparation of a 
radiolabelled form of the antigen to be measured and most usually entail 
labelling the tyrosine residues of the protein of interest with radioactive iodine 
(125I). Additionally RIA requires the substance to be measured to be available in 
pure form for antibody, tracer and calibrator production. RIA usually describes a 
competitive assay, where molecules compete for a single binding site on the 
antibody (Christopoulos and Diamandis 1996, Chaitoff 2008).  
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Double antibody methods (such as immunoradiometric assays, IRMA) are 
sandwich assays and require the antigen to have two (or more) binding sites 
conferring a superior measuring range to classical RIA. They have largely replaced 
classical RIAs in the measurement of ACTH due to greater sensitivity at the lower 
end. Additionally it is felt that single epitope detection, whilst identifying the 
intact ACTH(1-39) molecule, may additionally detect fragments of related 
molecules within the HPA-axis such as POMC, MSH, lipotropin, shorter ACTH 
analogues and endorphins (figure 1.2) (Talbot, Kane et al. 2003).  
 
2.1.1 Competitive RIAs 
 
The competitive technique entails adding known quantities of radioactive 
antigen (Ag*) and antibody (Ab) with unknown quantities of unlabelled antigen 
(Ag), (which maybe patient serum or a known standard). The Ag* and Ag 
compete to bind the antibody. The greater the quantity of unlabelled antigen 
that binds the more Ag* is left unbound and therefore the lower the ratio of 
antibody-bound-Ag* to free-Ag* (figure 3.1) (Chaitoff 2008). The competitive RIA 
technique must recognise the labelled and unlabelled antigen with the same 
affinity. Additionally it is important that the ligand-binding capacity of the 
antibody is not compromised by the presence of excess tracer such that half the 
tracer is displaced if half of the antibody sites are saturated with antibody. To 
this end antibody and tracer concentrations are varied during assay development 
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Figure 3.1 : Schematic diagram of a competitive radioimmunoassay. Features of the 
assay used in the current work are shown in red. *indicates radioactive labelling. Ag = 




The antigen-antibody complexes need to be separated from the free fraction 
prior to determining the radioactivity. The separation (of bound and free 
fractions) is usually achieved with the addition of a precipitant solution 
containing a second antibody, which binds to the antigen-antibody complex, 
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then	   removed	   either	   by	   decanting	   or	   aspiration.	   Other	   separation	   methods	  
include	  filtration	  and	  the	  use	  of	  a	  solid	  phase	  second	  antibody.	  The	  radioactivity	  
of	  the	  remaining	  antigen-­‐antibody	  complexes	  is	  quantified	  and	  the	  concentration	  
of	  the	  unknown	  sample	  determined	  by	  comparing	  the	  ratio	  of	  antibody-­‐bound-­‐
Ag*:free-­‐Ag*,	   with	   that	   produced	   by	   a	   series	   of	   standards	   containing	   known	  
amounts	  of	  the	  substance	  (unlabelled	  antigen,	  Ag)	  tested	  at	  the	  same	  time	  and	  










Figure	   3.2:	   Standard	   calibration	   curve	   for	   a	   competitive	   RIA.	   The	   curve	   is	   used	   to	  
determine	  the	  antigen	  concentration	  in	  a	  patient	  sample,	  example	  shown	  in	  red.	  	  
	  
A	   typical	   RIA	   dose-­‐response	   curve	   is	   sigmoidal	   as	   the	   addition	   of	   increasing	  
amounts	   of	   antigen	   progressively	   displaces	   Ag*	   from	   the	   antibody	   but	   with	  
saturation	  at	  high	  concentrations.	  The	  sigmoidal	  curve	  is	  logit	  transformed	  such	  
that	  the	  x-­‐axis	  of	  the	  dose-­‐response	  curve	   is	  expressed	  as	  a	   log,	  converting	  the	  
concentration	   of	   double	   diluted	   standards	   to	   linear	   for	   simpler	   numerical	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quantification	   (Personal	   communication,	   Martin	   Loxley)(Christopoulos	   and	  
Diamandis	  1996).	  	  
	  
2.1.2 Sandwich	  RIAs	  
 
Sandwich	  RIAs	  are	  a	  type	  of	  IRMA,	  which	  are	  non-­‐competitive	  in	  design	  and	  have	  
enhanced	  sensitivity	  over	  classical	  RIA.	  In	  IRMA	  it	  is	  the	  antibody	  that	  is	  labelled	  
so	  antigen	  and	  labelled	  antibody	  form	  complexes	  when	  incubated.	  The	  sandwich	  
format	  is	  a	  two-­‐site	  IRMA	  with	  two	  antibodies	  and	  detects	  two	  separate	  epitopes	  
of	   the	   antigen	   of	   interest.	   It	   requires	   two	   different	   antibodies,	   one	   which	  
captures	  and	  one	  which	  is	  radiolabelled	  (usually	  125I)	  and	  is	  used	  for	  detection.	  It	  
is	  a	  solid	  phase	  method,	  in	  which	  a	  “capture”	  antibody	  is	  immobilised	  (e.g.	  bound	  
to	  insoluble	  polystyrene	  beads	  or	  coated	  tubes)	  and	  binds	  the	  free	  fraction.	  The	  
unbound	  free	  fraction	  is	  washed	  away.	  The	  labelled	  antibody	  is	  then	  added	  and	  
binds	   at	   a	   separate	   site	   thus	   allowing	   detection	   and	   quantification	   of	   antigen.	  
Monoclonal	   antibodies	  are	  often	  used	  as	   they	  enable	   specific,	   non-­‐overlapping	  
epitopes	  of	  the	  antigen	  to	  be	  targeted.	  As	  this	  is	  non-­‐competitive,	  the	  amount	  of	  
antigen	  determined	  by	  the	  amount	  of	  bound	  fraction	  directly	  correlates	  unlike	  in	  
a	  competitive	  RIA	  where	  the	  amount	  of	  substance	  is	  inversely	  proportional	  to	  the	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3 Selecting a Synacthen assay 
 
The majority of ACTH assays currently in commercial use employ a “sandwich” 
analytical technique with monoclonal antibodies in a 2-site immunometric 
format, requiring the binding of two epitopes for detection (CIA or IRMA) (Pecori 
Giraldi, Saccani et al. 2011). The two epitopes are generally found at, or near the 
N and C termini respectively. The sandwich technique results in a complete lack 
of detection of Synacthen because, although the N-terminus is shared by 
ACTH(1-39) and its synthetic analogue Synacthen, the C-terminus is truncated 
and therefore is not recognized by the assay’s antibody.   
 
High Performance Liquid Chromatography (HPLC) was considered as a potential 
method of detection and quantification. Initially this method was explored locally 
but it was felt by laboratory colleagues to be excessively time–consuming and 
require considerable expertise to set up, especially in view of the need for a 
sensitive enough detector, with no guarantee of success. Additionally it was 
thought to be an inefficient method for the processing of hundreds of samples. A 
Synacthen HPLC is used by Archimedes Pharmaceuticals Ltd (Nottingham, UK), 
the pharmaceutical company whom manufactured the Synacthen doses for use 
in the second part of the project (NeSST2 study). They investigated whether it 
would be an appropriate technique for analysis of the volunteer plasma 
Synacthen samples in this work, however the lowest concentration detectable 
was found to be 0.5 mcg/ml, approximately 2000 times greater than the pg/ml 
plasma levels it would be required to detect.  
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Bachem (Bupendorf, Switzerland; the pharmaceutical company from whom the 
tetracosactide was purchased for manufacturing in NeSST2) and Alliance 
Pharmaceuticals (Wiltshire, UK; the company with the marketing authorisation 
for Synacthen in the UK) both use HPLC for the analytical work involved in quality 
controlling their products. Enquiries regarding whether their techniques were 
sensitive enough to be used in the analysis of our samples were made to both 
companies. The lower limit of detection of their HPLC methods was considerably 
higher than required. It was advised that to quantify down to the necessary 
concentration HPLC with detection by mass spectrometry would be needed. 
 
The head of the German group (Professor Thevis) who have developed a LC-
MS/MS method for the detection of Synacthen in doping tests was contacted for 
advice about adopting their method or for their assistance in processing the 
samples. The reply (June 2010) stated two major issues with Synacthen detection 
making the use of LC-MS/MS unviable. The German group had validated the LC-
MS/MS assay for detection of depot formulations of 1mg Synacthen (1000 times 
greater than the doses administered in the NeSST study). At these doses the LC-
MS/MS technique is already at the limit of its detection at the lower range. It was 
felt with considerably smaller doses, such as those following intranasal 
administration, the technique would not be adequately sensitive. The second 
concern was regarding the stability of Synacthen, recognising that it is not stable 
in plasma or urine and therefore rapid degradation may make detection even 
more challenging. They were unaware of any other laboratory doing analysis of 
this kind.  
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Mid-way through the study a paper from a French group was published 
describing improved sensitivity and limits of detection of Synacthen using cation 
exchange chromatography and solid-phase extraction and analysis by LC-MS/MS 
with positive-mode electrospray ionization using ACTH(7-38) as an internal 
standard. The recovery was quoted as 70% and lower limit of quantification as 15 
pg/ml (Chaabo, Ceaurriz et al. 2011). When contacted the corresponding author 
(Dr Lasne) responded that the technique developed did not provide enough 
recovery of Synacthen after the preparation step to be useful, being more a test 
of Synacthen presence than accurately quantifying plasma levels. 
 
On discussion with laboratory colleagues in Sheffield, it was felt that developing 
a sensitive enough LC-MS/MS technique may take years, if possible at all, and 
therefore the RIA, accepting its flaws, was chosen as the best assay available for 
the study. The single epitope RIAs used in the studies described above (section 1) 
are mostly out of production, having been superseded initially by more specific 
two-site IRMAs (Gibson, Pollock et al. 1989) and more recently by non-
radioisotopic, fully-automated techniques (Talbot, Kane et al. 2003). The RIA 
selected was sourced after extensive searching by the senior biomedical scientist 
(BMS) in the local endocrine laboratory and was thought to be the only assay 
available that had an antibody capable of detecting an epitope within the 
Synacthen molecule. It was an endogenous ACTH(1-39) assay which 
manufacturers, MP Biomedicals (Santa Ana, CA, USA), quote as cross-reacting 
100% with Synacthen and was later discovered to have been successfully 
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validated for plasma Synacthen detection by other researchers (Wade, Baid et al. 
2010).  
 
3.1 Selected assay characteristics 
The MP Biomedicals human ACTH (hACTH) RIA is a competitive RIA in which the 
antibody recognises human ACTH(5-18). This assay was selected for its quoted 
cross-reactivity with Synacthen (table 3.1). 
 
Table 3.1: Specificity of the antiserum of the MP Biomedicals hACTH RIA. Reproduced 
with permission from MP Biomedicals’ directional insert for hACTH RIA kit. 
Compound % Cross-reaction 
ACTH (1-39) 100 








The company quotes the minimum detectable dose to be approximately 5.7 
pg/ml. This had been ascertained by running 20 replicates of the zero standard 
and subtracting two standard deviations from the mean of the zero tubes, the 
standard calculation method for limit of detection (Rodbard 1978, MP 
Biomedicals 2012).  
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MP Biomedicals have calculated the intra (within batch) and inter-assay 
(between batch) variations for their assay using ten sets of data (table 3.2).  
 
Table 3.2: Intra-assay and inter-assay variation of MP Biomedicals hACTH RIA. 
Reproduced with permission from MP Biomedical directional insert for hACTH RIA kit. 
Values are in pg/ml. 
 Intra-assay variation (n=10) Inter-assay variation (n=10) 
Mean 40.9 139 36.3 107.5 
S.D 2.8 5.7 3.9 4.2 
C.V 6.8% 4.1% 10.7% 3.9% 
 
 
The kits are designed for human EDTA plasma samples and contain the following: 
 Eight ACTH(1-39) lyophilised standards 
o At the following target concentrations: 0, 10, 25, 50, 100, 250, 
500, 1000 pg/ml in human plasma 
 Anti-ACTH  
o A purified porcine ACTH-conjugate is used to generate this 
antiserum in rabbits 
o Diluted in a phosphate buffer to give pH 7.6 
o The anti-serum binds 20-40% of hACTH 125I (freshly iodinated) in 
the absence of nonradioactive hACTH 
 ACTH controls  
o A high and low concentration of ACTH added to human plasma  
 hACTH125I 
o Synthetic hACTH(1-39) 
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o Diluted in a phosphate buffer to give pH 7.6 
o This radioactive material contains less than 0.4 μCi (microcurie) 
per vial 
 Precipitant solution 
o Mixture of goat anti-rabbit gamma globulins and PEG 
(polyethylene  
glycol) is contained in a 0.1M Tris buffer 
o 0.5 ml will immediately precipitate all the antibody bound antigen, 
eliminating the need for a second incubation. 
 Polystyrene test tubes (uncoated) as it is advised not to use glass test 
tubes due to previous research showing adsorptive losses (Stouffer and 
Lipscomb 1963). 
 
MP Biomedicals quote the performance characteristics of their kit constituents, 
which were tested against standardised WHO 74/555 ACTH preparations (table 
3.3). 
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Table 3.3: Performance characteristics of MP Biomedical hACTH RIA. Adapted and 








Sample A = 40 pg/ml 
12.5 52.5 56 107 
25 65 70 108 
50 90 92 102 
125 165 180 109 
Sample B = 11 pg/ml 
12.5 23.5 23 98 
25 36 37 103 
50 61 64 105 
125 136 145 107 
Sample C = 20 pg/ml 
12.5 32.5 32 98 
25 45 45 100 
50 70 74 106 
125 145 150 103 
Sample D = 23 pg/ml 
12.5 35.5 37 104 
25 48 52 108 
50 73 76 104 
125 148 160 108 
 
 
The company additionally quote the response to serial dilution using four plasma 
samples diluted 1:2, 1:4, 1:6, 1:8 with the zero standard (table 3.4). 
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Table 3.4: Parallelism of MP Biomedicals hACTH RIA. Adapted and reproduced with 
permission from MP Biomedical directional insert for hACTH RIA kit. Values are in pg/ml 
with means in red. Dil = diluent 
Sample 1:2 ACTH 1:4 ACTH 1:6 ACTH 1:8 ACTH Mean 
A (225) 120 58 39 28  
A x dil 240 232 234 224 232.5 
B (370) 190 96 67 47  
B x dil 380 384 402 376 385.5 
C (550) 290 140 100 70  
C x dil 580 560 600 560 575 
D (760) 370 195 135 96  
D x dil 740 780 810 768 774.5 
 
 
4 Validation experiments 
 
The intention was to perform a series of dilution experiments prior to the 
analysis of volunteer samples, which would allow validation of the ACTH RIA, 
gain knowledge of its working characteristics and to ensure it reliably detected 
Synacthen. This proved considerably more difficult than anticipated, taking more 
than two years to successfully validate the assay. All experiments were 
undertaken in the manual endocrine laboratory at the Royal Hallamshire 
Hospital’s Clinical Chemistry department using accurate, calibrated laboratory 
equipment.  
 
As a clinician, with an ostensibly clinical project, much of the Synacthen assay 
validation work was considerably outwith my area of expertise. Close supervision 
was provided by Martin Loxley (ML), laboratory manager at the Department of 
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Clinical Chemistry, Royal Hallamshire Hospital, who has an extensive theoretical 
and working knowledge of RIA. ML and Victoria Moyse (VM) (senior BMS) 
provided training on the setting up and running of the assay, the laboratory 
equipment involved, appropriate handling of radioactive materials and safe 
laboratory practice. All the practical aspects of the laboratory work (except for 
validation experiment 1, during which ML trained me and experiment 11, which 
was carried out by VM to ensure that any inconsistency in results were not due 
to my relative laboratory inexperience) were performed by the author. However 
ML, with some input from VM, interpreted the results and suggested the 
methodology and theory behind each progressive attempt at assay validation. 
My contribution to this process increased over time as my understanding 
deepened. 
 
Two preparations of Synacthen are commercially available in the UK (Alliance 
Pharmaceuticals, Chippenham, Wiltshire, UK). A 1 mg depot preparation and a 
250 mcg/ml formulation used for all the assay validation experiments. The 
hACTH RIA detects ACTH in picomolar amounts and thus large dilutions were 
required to bring the Synacthen into a detectable range. Particular care was 
therefore taken to pipette accurately and mix solutions by vortexing thoroughly. 
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4.1 Set up and running of MP Biomedicals’ hACTH RIA 
 Step 1: The lyophilised reagents (hACTH standards, high and low quality 
controls, antiserum (Ab) and labelled antigen (hACTH-125I)) were 
reconstituted with water and refrigerated for a minimum of 15 minutes. 
 Step 2: Polystyrene test tubes were labelled (totals, blanks, standards 8 to 1, 
low and high quality controls and then sample tubes).  
 Step 3: The diluent water, hACTH standards, controls, samples, antiserum 
and hACTH-125I were added to the test tubes as illustrated in figure 3.3. A 
finnipipette 4540 (Thermo scientific, Waltham, MA, USA) with 2.5ml tip and 
wheel dial 1 was used to repeat pipette the antiserum and hACTH-125I. All 
standards, controls and samples were run in duplicate unless otherwise 
stated.  
 Step 4: The tubes were shaken for 30 seconds, then vortexed and incubated 
in the refrigerator until the following day (minimum 16 hours). 
 Step 5: Following incubation, samples had precipitant solution by a 
finnipipette 4540 (Thermo scientific, Waltham, MA, USA) with 25.0 ml tip 
and wheel dial 1 and were again shaken for 30 seconds and then vortexed 
thoroughly, ensuring a homogenous colour throughout. 
 Step 6: The samples were then centrifuged in a CellSep 6/720R centrifuge 
(Sanyo, Moriguchi, Osaka, Japan) at 3000 x g for 15 minutes at a 
temperature of 8c. 
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 Step 7: The supernatant was aspirated and the remaining precipitate 
counted in a DPC gamma C12 counter (Berthold technologies, Bad Wildbad, 
Germany). 
 Step 8: AssayZap 3.1 (Biosoft, Palo Alto, CA, USA), assay calculator software, 
was used to generate a standard curve and derive sample results. 
 
All RIA kits were used within the 5-week expiry window and most within a 
fortnight of production, ensuring maximum sensitivity. Tracer decay reduces the 
sensitivity of the assay as the counts become lower and the curve becomes 
flatter resulting in less differentiation between values. In all experiments 
standards and samples were run in duplicate unless otherwise stated. When 
poor duplicates were obtained the likely erroneous result was excluded. 
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Figure 3.3: Protocol for MP Biomedical hACTH RIA. Instruction for use: ImmuChem 
Double Antibody hACTH 125I RIA kit (MP Biomedicals 2012). Reproduced with permission 
from MP Biomedicals. 
 
4.1.1 Quality Controls (QCs) and Coefficient of Variations (CVs) 
A high and low QC was supplied with the hACTH RIA kit. These help to give an 
estimate of inter-assay (batch-to-batch) variability with repeated analysis. As 
there is no independently sourced material containing Synacthen (Alliance 
Pharmaceuticals have the Marketing Authorisation and are the sole supplier of 
Synacthen in the UK) the kit ACTH QCs were used for experiments 1-14. 
The QCs quoted for the kit were: 
 Low 43 (33-53 pg/ml) 
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 High 121 (100-142 pg/ml) 
 
These ranges enable the calculation of inter-assay coefficient of variations (CVs), 
an estimation of measurement error and therefore represent the acceptable 
range for the dispersion of results between assay batches. CVs are a ratio of the 
standard deviation (SD) to the mean and are expressed as a percentage. 
 
Standard laboratory practice (Levey-Jennings method) is to accept an assay when 
QCs are within +/- 2 SDs. Results between 2-3 SDs acts as an alert that a 
laboratory should be aware of a potential flaw and if more than +/- 3 SDs the 
results would be rejected (personal communication, ML). 
 
For the low QC, 33-53 pg/ml a range of 20 pg/ml is given, this represents 4 SDs 
(+/- 2) and thus 1 SD is 5 pg/ml. Similarly for the high QC, the range of 100-142 is 
42 pg/ml, so that 1 SD is 10.5 pg/ml.  
 Low QC - the inter-assay CV is therefore 5/43 = 11.6%. 
 High QC - the inter-assay CV is therefore 14/121 = 8.7%. 
Inter-assay CVs of around 10% are typical for a competitive RIA of this type 
(personal communication, ML). If one uses a cut-off of 3 SDs then acceptable 
results are 28-58 pg/ml for the low QC and 89.5-152.5 pg/ml for the high QC. 
These were the ranges used to assess the QC results obtained with each assay 
(vide infra, table 3.23). 
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No assessment of intra-assay variability (within batch), where the same samples 
are run multiple times on the same assay, was performed. Inter-assay variability 
is a more useful metric of assay performance and has typically higher values than 
intra-assay variability. It was felt that establishing intra-assay variability would 
take up a large number of tubes in an already expensive assay without adding 
significant meaningful information concerning the practical aspects of the assay. 
 
The experiments undertaken to validate the assay for the quantification of 
Synacthen are described in detail below (section 4.2 – 4.20). A summary table of 
the experiments is included below (table 3.5).  
  




Summary of theory behind experiment Summary of methodology Summary of results 
1 Simple serial dilution experiment to find sensitive 
part of the RIA measuring curve. 
Dilution of 250mcg/ml Synacthen in 0.9% saline to give 
7 concentrations from 250,000 to 31.3 pg/ml. 
All samples over the upper limit of assay 
detection. 
2 
Repeat of serial dilution experiment to find the 
most sensitive part of the RIA measuring curve. 
Dilution of 250mcg/ml Synacthen in 0.9% saline to give 
7 concentrations from 250 to 3.9 pg/ml. 
No obvious relationship between observed and 
expected values, however some samples on scale 
and approximately 250 pg/ml appeared to be 
most sensitive part of the curve. 
3 
Synacthen is an inherently unstable protein 
therefore its degradation in room temperature 
was tested. 
Three concentrations of Synacthen (25, 5 and 2.5 
pg/ml) were diluted in 0.9% saline and left for 
between 0 minutes and 24 hours (8 time points) at 
room temperature. 
All samples over the upper limit of assay 
detection. 
4 Investigation of the matrix effect – using a more 
physiological matrix may enable Synacthen to 
retain its 3D configuration and be detected by 
the RIA.  
Dilution of 250mcg/ml Synacthen in 0.9% saline and 
PBS BSA* to give 9 concentrations from 1000 to 3.9 
pg/ml. Controlled temperature variation more closely 
(for all experiments thereafter). 
Some linearity between observed and expected 
values for saline samples between 150-500 
pg/ml. PBS BSA showed minimal detection of 
Synacthen. 
5 
Repeat of experiment 4 with controlled 
temperature conditions and saline as diluent. 
Dilution of 250mcg/ml Synacthen in 0.9% saline to give 
11 concentrations from 1000 to 31.3 pg/ml.  
Linearity of experiment 4 not replicated. All 
samples much lower than expected values with 
no discernable relationship. 
6 
Matrix effect investigated again. 
Dilution of 250mcg/ml Synacthen in 0.9% saline, 
PBS** and PBS BSA* to give 5 concentrations from 
2500 to 125 pg/ml. Controlled temperature 
conditions. 
Similar results obtained from saline and PBS 
samples, both lower than expected but some 
degree of linearity. Results from PBS BSA samples 
higher than expected.  
7 
Use of stock solution to remove the possibility of 
dilution errors. 
Stock solutions of dilutions of 250mcg/ml Synacthen in 
0.9% saline and PBS giving 6 concentrations from 750 
to 125 pg/ml were made up and run on three different 





 runs showed consistency for saline and 
PBS and yet different from each other. The 2
nd
 
run gave higher results for both and more similar 
to one another. Although limited interpretation 
possible PBS appeared the better matrix. 
8 
Matrix effect investigated again. 
Dilution of 250mcg/ml Synacthen in ACTH deplete, 
pooled human EDTA plasma to give 7 concentrations 
from 750 to 94 pg/ml. 
No obvious relationship between observed and 
expected values with samples much higher than 
anticipated. ACTH depletion not successful – high 
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ACTH in pooled plasma. 
9 Use of external quality assurance samples to test 
ability of RIA to detect ACTH. 
Three external quality assurance samples run in RIA 
and compared to UKNEQAS
$
 results 
Results considerably higher than expected from 
UKNEQAS even when bias correction was applied.  
10 Re-analysis of research samples to investigate 
inter-assay reliability. 
Three volunteer samples from NeSST Study rerun with 
11-month lag and additional freeze-thaw cycle. 




Use of an acidified buffer to replicate previously 
published work. 
Dilution of 250mcg/ml Synacthen in PBS BSA acidifed 
to pH to give 12 concentrations from 1000 to 23.5 
pg/ml. Samples run in quadruplicate and assay set up 
and run by senior BMS. 
Acidified buffer with no Synacthen recorded 
measurable ACTH. A relationship between 
observed and expected was seen whereby for 
each 1:1.5 dilution between 187.5-23 pg/ml a 1.4 
fold concentration reduction was noted. 
12 
Use of external quality assurance samples to test 
ability of RIA to detect ACTH again. 
Three external quality assurance samples run in 
quadruplicate and compared to UKNEQAS
$
 results 
Results considerably lower than expected from 
UKNEQAS even when bias correction was applied. 
Possible effect of freezing the NEQAS standards. 
13 
Matrix effect investigated using spiked human 
plasma. 
ACTH depleted human blood was spiked with 
Synacthen to give 2 concentrations 250 and 124 
pg/ml. Samples run in sextruplicate and assay set up 
and run by senior BMS. 
Values higher than expected, with considerable 
variability between samples of the same 
concentration. Unspiked control had much higher 
ACTH than when run on Immulite. 
14 
Re-analysis of research samples to investigate 
inter-assay reliability. 
Seven volunteer samples were re-run 17 months after 
the initial analysis and with an additional freeze-thaw 
cycle.  
Results were 2.1-3 fold lower than those obtained 
previously.  
15 
Create standards using the same buffer as in the 
assay 
Dilution of 250mcg/ml Synacthen in MP Biomedicals 
hACTH RIA zero standard to give 7 serial 
concentrations from 1000 to 15.6 pg/ml. Samples 
made up and frozen then run on 3 separate assays. 
All three runs showed similar results with close 
relationship between observed and expected 
values. 
16 Test of repeatability and reliability of assay using 
Synacthen standards 
Synacthen standards made as part of experiment 15 
were frozen and run with each assay. 
Very good linearity and correlation between 
observed and expected. 
 
*PBS BSA - Phosphate buffered saline with bovine serum albumin    ** PBS - Phosphate buffered saline    $ - UKNEQAS – UK National External Quality Assessment Service   BMS – Biomedical Scientist
4.2 Validation experiment 1 
4.2.1 Aim 
The aim was to validate the assay prior to the analysis of volunteer samples by 
performing serial dilution experiments. This would allow its working 
characteristics to be ascertained and to ensure it reliably detected Synacthen. 
 
4.2.2 Method 
The first experiment involved dilution of Synacthen (250 mcg/ml) in 0.9% saline 
to give the concentrations given in table 3.6a. 
 
Table 3.6a: Dilution ratios, summarised method and resultant solutions of experiment 
1 – serial Synacthen dilution in 0.9% saline. Final solutions assayed displayed in bold. 
Dilution ratio Dilution method Resultant concentration 
1:1000 0.1ml of 250 mcg/ml Synacthen in 99.9ml of 0.9% 
saline 
250,000 pg/ml 
1:25 0.4 ml of resultant solution in 9.6 ml of 0.9% saline 10,000 pg/ml 
1:10 0.1 ml of resultant solution in 0.9 ml of 0.9% saline 1000 pg/ml 
1:4 0.5 ml of resultant solution in 2 ml of 0.9% saline 250 pg/ml 
1:2 1 ml of resultant solution in 1 ml of 0.9% saline 125 pg/ml 
1:2 1 ml of resultant solution in 1 ml of 0.9% saline 62.5 pg/ml 








Table 3.6b: Experiment 1 – serial Synacthen dilution in 0.9% saline. Raw data and 
mean of duplicate results are displayed. Standards and QCs shown.  
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max* 
Standard 7 535 513.5 
Standard 6 255 246.2 
Standard 5 86 90.3 
Standard 4 39 37.0 
Standard 3 19 21.1 
Standard 2 8 < min** 
Low Quality control (QC) 43 (28-58) 44.0 
High Quality control (QC) 121 (89.5-152.5) 150.7 
Sample 1 250,000 > max* 
Sample 2 10,000 > max* 
Sample 3 1000 > max* 
Sample 4 250 > max* 
Sample 5 125 > max* 
Sample 6 62.5 > max* 
Sample 7 31.3 > max* 
* > max = more than maximum standard measurable by hACTH RIA (> 1098 pg/ml) 
** <min = less than the minimum standard measurable by hACTH RIA (< 8 pg/ml) 




Despite acceptable QCs and a reasonable fit standard curve all the dilution 
samples were above the measurable scale. This was unexpected as a large range 
had been tested (250,000 – 31.3 pg/ml) and the standard curve range indicated 
that the detectable range would be between those values.  
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Despite plotting expected (assumed Synacthen concentration following dilution) 
against observed (RIA results obtained) values the expectation was not to see 
identical or even similar values. It was acknowledged that Synacthen was likely to 
behave differently from ACTH(1-39) and would not cross-react in identical 
amounts. To validate the assay for the detection of Synacthen a consistent and 
interpretable relationship between observed and expected values was required.   
 
 
4.3 Validation experiment 2 
4.3.1 Method 
Following the disappointing results of the first serial dilution experiment the 
range was extended down to 3.9 pg/ml although it was thought that the most 
sensitive part of the assay curve was likely to be around 250 pg/ml. The 250 
mcg/ml Synacthen was again diluted in 0.9% saline to give the following 
concentrations. 
 
Table 3.7a: Dilution ratios, summarised method and resultant solutions for experiment 
2. The final solutions assayed displayed in bold. 
Dilution ratio Dilution method Resultant 
concentration 
1:100 0.1ml of 250mcg/ml Synacthen in 9.9 ml of 0.9% 
saline 
 2500 ng/ml 
1:100 0.1ml of 2500ng/ml solution in 9.9 ml of 0.9% saline 25,000 pg/ml 
1:100 0.1ml 0f 25,000pg/ml solution in 9.9 ml of 0.9% saline 250 pg/ml 
1:2 1 ml of resultant solution in 1 ml of 0.9% saline 125 pg/ml 
1:2 1 ml of resultant solution in 1 ml of 0.9% saline 62.5 pg/ml 
1:2 1 ml of resultant solution in 1 ml of 0.9% saline 31.3 pg/ml 
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1:2 1 ml of resultant solution in 1 ml of 0.9% saline 15.6 pg/ml 
1:2 1 ml of resultant solution in 1 ml of 0.9% saline 7.8 pg/ml 




Table 3.7b: Experiment 2: raw data and the mean of duplicate results. Standards and 
QCs shown. 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 474.1 
Standard 6 255 266 
Standard 5 86 73.3 
Standard 4 39 43.5 
Standard 3 19 23.0 
Standard 2 8 < min 
Low Quality control (QC) 43 (28-58) 28.5 
High Quality control (QC) 121 (89.5-152.5) 122.1 
Sample 1 250 894.4 
Sample 2 125 212.3 
Sample 3 62.5 52.4 
Sample 4 31.3 < min 
Sample 5 15.6 < min 
Sample 6 7.8 12.6 
Sample 7 3.9 < min 
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Figure	  3.4:	  Validation	  experiment	  2:	  Scatter	  graph	  depicting	  the	  relationship	  between	  
observed	  and	  expected	  values	  when	  Synacthen	  is	  serially	  diluted	  in	  0.9%	  saline.	  Values	  
less	  than	  the	  minimum	  standard	  are	  plotted	  as	  7	  pg/ml.	  Line	  denotes	  perfect	  positive	  
correlation	  (ideal	  fit).	  	  
	  
4.3.3 Interpretation	  
The	  QCs	  were	  acceptable	  and	  the	  standard	  curve	  a	  reasonably	  good	  fit.	  This	  was	  
the	   first	   assay	   set	   up	   and	   run	   by	   the	   author	   and	   the	   results	   showed	   poor	  
correlation	  between	  the	  duplicate	  samples.	  The	  results	  reflected	  the	  prediction	  
that	  the	  most	  sensitive	  part	  of	  the	  curve	  was	  around	  250	  pg/ml.	  The	  curve	  (vide	  
supra	  figure	  3.4)	  may	  appear	  logarithmic,	  or	  to	  be	  the	  bottom	  part	  of	  a	  sigmoidal	  
curve,	  however	  there	  are	  too	  few	  data	  points,	  with	  the	  possible	  undue	  influence	  
of	  outliers,	  to	  draw	  significant	  conclusions.	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4.4 1 mcg dilution accuracy experiment (performed between 
validation experiments 2 and 3) 
Having selected 250 pg/ml as the most sensitive part of the curve an experiment 
was carried out looking at the reliability and accuracy of diluting Synacthen to 1 
mcg for use in the low-dose Short Synacthen Test (LDSST). The literature 
describing dilution strategies for the LDSST coupled with the recent British 
Society of Paediatric Endocrinology and Diabetes (BSPED) survey had revealed 
more than 14 different dilution methods (Elder, Sachdev et al. 2012).  
 
In this experiment ten of the dilution strategies were chosen (based on 
popularity) and replicated five times, with three samples taken from each bag of 
diluent. These 150 samples were diluted in 0.9% saline to a presumed 
concentration of 250 pg/ml and run in duplicate on the hACTH RIA. The results 
were all below the lower limit of detection. Higher concentration solutions (from 
the same 1 mcg dilution accuracy experiment), which had been stored for six 
weeks and frozen at -20°C, were run. The 25,000, 10,000 and 5000 pg/ml 
samples analysed were all below the lower limit of detection. 
 
It was thought that these results may have been due to the inherent instability of 
Synacthen, with rapid degradation at room temperature. The experiment making 
up the 1 mcg dilutions of Synacthen and sampling from them had been 
performed on a hot day in July 2010, with faulty air conditioning in the 
laboratory. Samples were left unrefrigerated for considerably longer than would 
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be recommended due to the large numbers and this is likely to have resulted in 
degradation of the Synacthen to undetectable levels.  
 
 
4.5 Validation experiment 3 – Synacthen stability 
It is widely recognised that ACTH and Synacthen rapidly degrade. Little exists in 
the literature about Synacthen stability. Alliance Pharmaceuticals were 
approached but were unable to provide stability data. They recommend that 
Synacthen be protected from light as it rapidly degrades and should be stored 
between 2-8°C and not be exposed to temperatures of more than 8°C for more 
than a few hours (personal communication, Alliance Pharmaceuticals, Wiltshire, 
UK). A group using the MP Biomedicals hACTH RIA reported no difference 
between results of Synacthen samples processed immediately and those left at 
room temperature for 60 minutes (Wade, Baid et al. 2010). They did however 
find, as others have before, that plastic tubing reduces recovery of Synacthen 
(22-59% loss), presumed to be by adsorptive losses (Murphy, Livesey et al. 1998, 
Wade, Baid et al. 2010). In view of the stability concerns following the 1 mcg 
dilution accuracy work an experiment was devised to look at Synacthen 




Synacthen stability was assessed by testing three different concentrations, 
diluted in 0.9% saline, and leaving them for increasing lengths of time at room 
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temperature prior to freezing. The final three Synacthen concentrations (25 
pg/ml, 5 pg/ml and 2.5 pg/ml) were separated into eight aliquots of 
approximately 1 ml each. The first was frozen immediately, the others were left 
at room temperature for the following times: 15 minutes, 30 minutes, one hour, 
two hours, four hours, six hours and 24 hours. All samples were frozen at -20°C 
and were then thawed, vortexed and run six days later.  
 
Table 3.8a: Dilution ratios, summarised method and resultant solutions of experiment 
3. Final solutions assayed displayed in bold. 
Dilution ratio Dilution method Resultant 
concentration 
1:100 0.1ml of 250mcg/ml Synacthen in 9.9 ml of 0.9% 
saline 
 2500 ng/ml 
1:100 0.1ml of 2500ng/ml solution in 9.9 ml of 0.9% saline 25,000 pg/ml 
1:100 0.1ml 0f 25,000pg/ml solution in 9.9 ml of 0.9% saline 250 pg/ml 
1:10 1 ml of 250 pg/ml solution in 9 ml of 0.9% saline 25 pg/ml 
1:50 0.2 ml of 250 pg/ml in 9.8 ml of 0.9% saline 5 pg/ml 
1:100 0.1 ml of 250 pg/ml in 9.9 ml of 0.9% saline 2.5 pg/ml 
 
  




Table 3.8b: Standards and QCs shown for experiment 3. The mean of duplicate results 
displayed. 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 229.9 
Standard 6 255 129.3 
Standard 5 86 86.1 
Standard 4 39 37.2 
Standard 3 19 26.9 
Standard 2 8 < min 
Low Quality control (QC) 43 (28-58) 61.5 
High Quality control (QC) 121 (89.5-152.5) 80.5 
 
All the samples from all three dilutions and at all time points gave results more 
than the maximum standard.  
 
4.5.3 Interpretation 
These results were very unexpected, especially in view of the low concentrations 
chosen to test, and were in stark contrast to those obtained previously. The 
standard curve and QCs, although poor, were not felt to be an adequate 
explanation. A dilution error may have occurred such that higher concentrations 
than thought were being tested. An alternative interpretation is that the 
disparity was due to a matrix effect.  
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The matrix describes all the components in the mixture other than the analyte 
(ACTH(1-24)). The effect the matrix rather than the analyte has on the results is 
known as the matrix effect. The 250 mcg/ml vial of Synacthen contains acetic 
acid, sodium acetate, sodium chloride and water (Alliance Pharmaceuticals 
2011). It was considered that Synacthen may behave differently to ACTH in the 
0.9% saline diluent, causing it to have a different 3-dimensional configuration 
and either increase or decrease binding in the assay. Analogues or related 
compounds may cross-react more or less than the analyte the assay is designed 
to detect as was found by Darmon et al who noted Synacthen cross-reacting five 
times more on a mass basis than ACTH(1-39) when using a similar RIA (Darmon, 
Dadoun et al. 1999). Why such disparate results were obtained when using the 
same matrix is difficult to explain, however it was felt important to investigate 
this as a cause of the inconsistent results.  
 
4.6 Validation experiment 4 
Despite not having satisfactorily validated the hACTH RIA for use detecting 
Synacthen considerable time constraints meant that study volunteer samples 
(EDTA plasma samples containing Synacthen following either i.v or intranasal 
(i.n) administration (vide infra, chapter 4) were processed prior to validation 
experiment 4. The results from the volunteer samples demonstrated 
considerable inter-individual variation in plasma Synacthen levels following 
administration with 1 mcg of i.v Synacthen (table 3.9)(mean peak plasma 
Synacthen level was 222.7 pg/ml (SD 87 pg/ml) (range 103.6 to 360.8 pg/ml) yet 
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detection of Synacthen in a consistent and interpretable manner in plasma (vide 
infra, chapter 4, figure 4.4a) giving credence to the matrix effect hypothesis. 
 
 
Table 3.9 Ranges, means and standard deviations (SDs) (in brackets) of plasma 
Synacthen on hACTH RIA for 11 volunteers after administration of 1 mcg i.v Synacthen.  
Time (mins) -1 5 10 15 20 
Plasma Synacthen 
range (mean and SD) 
(pg/ml) 
22.4-168.7 
(48.3 ± 39.2) 
162.4-463.7 
(261.7 ± 104.8) 
56.2-273.2 
(108.2 ± 54.4) 
41.1-196.1 
(71.5 ± 41.4) 
32.7-192.7 
(60.3 ± 43.2) 
Time (mins) 30 40 50 60 75 
Plasma Synacthen 
range, mean and SD 
(pg/ml) 
31.5-189.1 
(56.6 ± 43.5) 
24.5-174.7 
(51.6 ± 40.3) 
25.1-173.9 
(50.8 ± 40.2) 
22.9-162.7 
(48.3 ± 37.4) 
21.8-162.8 
(48.8 ± 36.7) 
Time (mins) 90 120 150 180 
Plasma Synacthen 
range, mean and SD 
(pg/ml) 
25.8-165.4 
(46.4 ± 38.4) 
21.8-166 
(48.3 ± 38.7) 
15.3-172.4 
(46.2 ± 40.8) 
11.3-155.5 
(45.0 ± 36.2) 
 
4.6.1 Method 
In order to investigate whether the inconsistent response of the assay was due 
to the matrix effect Synacthen was serially diluted in two different matrices: 
0.9% saline and Phosphate buffered saline with bovine serum albumin (PBS BSA), 
also known as Midgley’s Buffer (table 3.10a).  
 
Phosphate buffered saline with bovine serum albumin is a more physiological 
buffer with a pH of 7.4 (pH of normal saline is approximately 5.5). It was chosen 
to more accurately replicate the pH and ionic strength found in human plasma. 
Plasma is essentially a phosphate buffer in saline with additional proteins. The 3-
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dimensional structure of fragile peptides is known to unravel in solutions of low 
ionic strength and thus PBS BSA offers some protection. It is made up in the RHH 
laboratory and contains the following constituents: phosphate disodium 
hydrogen phosphate dihydrate 7.5g, sodium dihydrogen phosphate dihydrate 
1.2g, EDTA 37.3g, sodium chloride 41.1g, bovine saline albumin 50g, sodium 
azide 5g in 5 litres of distilled water. 
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Table 3.10a: Dilution ratios, summarised method and resultant solutions of experiment 
4. Final solutions assayed displayed in bold. 
Dilution ratio Dilution method Resultant 
concentration 
1:100 0.1ml of 250mcg/ml Synacthen in 9.9 mls of 0.9% 
saline and PBS BSA buffer 
2500 ng/ml 
1:100 0.1ml of 2500 ng/ml solution in 9.9 mls of 0.9% saline 
and PBS BSA buffer 
25 ng/ml 
1:25 0.1ml of 25 ng/ml solution in 2.4mls of 0.9% saline 
and PBS BSA buffer  
 1000 pg/ml 
1:2 0.5ml of 1000 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
500 pg/ml 
1:2 0.5ml of 500 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
250 pg/ml 
1:2 0.5ml of 250 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
125 pg/ml 
1:2 0.5ml of 125 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
62.5 pg/ml 
1:2 0.5ml of 62.5 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
31.3 pg/ml 
1:2 0.5ml of 31.3 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
15.6 pg/ml 
1:2 0.5ml of 15.6 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
7.8 pg/ml 
1:2 0.5ml of 7.8 pg/ml solution in 0.5 ml of 0.9% saline 
and PBS BSA buffer 
3.9 pg/ml 
 
Due to the assumed instability of Synacthen at room temperature the conditions 
were controlled as far as possible. The dilutions and the assay set up for all 
experiments from this point onwards were performed in an ice bath at 
approximately 4°C and the diluents and Synacthen were refrigerated up until the 
moment of use. Measures to improve the speed and efficiency were additionally 
taken to reduce the overall experiment time.  





Table 3.10b: Experiment 4 raw data. Standards and QCs shown 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 1017.3 
Standard 7 535 515.9 
Standard 6 255 254.6 
Standard 5 86 75.7 
Standard 4 39 41.4 
Standard 3 19 21.7 
Standard 2 8 < min 
Low Quality control (QC) 43 (28-58) 49.4 
High Quality control (QC) 121 (89.5-152.5) 124.8 
  0.9% saline PBS BSA 
Sample 1 1000 > max 120.3 
Sample 2  500 490.3 59.5 
Sample 3  250 315.7 39.5 
Sample 4  125 94.7 20.3 
Sample 5  62.5 23.4 14.5 
Sample 6  31.3 15.1 < min 
Sample 7  15.6 < min < min 
Sample 8  7.8 < min 10.2 
Sample 9  3.9 < min 14.5 
 
  




Figure	  3.5:	  Validation	  experiment	  4:	  Scatter	  graph	  depicting	  the	  relationship	  between	  
observed	  and	  expected	  values	  when	  Synacthen	  is	  serially	  diluted	  in	  0.9%	  saline	  and	  
PBS	  BSA.	  Values	  less	  than	  the	  minimum	  standard	  are	  plotted	  as	  7	  pg/ml	  and	  those	  more	  
than	  the	  maximum	  standard	  are	  plotted	  as	  1100	  pg/ml.	  The	  grey	  line	  denotes	  the	  
maximum	  measureable	  value.	  The	  black	  line	  denotes	  perfect	  positive	  correlation.	  	  
	  
4.6.3 Interpretation	  
The	  QCs	  and	  standards	  were	  satisfactory,	  perhaps	  indicating	  that	  with	  repeated	  
assay	   set	   up	   the	   author’s	   technical	   abilities	   were	   improving	   and	   causing	   less	  
discrepant	   results.	   Unlike	   previous	   experiments	   the	   serial	   dilutions	   with	   saline	  
appeared	  to	  show	  some	  linearity,	  with	  observed	  and	  expected	  values	  correlating	  
well,	  especially	  between	  150-­‐500	  pg/ml.	  Results	  with	  PBS	  BSA	  showed	  minimal	  
detection	   of	   Synacthen.	   Saline	   was	   therefore	   assumed	   to	   be	   an	   appropriate	  
diluent,	  with	  the	  controlled	  temperature	  conditions	  having	  prevented	  significant	  
Synacthen	   degradation,	   and	   perhaps	   surprisingly	   a	   more	   suitable	   matrix	  
compared	  with	  PBS	  BSA.	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4.7 Validation experiment 5 
In order to validate the use of the hACTH RIA for detecting Synacthen it was 
necessary to repeat experiment 4 in an attempt to reproduce the closely 
correlated results.  
 
4.7.1 Method 
Serial dilutions from 1000 to 31.25 pg/ml were made up as detailed in table 
3.11a. Results from experiment 4 had indicated a lack of sensitivity when 
analysing the most dilute samples, these were removed and replaced with 
additional samples in the most sensitive (steepest) part of the curve.  
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Table 3.11a: Dilution ratios, summarised method and resultant solutions of experiment 
5. Final solutions assayed displayed in bold. 
Dilution ratio Dilution method Resultant 
concentration 
1:100 0.1ml of 250mcg/ml Synacthen in 9.9 mls of 0.9% 
saline  
2500 ng/ml 
1:100 0.1ml of 2500 ng/ml solution in 9.9 mls of 0.9% saline  25 ng/ml 
1:25 0.1ml of 25 ng/ml solution in 2.4mls of 0.9% saline   1000 pg/ml 
1:15 0.25ml of 1000pg/ml and 0.25ml of 500pg/ml 
solution 
750 pg/ml 
1:2 0.5ml of 1000 pg/ml solution in 0.5 ml of 0.9% saline  500 pg/ml 
1:2 0.25ml of 750 pg/ml solution in 0.25 ml of 0.9% saline 375 pg/ml 
1:2 0.5ml of 500 pg/ml solution in 0.5 ml of 0.9% saline  250 pg/ml 
1:2 0.25ml of 375 pg/ml solution in 0.25 ml of 0.9% saline 187.5 pg/ml 
1:2 0.5ml of 250 pg/ml solution in 0.5 ml of 0.9% saline  125 pg/ml 
1:2 0.25ml of 187.5 pg/ml solution in 0.25 ml of 0.9% 
saline 
94 pg/ml 
1:2 0.5ml of 125 pg/ml solution in 0.5 ml of 0.9% saline  62.5 pg/ml 
1:2 0.25ml of 94 pg/ml solution in 0.25 ml of 0.9% saline 47 pg/ml 
1:2 0.5ml of 62.5 pg/ml solution in 0.5 ml of 0.9% saline  31.3 pg/ml 
 
  




Table 3.11b: Experiment 5 raw data. Standards and QCs shown 
 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 1063.3 
Standard 7 535 479.4 
Standard 6 255 302.2 
Standard 5 86 67.5 
Standard 4 39 47.1 
Standard 3 19 20.8 
Standard 2 8 10.5 
Low Quality control (QC) 43 (28-58) 34.3 
High Quality control (QC) 121 (89.5-152.5) 84.5 
Sample 1  1000 411.9 
Sample 2  750 72.5 
Sample 3  500 94.9 
Sample 4  375 9.87 
Sample 5  250 21.2 
Sample 6 187.5 < min 
Sample 7  125 < min 
Sample 8  94 < min 
Sample 9  62.5 40.4 
Sample 10  47 < min 
Sample 11 31.3 < min 
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4.7.3 Interpretation 
The standard curve was a good fit, although the high QC was poor. The results 
were disappointing with the linearity seen in experiment 4 not replicated. Once 
again the matrix effect was considered, whereby Synacthen with its different 
molecular weight and 3-D configuration, behaves differently in the non-
physiological media compared with ACTH(1-39). Despite the unexpected results 
from experiment 4, where saline had appeared better than PBS BSA, it was 
considered reasonable to investigate this area further. 
 
4.8 Validation experiment 6 
To investigate the matrix effect further three different buffers were compared 
with serial dilutions of Synacthen. 
 
4.8.1 Method 
The three buffers chosen were 0.9% saline, phosphate buffer saline (PBS) and 
PBS BSA. The 0.9% saline is the least physiological and PBS BSA the most 
physiological diluent. PBS is made up to a pH of 7.4 but has a different ionic 
strength to plasma due to its lack of protein. Table 3.12a displays the dilutions 
performed with all three buffers. 
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Table 3.12a: Dilution ratios, summarised method and resultant solutions of experiment 
6. Final solutions assayed displayed in bold. All dilution methods were done using the 
three diluents: 0.9% saline, PBS and PBS BSA.  
Dilution ratio Dilution method Resultant 
concentration 
1:100 0.1ml of 250mcg/ml Synacthen in 9.9 mls of the 3 
diluents  
2500 ng/ml 
1:10 1ml of 2500 ng/ml solution in 9 mls of the 3 diluents  250 ng/ml 
1:10 1ml of 250 ng/ml solution in 9 mls of the 3 diluents 25 ng/ml 
1:10 1ml of 25 ng/ml solution in 9 mls of the 3 diluents  2500 pg/ml 
1:25 0.1ml of 2500 pg/ml solution in 2.4 mls of the 3 
diluents 
1000 pg/ml 
1:2 1ml of 1000 pg/ml solution in 1 ml of the 3 diluents 500 pg/ml 
1:2 1ml of 500 pg/ml solution in 1 ml of the 3 diluents 250 pg/ml 
1:2 1ml of 250 pg/ml solution in 1 ml of the 3 diluents 125 pg/ml 
 
  




Table 3.12b: Experiment 6 raw data. Standards and QCs shown 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 526.6 
Standard 6 255 239.5 
Standard 5 86 97.7 
Standard 4 39 28.2 
Standard 3 19 19.4 
Standard 2 8 9.4 
Low Quality control (QC) 43 (28-58) 22.9 
High Quality control (QC) 121 (89.5-152.5) 122.8 
 0.9% PBS PBS BSA 
Sample 1  2500 > max > max > max 
Sample 2  1000 340.4 499.23 > max 
Sample 3  500 42.2 115.5 > max 
Sample 4  250 < min 102.6 571.3 
Sample 5  125 < min 40.3 295.8 
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Figure	  3.6:	  Validation	  experiment	  6:	  Scatter	  graph	  depicting	  the	  relationship	  between	  
observed	  and	  expected	   values	  when	   Synacthen	   is	   serially	   diluted	   in	   0.9%	   saline,	   PBS	  
BSA	  and	  PBS.	  Values	  less	  than	  the	  minimum	  standard	  are	  plotted	  as	  7	  pg/ml	  and	  those	  
more	  than	  the	  maximum	  standard	  are	  plotted	  as	  1100	  pg/ml. The	  grey	  line	  denotes	  the	  
maximum	  measureable	  value.	  The	  black	  line	  denotes	  the	  perfect	  positive	  correlation.	  	  
	  
4.8.3 Interpretation	  
The	  standard	  curve	  was	  a	  reasonable	  fit.	  The	  high	  QC	  was	  good,	  the	  low	  QC	  poor.	  
Some	   linearity	   was	   evident	   with	   each	   of	   the	   buffers,	   although	   with	   the	   small	  
number	   of	   data	   points	   and	   some	   values	   reaching	   the	   limit	   of	   detection	  
interpretation	   is	   difficult.	   The	   results	   demonstrated	   that	   Synacthen	   in	   PBS	  BSA	  
behaved	  differently	   compared	  with	   0.9%	   saline	   and	  PBS,	   possibly	   explained	  by	  
matrix	  differences.	  There	  was	  a	   lack	  of	  consistency	  of	  results	  with	  the	  PBS	  BSA,	  
results	   from	   experiments	   4	   and	   6	   differing	   considerably.	   It	   was	   becoming	  
increasingly	  difficult	   to	  explain	  why	   the	  assay,	  which	  appears	   to	   function	  when	  
using	  human	  plasma,	  does	  not	  produce	  consistent	  and	  reproducible	  results	   in	  a	  
serial	   dilution	   experiment	   conducted	   in	   a	   more	   physiological	   matrix.	   The	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possibility of an interfering molecule, variably cross-reacting and causing the 
Synacthen to bind inconsistently, was considered. 
 
4.9 Validation experiment 7 
In order to examine the issue of assay inconsistency and address the concerns 
that this was being caused by dilution errors an experiment was performed with 




A stock solution of 1000 pg/ml was made up by a three-step dilution of 250 
mcg/ml in both 0.9% saline and PBS. These were divided into five aliquots of 2 ml 
and frozen at -20°C. One week later one aliquot of each of the diluents was 
thawed and further dilutions made and run (table 3.13a). This was repeated on 
two further occasions 13 and 14 days later.  The three assays were from the 
same manufacturing lot.  
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Table 3.13a: Dilution ratios, summarised method and resultant solutions of experiment 
7. Final solutions assayed displayed in bold. All dilution methods were done using both 
0.9% saline and PBS.  
Dilution ratio Dilution method Resultant 
concentration 
1:25 0.4ml of 250 mcg/ml Synacthen in 9.6 mls of both 
diluents  
10 mcg/ml 
1:100 0.1ml of 10 mcg/ml solution in 9.9 mls of both 
diluents  
100 ng/ml 
1:100 0.1ml of 100 ng/ml solution in 9.9 mls of both 
diluents 
1000 pg/ml 
1:1.5 0.5ml of 1000pg/ml and 0.5ml of 500pg/ml solution 750 pg/ml 
1:2 0.5ml of 1000 pg/ml solution in 0.5 ml of both 
diluents 
500 pg/ml 
1:2 0.5ml of 750 pg/ml solution in 0.5 ml of both diluents 375 pg/ml 
1:2 0.5ml of 500 pg/ml solution in 0.5 ml of both diluents 250 pg/ml 
1:2 0.5ml of 375 pg/ml solution in 0.5 ml of both diluents 187.5 pg/ml 
1:2 0.5ml of 250 pg/ml solution in 0.5 ml of both diluents 125 pg/ml 
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4.9.2 Results 
Table 3.13b: Experiment 7a raw data. Standards and QCs shown 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 491.8 
Standard 6 255 251.9 
Standard 5 86 93.6 
Standard 4 39 39.8 
Standard 3 19 19.2 
Standard 2 8 9.4 
Low Quality control (QC) 43 (28-58) 34.5 
High Quality control (QC) 121 (89.5-152.5) 120.0 
 0.9% PBS 
Sample 1  750 40.1 500.6 
Sample 2  500 < min 328.4 
Sample 3  375 < min 48.9 
Sample 4  250 < min 70.8 
Sample 5  187 < min 15.5 
Sample 6 125 13.5 < min 
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Table 3.13c: Experiment 7b raw data. Standards and QCs shown 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 576.3 
Standard 6 255 241.4 
Standard 5 86 91.8 
Standard 4 39 39.1 
Standard 3 19 21.9 
Standard 2 8 < min 
Low Quality control (QC) 43 (28-58) 48.7 
High Quality control (QC) 121 (89.5-152.5) 123.7 
 0.9% PBS 
Sample 1  750 > max 1025.7 
Sample 2  500 853.3 674.6 
Sample 3  375 543.1 530.7 
Sample 4  250 79.4 255.8 
Sample 5  187 106.7 72.9 
Sample 6 125 40.9 50.1 
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Table 3.13d: Experiment 7c raw data. Standards and QCs shown 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 491.8 
Standard 6 255 251.9 
Standard 5 86 93.6 
Standard 4 39 39.8 
Standard 3 19 19.2 
Standard 2 8 9.4 
Low Quality control (QC) 43 (28-58) 34.5 
High Quality control (QC) 121 (89.5-152.5) 120.0 
 0.9% PBS 
Sample 1  750 < min 593.1 
Sample 2  500 < min 396.5 
Sample 3  375 < min 63.6 
Sample 4  250 < min 16.1 
Sample 5  187 < min < min 








	  Figure	  3.7:	  Validation	  experiment	  7a-­‐c:	  Line	  graph	  depicting	  the	  relationship	  between	  
observed	   and	   expected	   values	  when	   Synacthen	   is	   serially	   diluted	   in	   0.9%	   saline	   and	  
PBS	  and	   samples	   are	   run	  on	   three	  different	   occasions.	  Values	   less	   than	  the	  minimum	  
standard	  are	  plotted	  as	  7	  pg/ml	  and	  those	  more	  than	  the	  maximum	  standard	  are	  plotted	  
as	  1100	  pg/ml.	  a,	  b	  and	  c	  denote	  the	  three	  experiments	  run	  on	  different	  days.	  The	  grey	  





Once	  again	  the	  results	  were	  inconsistent	  and	  difficult	  to	  interpret.	  There	  was	  no	  
discernable	   consistency	   between	   the	   three	   assays,	   7a	   and	   7c	   being	   similar	   yet	  
markedly	  different	   to	  7b.	  Both	   saline	  and	  PBS	   results	  were	   similarly	   low	   for	  7a	  
and	  7c	  but	  very	  high	  in	  7b.	  A	  dilution	  error	  may	  explain	  the	  higher	  results	  in	  7b,	  
however	   the	   progression	   of	   fall	   off	   (curve)	   does	   not	   entirely	   support	   this;	   the	  
curve	  is	  a	  different	  shape,	  not	  just	  shifted	  left.	  	  
	  
In	   contrast	   to	   previous	   results	   at	   the	   same	   dilutions,	   the	   saline	   results	   were	  
unexpectedly	  low	  in	  7a	  and	  7c	  and	  unexpectedly	  high	  in	  7b.	  The	  results	  with	  PBS	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were more expected, with results lower than the diluted amount, as would be 
anticipated in a competitive RIA, especially one designed for the detection of a 
related but different molecule. However in both 7a and 7c the drop off, after 
initially promising results, at about 375 pg/ml, was precipitate and again difficult 
to explain. Although only limited interpretation is possible PBS looked to be the 
superior diluent. 
 
4.10 Validation experiment 8 
Having obtained interpretable results when Synacthen was assayed in human 
plasma, an attempt was made to further ameliorate the presumed matrix effect. 
This assumes the 3-dimensional configuration of Synacthen is different in non-
physiological matrices and therefore a dilution experiment was performed using 
diluted pooled human plasma. 
 
4.10.1 Method 
Pooled human EDTA plasma was used as the diluent. Locally, ACTH samples are 
collected in EDTA, booked in at clinical chemistry where they are spun, separated 
and frozen until weekly batch analysis. Residual EDTA plasma following patient 
sample analysis was pooled, left at room temperature overnight to allow the 
endogenous ACTH to degrade and refrozen.  
 
The pooled EDTA plasma was thawed and vortexed before serial dilutions were 
undertaken (table 3.14a). To ensure the ACTH in the pooled plasma was 
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sufficiently degraded a sample was analysed on the Immulite 2000 assay 
(Siemens).  
 
EDTA (ethylenediaminetetraacetic acid) is a polyamino carboxylic acid with a 
hexagonal structure, which in part confers its property as a chelating agent. If the 
enzymes that degrade a molecule are calcium or magnesium dependent the 
EDTA removes them by chelation thus preventing significant loss by degradation 
before analysis. ACTH (and Synacthen) samples are collected in EDTA so that 
endopeptidases are chelated and prevented from breaking down the ACTH. 
 
Table 3.14a: Dilution ratios, summarised method and resultant solutions of experiment 
8. Final solutions assayed displayed in bold.  
Dilution ratio Dilution method Resultant 
concentration 
1:25 0.2 ml of 250mcg/ml Synacthen in 4.8 mls of EDTA 
plasma  
10 mcg/ml 
1:100 0.1 ml of 10 mcg/ml solution in 9.9 mls of EDTA 
plasma  
100 ng/ml 
1:100 0.1 ml of 100 ng/ml solution in 9.9 mls of both 
diluents 
1000 pg/ml 
1:1.5 0.5 ml of 1000pg/ml and 0.5ml of 500pg/ml solutions 750 pg/ml 
1:2 1 ml of 1000pg/ml and 1ml EDTA plasma 500 pg/ml 
1:2 0.5 ml of 750 pg/ml solution and 0.5ml of EDTA 
plasma 
375 pg/ml 
1:2 1 ml of 500 pg/ml solution in 1 ml EDTA plasma 250 pg/ml 
1:2 0.5 ml of 375 pg/ml solution and 0.5ml of EDTA 
plasma 
187.5 pg/ml 
1:2 1 ml of 250 pg/ml solution in 1 ml EDTA plasma 125 pg/ml 
1:2 0.5 ml of 375 pg/ml solution in 0.5 ml of both diluents 94 pg/ml 
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4.10.2 Results 
Table 3.14b: Experiment 8 raw data. Standards and QCs shown 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 1058.1 
Standard 7 535 508.7 
Standard 6 255 259.6 
Standard 5 86 83 
Standard 4 39 33.3 
Standard 3 19 19.5 
Standard 2 8 13.3 
Low Quality control (QC) 43 (28-58) 43.4 
High Quality control (QC) 121 (89.5-152.5) 125.5 
Sample 1  750 > max 
Sample 2  500 > max 
Sample 3  375 > max 
Sample 4  250 1058.2 
Sample 5  187 1015 
Sample 6 125 871.8 
Sample 7 94 812.1 
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Figure	  3.8:	  Validation	  experiment	  8:	  Scatter	  graph	  depicting	  the	  relationship	  between	  
observed	   and	   expected	   values	   when	   Synacthen	   is	   serially	   diluted	   in	   EDTA	   plasma.	  
Values	   more	   than	   the	   maximum	   standard	   are	   plotted	   as	   1100	   pg/ml.	   The	   grey	   line	  




The	   pooled	   plasma	  was	   analysed	   on	   the	   ACTH	   Immulite	   2000	   assay	   (Siemens)	  
and	  results	  given	  below	  (table	  3.14c).	  
	  
Table	  3.14c:	  Experiment	  8	  pooled	  plasma	  ACTH	  results	  from	  Siemens	  Immulite	  2000.	  	  
Date	  of	  addition	  to	  pool	  and	  freezing	   ACTH	  result	  (pg/ml)	  
22/9/11	   14.9	  
29/11/11	   45	  
6/10/11	   66.4	  
14/10/11	   159	  
Pooled	   76.4	  
Normal	  range:	  9am	  <46	  pg/ml;	  Midnight	  <15	  pg/ml	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4.10.3 Interpretation 
In order to avoid the potential deleterious effects of a further freeze-thaw cycle 
the Immulite ACTH results were not known prior to the Synacthen dilution 
experiment. Unfortunately the ACTH in the pooled plasma had not sufficiently 
degraded and therefore contained a considerably higher concentration of ACTH 
than anticipated. It is likely that the high background ACTH, detectable by the 
RIA, contributed to the high values obtained, although should not have 
accounted for the lack of correlation between observed and expected values. 
 
4.11 Validation experiment 9 
With considerable doubt being cast over the ability of the RIA to reliably detect 
Synacthen, another experiment was planned to establish whether it could 




The three external quality assurance samples for ACTH, provided to the lab by UK 
NEQAS (UK National External Quality Assessment Service) for quality control 
purposes and to allow comparison with other laboratories and other methods, 
were run on the hACTH RIA (October 2011). These were run in duplicate on the 
same assay used in experiment 8. 
 
 






Table 3.15: Experiment 9: UK NEQAS samples (performed on same assay as used in 
experiment 8). All results in pg/ml. 
 Base pool EDTA 
plasma 
Base pool EDTA plasma 
with synthetic ACTH 
153.6  
Base pool EDTA plasma 




56.5 218.4 643.3 
UKNEQAS results  7.2 160.5 339.3 
NEQAS results with + 
bias of 27.1% 
9.2 204.0 431.2 
 
The UK NEQAS results shown are the target ACTH values. The UK NEQAS data did 
not display the same method as the MP Biomedicals RIA for direct comparison. 
The most similar method was the BRAHMS RIA but only bias data were given, 
showing a positive bias of 27.6% (N = 1). The MP Biomedicals results obtained 
were accordingly adjusted for this positive bias as shown in table 3.15.  
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Figure	   3.9:	   Validation	   experiment	   9:	   Bar	   chart	   depicting	   the	   ACTH	   values	   obtained	  
when	  UK	  NEQAS	  reference	  samples	  were	  run	  on	  MP	  Biomedicals’	  RIA.	  Adjustment	  for	  
the	  positive	  bias	  seen	  with	  similar	  method	  is	  also	  shown.	  	  
	  
4.11.3 Interpretation	  
Correction	   for	   the	   positive	   bias	   seen	   with	   the	   similar	   method	   improved	   the	  
significant	   disparity	   between	   the	   expected	   (UK	   NEQAS	   target	   value)	   and	   the	  
observed	  results.	  However	  the	  RIA	  results,	  particularly	  for	  the	  baseline	  value	  and	  
higher	  concentration	  pool,	  were	  disappointing.	  Using	  an	  hACTH	  assay	  to	  detect	  
Synacthen	   has	   obvious	   limitations	   but	   the	   NEQAS	   samples	   are	   synthetic	  
hACTH(1-­‐39)	  and	  should	  have	  been	  detected	  relatively	  accurately.	  This	  led	  to	  the	  
supposition	   that	   there	  was	   something	   fundamentally	  wrong	  with	   ability	   of	   the	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4.12 Validation experiment 10 




Re-analysis of three research volunteer samples (vide infra, chapter 4) was 
undertaken and the results from the two runs compared. There was an eleven-
month gap between the first and the second analysis, during which the samples 
were kept at -80°C. In order to be reanalysed they had undergone an additional 
freeze-thaw cycle. The samples were run on the assay used in both experiments 
8 and 9.  
 
4.12.2 Results 
Table 3.16: Experiment 10 NeSST study volunteer sample repeats (performed on same 
assay as used in experiment 8).  
 Volunteer sample 1 
(25mcg nasal 0 mins) 
Volunteer sample 2 
(25mcg nasal 15 min) 
Volunteer sample 3 





12.7 13.8 11.8 
2
nd
 Analysis  
October 2011  
42.6 53.7 49.3 
 
 




Figure	   3.10:	   Validation	   experiment	   10:	   Bar	   chart	   depicting	   the	   Synacthen	   values	  
obtained	  when	  three	  volunteer	  samples	  run	   in	  November	  2010	  and	  re-­‐run	   in	  October	  
2011	  were	  compared.	  	  
	  
4.12.3 Interpretation	  
Unexpectedly	   rather	   than	   lower	   values,	   caused	   by	   additional	   degradation	  
associated	  with	   an	  extra	   freeze-­‐thaw	  cycle,	   the	   results	  were	  higher.	   The	   cross-­‐
reactivity	   of	   the	   Synacthen	   epitope	   and	   the	   tracer	   antibody	   seems	   to	   vary,	  
yielding	   inconsistent	   results.	   Whether	   the	   additional	   freeze-­‐thaw	   cycle	  
exacerbated	   this	   effect	   can	   only	   be	   postulated.	   The	   epitope	   recognised	   by	   the	  
RIA,	   although	   structurally	   the	   same	   in	   2-­‐dimensions,	   may	   be	   presented	  
differently	   in	  ACTH	  and	  Synacthen	  in	  3-­‐dimensions.	  This	  may	  cause	  times	  when	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4.13 Assay meeting and manufacturer contact 
Following 17 months of work attempting to validate the MP Biomedicals hACTH 
RIA to reliably detect plasma Synacthen the results of the various experiments 
continued to be contradictory and difficult to explain. There were two problems: 
the inability to validate the RIA for use measuring Synacthen, with erratic results 
during serial dilution experiments, and high baseline plasma ACTH values in 
dexamethasone suppressed research volunteers. Only discussion of the first 
problem is covered in this chapter (vide infra chapter 4, section 5.1 for discussion 
of assay interference).  
 
A meeting with the following attendees: 
 PhD supervisor (Dr N Wright) 
 Supervisor of laboratory work (Mr M Loxley) 
 Senior Biomedical Scientist (BMS) in endocrine laboratory (Ms V Moyse) 
 Associate Specialist in Chemical Pathology (Dr K Page).  
All three of the laboratory personnel have a particular interest and expertise in 
RIA and endocrine laboratory medicine and had all been involved to a greater or 
lesser extent advising on the laboratory methodology of the project. 
 
Data pertaining to the assay, the author presented the methodology and results 
of each one of the experiments to date with pertinent literature from the few 
other groups who have measured Synacthen. The main discussion points of the 
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meeting are presented below and the plan for further validation work follows 
(section 4.13.1)  
1. There was no significant concern about my assay preparation technique. 
Although the QCs presented (table 3.23) revealed some inconsistencies it 
was felt they were not adequate to explain the lack of interpretable 
results. The low QC was less than the high QC and thus the trend was 
adequate even if individual results were poor. 
2. The possibility of conformational change in the Synacthen on freezing 
was raised, although most of the experiments were performed with fresh 
samples. No information was available from Alliance Pharmaceuticals 
about the impact of freezing, although it is not advised with the depot 
preparation (which was not used in any of the experiments). ACTH is 
stable when frozen and on reviewing the constituents of the Synacthen 
vial it seemed unlikely that freezing would have a significant impact.  
3. The ambient laboratory temperature may have caused Synacthen to 
degrade, although after steps were taken to ameliorate this the results 
continued to show considerable inconsistency, incompatible with 
degradation. 
4. Some molecules have a greater affinity for RIA than others, with reports 
of 5 times greater binding of related molecules (Darmon, Dadoun et al. 
1999). It was postulated that the antibody binds more easily to ACTH(1-
24) compared with ACTH(1-39) however the results are inconsistent not 
just high, it was suggested that the binding of Synacthen may be variable 
and at times all or nothing. 
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5. Dr Page examined the molecular structure of Synacthen, commenting on 
its basic N-terminus and acidic C-terminus, causing attraction and 
conformational folding. He postulated that it may be a molecule that is 
particularly sensitive to changes in pH. I presented the methodology from 
two papers in which extraction techniques had been used and both had 
acidified down to a low pH (Krishnan, Ritchie et al. 1988, Alia, Villabona et 
al. 2006). 
 
4.13.1 Plan for on-going validation work 
 Perform an experiment in which the matrix is acidified, as described by 
Krishnan et al (Krishnan, Ritchie et al. 1988) 
 Analyse the next batch of UK NEQAS ACTH samples 
 Re-analyse more research volunteer samples from the NeSST study 
 Perform an experiment in which whole blood is used as the matrix. The 
assay appeared to work more reliably in the volunteer samples and 
therefore it was postulated that more reliable results may be obtained 
when Synacthen is directly added to and serially diluted in whole blood 
(an in vitro version of the Synacthen Test).  
 Produce Synacthen standards in order to calibrate the assay 
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4.13.2 Correspondence with MP Biomedicals 
The manufacturer of the hACTH RIA was contacted to raise concerns about the 
assay and request advice about the use of their assay for our purposes. The data 
were shared with regard to the high baseline values following dexamethasone 
suppression (chapter 4, section 4.3.1), inconsistent results with serial Synacthen 
dilution experiments, UK NEQAS comparison and different results when re-
analysing the research volunteer samples. Although not immediately 
forthcoming a response was forthcoming.   
 
Despite quoting 100% cross-reactivity in the hACTH RIA directional insert, MP 
Biomedicals have never validated the assay for Synacthen. It was an assumption 
made based on the fact that the assay recognises the 5-18 portion of the 
molecule, shared by both ACTH and Synacthen. During further correspondence 
they were unable to offer an explanation for our inability to obtain consistent 
results with ACTH or Synacthen.  
 
4.14 Validation experiment 11 
Following the assay meeting an experiment was performed as discussed above 
with an acidifed buffer in an attempt to replicate the results of other studies 
(Krishnan, Ritchie et al. 1988, Alia, Villabona et al. 2006). 
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4.14.1 Methods 
PBS BSA was acidified down to a pH of 3 with hydrochloric acid (HCL). A vial of 
250 mcg/ml Synacthen was diluted in the acidified buffer to give the 
concentrations below (table 3.17a). All samples were run in quadruplicate in an 
attempt to increase the accuracy of results. VM (senior BMS) made up the 
acidifed buffer, performed the dilutions and assay set-up, with the author 
present, in order to examine whether the previous results were partly 
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Table 3.17a: Dilution ratios, summarised method and resultant solutions of experiment 
11. Final solutions assayed displayed in bold.  
Dilution ratio Dilution method Resultant 
concentration 
1:1000 50 mcl of 250mcg/ml Synacthen in 50 mls acidified 
buffer  
250 ng/ml 
1:250 200 mcl of 250 ng/ml solution in 50 mls of acidified 
buffer 
1000 pg/ml 
1:1.5 0.5 ml of 1000pg/ml and 0.5ml of 500pg/ml solutions 750 pg/ml 
1:2 0.5 ml of 1000 pg/ml solution in 0.5 mls of acidified 
buffer 
500 pg/ml 
1:2 0.5 ml of 750 pg/ml solution in 0.5 mls of acidified 
buffer 
375 pg/ml 
1:2 0.5 ml of 500 pg/ml solution in 0.5 mls of acidified 
buffer 
250 pg/ml 
1:2 0.5 ml of 375 pg/ml solution in 0.5 mls of acidified 
buffer 
187.5 pg/ml 
1:2 0.5 ml of 250 pg/ml solution in 0.5 mls of acidified 
buffer 
125 pg/ml 
1:2 0.5 ml of 187.5 pg/ml solution in 0.5mls of acidified 
buffer 
94 pg/ml 
1:2 0.5 ml of 125 pg/ml solution in 0.5 mls of acidified 
buffer 
62.5 pg/ml 
1:2 0.5 ml of 94 pg/ml solution in 0.5mls of acidified 
buffer 
47 pg/ml 
1:2 0.5 ml of 62.5 pg/ml solution in 0.5mls of acidified 
buffer 
31.3 pg/ml 
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Table 3.17b: Experiment 11 raw data. Standards and QCs shown 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 470.9 
Standard 6 255 244.4 
Standard 5 86 94 
Standard 4 39 33.3 
Standard 3 19 20.9 
Standard 2 8 < min 
Low Quality control (QC) 43 (28-58) 23.0 
High Quality control (QC) 121 (89.5-152.5) 83.4 
Sample 1 1000 > max 
Sample 2 750 > max 
Sample 3  500 > max 
Sample 4  375 > max 
Sample 5  250 973.3 
Sample 6 187.5 530.1 
Sample 7 125 371.7 
Sample 8 94 237.2 
Sample 9 62.5 145.7 
Sample 10 47 114 
Sample 11 31.3 77.1 
Sample 12 23 63.2 
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Figure	   3.11:	   Validation	   experiment	   11:	   Scatter	   graph	   depicting	   the	   relationship	  
between	  observed	  and	  expected	  values	  when	  Synacthen	  is	  serially	  diluted	  in	  acidified	  
PBS	  BSA.	  Values	  more	  than	  the	  maximum	  standard	  are	  plotted	  as	  1100	  pg/ml.	  The	  grey	  




Despite	   an	   experienced	   BMS	   performing	   the	   dilutions	   and	   assay	   set-­‐up	   the	  
standard	   curve	  was	   a	   less	   good	   fit	   than	   in	  most	   previous	   experiments	   and	   the	  
QCs	  were	  both	  more	  than	  3	  SDs	  below	  the	  acceptable	  range	  (but	  within	  4	  SDs).	  
This	  may	  have	  been	  due	  to	  VM’s	  lack	  of	  familiarity	  with	  this	  particular	  RIA.	  There	  
appeared	  to	  be	  greater	  sensitivity	  at	  the	  lower	  concentrations,	  not	  always	  seen	  
previously.	  	  
	  
The	  unspiked	  (no	  Synacthen	  added)	  acidified	  buffer	  was	  analysed	  as	  having	  24.4	  
pg/ml	  of	  ACTH,	  more	  than	  the	  lowest	  standard	  (8	  pg/ml).	  Once	  again	  the	  values	  
were	   considerably	   higher	   than	   expected,	   indicating	   either	   a	   greater	   binding	  
affinity	   of	   Synacthen	   compared	  with	   ACTH(1-­‐39)	   or	   an	   interfering	  molecule.	   A	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relational change was seen whereby for each 1:1.5 dilution from 187.5 pg/ml 
down to 23 pg/ml there was an approximately 1.4 times concentration 
reduction. The expectation of these serial dilution experiments is not a perfect 
correlation between expected and observed values but a reproducible and 
consistent relationship between the two. Acidification of the buffer did appear to 
result in some linearity and therefore improved the reliable and accurate 
detection of Synacthen. 
 
4.15 Validation experiment 12 
The next UK NEQAS samples were run on the MP Biomedicals hACTH RIA and 
compared to results from other similar assays nationally. 
 
4.15.1 Method 
The three UK NEQAS samples were run in quadruplicate on the same assay as 
used in experiment 11, set up by the endocrine laboratory’s senior BMS and 
under the same controlled conditions. The UK NEQAS materials are supplied 
lyophilised and made up prior to use. Due to the timing of the assay kit delivery 
from USA the reconstituted samples were frozen at -20°C then thawed and 
analysed the following week. As before the results were later compared to 
national data (N= 92) and data derived from centres using similar methods (N=1).  
 
Additionally the low and high QCs from the Immulite 2000 (Siemens), the 
sandwich immunoassay used locally for ACTH quantification, were run on the 
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RIA. These were run in triplicate, under controlled conditions and set up by the 
same senior BMS.  
 
Table 3.18a: Experiment 12a: UK NEQAS samples (performed on same assay as in expt 
11).  
 Base pool EDTA 
plasma 
Base pool EDTA plasma 
with synthetic ACTH 219 
ng/l 
Base pool EDTA plasma 
with synthetic ACTH 878 
ng/l 
MP Biomedicals hACTH 
RIA 
19.5  17.7 66.3 
UKNEQAS results  19.8 311.8 1149.6 
NEQAS results with + bias 
of 24.7% 
24.6 388.8 1433.6 
 
The UK NEQAS results shown are the target ACTH values. The UK NEQAS data did 
not display the same method as the MP Biomedicals RIA for direct comparison. 
The most similar method was the CIS ELISA IRMA but only bias data were given, 
showing a positive bias of 24.7% (N = 1). The MP Biomedicals results obtained 
were accordingly adjusted for this positive bias as shown in table 3.18a. 




Figure	  3.12:	  Validation	  experiment	  12:	  Bar	  chart	  depicting	   the	  ACTH	  values	  obtained	  
when	  UK	  NEQAS	  reference	  samples	  were	  run	  on	  MP	  Biomedicals’	  RIA.	  Adjustment	  for	  




Table	  3.18b:	  Experiment	  12b:	  Siemens’	  Immulite	  2000	  hACTH	  high	  and	  low	  QCs	  
(performed	  on	  same	  assay	  as	  in	  experiment	  11).	  Results	  in	  pg/ml	  
	   High	  QC	   Low	  QC	  
MP	  Biomedicals	  hACTH	  
RIA	  
>	  max	  	   262	  
Immulite	  2000	  	   434	  	   33	  
	  
4.15.2 Interpretation	  
In	  experiment	  12	  the	  hACTH	  RIA	  was	  being	  used	  to	  detect	  ACTH	  not	  Synacthen.	  
This	  was	  to	  test	  the	  theory	  that	  it	  was	  the	  conformational	  change	  of	  the	  epitope	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detection. It was concerning that both the UK NEQAS samples and the Immulite 
QCs showed very poor correlation with the values expected of an ACTH assay.  
 
So few laboratories use RIA to measure ACTH that the most similar method from 
the UK NEQAS data for comparison, used by one centre only, was the CIS ELISA 
IRMA. It had a 24.7% positive bias from target on its submitted results, making 
the values obtained in experiment 12 even more disparate. The results from the 
two samples spiked with synthetic ACTH(1-39) are so much lower than expected 
as to make any possible variance caused by different assay methods irrelevant. 
The explanations for these results are an interfering molecule, a significant 
problem with the ability of the RIA to detect ACTH and Synacthen or that the 
freeze-thaw process in some way damaged the molecule, changing its 3-D 
configuration. It may be a combination as the results from experiment 9, whilst 
poor in comparison with the UK NEQAS targets, where considerably closer than 
those in experiment 11 and the difference may have been the freezing the 
NEQAS samples.  
 
4.16 Validation experiment 13  
Concerns over a possible matrix effect had been tested with a number of 
different buffers and matrices in an attempt to emulate the interpretable results 
seen when the volunteer samples were analysed. To further investigate the 
ability of the RIA to detect Synacthen reliably in human plasma an experiment 
was conducted using Synacthen spiked human blood.  
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4.16.1 Method 
On the same day as experiment 12 a further RIA was set up with samples of 
Synacthen spiked human plasma. The author had 30 mls of blood taken and 
stored in EDTA. The blood was left at room temperature for six hours to allow 
the endogenous ACTH to degrade. The whole blood was then spun and 
separated. The remaining 15 mls of plasma was spiked with Synacthen as 
displayed in table 3.19a. The two concentrations tested were chosen as those 
most likely to be on the steepest (most sensitive) part of the curve. The unspiked 
plasma was also run, both on the RIA and on the Siemens’ Immulite 2000 
sandwich assay for comparison. Samples were run in sextriplicate. Senior BMS, 
Victoria Moyse, performed the dilutions and set up the assay with the author. 
 
Table 3.19a: Dilution ratios, summarised method and resultant solutions of experiment 
13. Final solutions assayed displayed in bold.  
Dilution ratio Dilution method Resultant 
concentration 
1:1000 0.01ml of 250mcg/ml Synacthen in 9.99 mls of CJE’s 
plasma 
250 ng/ml 
1:500 0.02ml of 250ng/ml Synacthen in 9.98 mls of CJE’s 
plasma 
500 pg/ml  
1:2 1 ml of 500pg/ml and 1 ml of CJE’s plasma 250 pg/ml 
1:2 1 ml of 1000 pg/ml solution in 1 mls of CJE’s plasma 125 pg/ml 
 
  




Table 3.19b: Experiment 13 raw data. The means of each duplicate and the sextriplicate 
results are displayed. Standards and QCs shown, SDs given in brackets after mean. 
Sample/Standard Expected (pg/ml) Obtained (pg/ml) 
Standard 8 1098 > max 
Standard 7 535 468 
Standard 6 255 278 
Standard 5 86 75.7 
Standard 4 39 42.2 
Standard 3 19 23.2 
Standard 2 8 < min 
Low Quality control (QC) 43 (28-58) 18.5 
High Quality control (QC) 121 (89.5-152.5) 88.9 
Sample 1 250 600.8 
Sample 2 250 1078.0 
Sample 3 250 986.7 
 Mean = 888.5 (253.3) 
Sample 4 125 363.3 
Sample 5 125 341.6 
Sample 6 125 354.6 
 Mean = 353.2 (10.9) 
Sample 7 (unspiked plasma) <8 21.4 
Sample 8 (unspiked plasma) <8 19.7 
Sample 9 (unspiked plasma) <8 21.1 
 Mean = 20.7 (0.9) 
Unspiked plasma results on Immulite = 5.8 and 7.2 pg/ml (normal <46 pg/ml) 








Figure	   3.13:	   Validation	   experiment	   13:	   Graph	   depicting	   the	   relationship	   between	  
observed	   and	   expected	   values	   when	   human	   plasma	   is	   spiked	   with	   two	   different	  
concentrations	   of	   Synacthen–	   250	   pg/ml	   and	   125	   pg/ml.	   The	   black	   line	   denotes	   the	  




As	  seen	  in	  experiment	  12	  the	  QCs	  were	  both	  low	  and	  the	  standard	  curve	  not	  as	  
good	   as	   previously.	   This	   may	   be	   a	   result	   of	   inter-­‐operator	   variability,	   despite	  
VM’s	  experience.	  The	  low	  QCs	  were	  not	  so	  abnormal	  as	  to	  invalidate	  the	  results.	  	  
 
The	  results	  of	  the	  Synacthen	  spiked	  plasma	  were	  disappointing	  as	   it	  was	  hoped	  
that	   eliminating	   the	   matrix	   effect	   would	   provide	   more	   reliable,	   repeatable	  
results.	   The	   values	   were	   significantly	   higher	   than	   expected	   and	   showed	  
considerable	  variability	  at	  the	  250	  pg/ml	  concentration.	  It	  is	  unlikely	  that	  dilution	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error would account for this variance. The unspiked plasma values were over 
three times higher using the RIA compared with the Immulite.  
 
Human error has to be considered as an explanation for the unexpected results 
in all the experiments however the assay is not especially complex to set up and 
run and it is unlikely that errors could account for the inconsistency of results 
both within and between assays. These results led to serious concern about the 




4.17 Validation experiment 14 
Part of the attempt to validate this assay was to test its reliability through 
repeatability. To this end a selection of the volunteer samples from winter 2010 
were re-run. 
4.17.1 Method 
A random selection of seven volunteer samples was chosen. They ranged from a 
baseline sample to one at 50 minutes and all were from one or other of the nasal 
Synacthen visits (vide infra chapter 4). The samples had previously been thawed 
and then re-frozen after the initial analysis 17 months before. The samples were 
run on the same assay as used in experiment 13 and therefore the same 
controlled conditions and set up by a senior BMS. The samples were run in 
duplicate. 
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4.17.2 Results	  
Table	  3.20:	  Experiment	  14	  raw	  data.	  The	  mean	  of	  duplicate	  results	  displayed.	  
Standards	  and	  QCs	  shown	  
Sample	   Expected	  (pg/ml)	  
(results	  from	  2010	  
analysis)	  
Obtained	  (pg/ml)	  
(results	  from	  2011	  
analysis)	  
Factor	  difference	  
from	  2010	  analysis	  
N1a03	  v3*,	  -­‐1	  min**	   188	   80.9	   X	  2.3	  
N1a03	  v3*,	  10	  min**	   187.6	   88.8	   X	  2.1	  
N1a03	  v3*,	  40	  min**	   187.0	   88.8	   X	  2.1	  
N1a12	  v2*,	  15	  min**	   56.3	   18.7	   X	  3.0	  
N1a12	  v2*,	  20	  min**	   59.5	   22.8	   X	  2.6	  
N1a12	  v2*,	  40	  min**	   46.6	   19.4	   X	  2.4	  
N1a12	  v2*,	  50	  min**	   44.5	   17.6	   X	  2.5	  
*v2	  =	  Visit	  2,	  100	  mcg	  nasal	  Synacthen,	  v3	  =	  visit	  3,	  25	  mcg	  nasal	  Synacthen	  administered	  







Figure	   3.14:	   Validation	   experiment	   14:	   Bar	   chart	   depicting	   comparison	   of	   seven	  
volunteer	  samples	  run	  in	  November	  2010	  and	  re-­‐run	  in	  May	  2012.	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4.17.3 Interpretation 
All the results are considerably lower, between 2.1 and 3 times, when re-
analysed 17 months after the first analysis. There is consistency in relative loss of 
Synacthen between the two analyses, especially for the higher value samples. 
This suggests the change may have been due to degradation of Synacthen or the 
effect of the second freeze-thaw cycle rather than inconsistency within the 
assay. This loss of Synacthen is in strict contrast to the results of experiment 10 
(section 4.12.2) where values had increased on re-analysis. 
 
On reflection re-analysing a wider range of samples including those from visit 1, 
where 1 mcg of Synacthen was administered intravenously, would have been 
preferable. This may have served to further test the degradation theory, as the 
range of Synacthen values would have been greater. Additionally, when samples 
were originally spun after being taken from the volunteers they were split into 
two aliquots to allow for further analysis at a later date if necessary. At the time 
of experiment 14, with continued failure to validate the RIA, the sourcing of a 
new assay was being actively pursued and therefore there was a possibility of re-
running all the study samples.  The second aliquot was kept for that purpose and 
experiment 14 performed on samples that had already undergone a freeze-thaw 
cycle. Running the second aliquot samples may have provided different results.  
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4.18 Validation experiment 15 
The RIA chosen did not appear fit for purpose. The RIA antibody appeared at 
times to be cross-reacting with higher affinity for Synacthen compared with 
ACTH and at other times to barely bind it. Synacthen, like ACTH, is an unstable 
molecule but measures were taken to prevent excess degradation and the 
results were not all consistent with Synacthen loss. Additionally the matrix effect 
had been extensively examined and did not appear to improve results.  
 
A number of sources had suggested that using an ACTH standard curve may be 
the cause of the inconsistency as ACTH and Synacthen are molecules of different 
molecular weights and are thus likely to behave differently in the RIA. It was 
recommended that to overcome this the standards should be incubated in the 
same buffer as the samples.  
 
At this time a paper came to light which reported a validated method using the 
MP Biomedicals RIA to measure Synacthen (Wade, Baid et al. 2010). The 
corresponding author of the paper, Dr Lynette Nieman (NIH, USA), was 
contacted for advice. The author responsible for the RIA work on the study, 
Professor Hershel Raff, responded that in his experience the RIA did cross-react 
100% with Synacthen. He suggested using the MP Biomedicals zero standard as 
the diluent for Synacthen standards, to reduce matrix effects, and to consider 
plasma extraction procedures. However he also pointed out that they had only 
used the RIA for their in vitro work, not to measure plasma Synacthen levels on 
their research participants. Finally he only knew of one other ACTH RIA that 
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would measure Synacthen but reported it was “much more labour intensive and 
gives similar results”. 
 
It was decided to repeat a serial dilution experiment using Synacthen standards 
and the MP Biomedicals zero standard as the diluent. 
 
4.18.1 Method 
Frozen zero standard was purchased from MP Biomedicals, thawed on the day of 
use and used as a diluent for the dilutions outlined in table 3.21a. Due to 
financial constraints and the expense of the zero standard large dilutions were 
required to make up the standards and therefore a positive displacement pipette 
was used to improve accuracy. The pipette was internally calibrated and a CV for 
10 mcl calculated by ten serial weights on laboratory weighing scales. The CV was 
1.01%.  
 
A high concentration stock (250,000 pg/ml) was created after the first dilution 
step, split into seven aliquots and six were frozen at -20°C. Following the second 
dilution step a standard stock was formed (1000 pg/ml) which was similarly split 
and frozen. One aliquot of the standard stock was used to dilute to the 
concentrations shown in table 3.21a and the unused volume of the final dilutions 
(500, 250, 125, 62.5 pg/ml) was divided into two aliquots and frozen. Experiment 
15a involved running 1000, 500, 250, 125 and 62.5 pg/ml in triplicate. 
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The results obtained supported continuation using Synacthen standards made up 
in zero standard and therefore experiment 15b, performed one month later, 
used thawed samples made up at the time of experiment 15a with the addition 
of a zero standard sample (unspiked) and a 31.3 pg/ml sample diluted using the 
zero standard provided with the assay kit. Samples in experiment 15b were run 
in triplicate. 
 
Finally experiment 15c, carried out three weeks after 15b, again utilised the 
frozen dilutions from experiment 15a this time with the addition of a 15.6 pg/ml 
sample and a zero standard sample made up that day from the lyophilised 
sample in the RIA kit. Samples for all experiment 15c were run in duplicate. 
 
Table 3.21a: Dilution ratios, summarised method and resultant solutions of experiment 
15. Final solutions assayed displayed in bold.  
Dilution ratio Dilution method Resultant 
concentration 
1:1000 10 mcl of 250mcg/ml Synacthen in 10mls of zero 
standard  
250 ng/ml 
1:250 20 mcl of 250 ng/ml solution in 5 mls of zero standard 1000 pg/ml (15a+b) 
1:2 0.5 ml of 1000 pg/ml solution in 0.5 mls of zero 
standard 
500 pg/ml 
1:2 0.5 ml of 500 pg/ml solution in 0.5 mls of zero 
standard 
250 pg/ml 
1:2 0.5 ml of 250 pg/ml solution in 0.5 mls of zero 
standard 
125 pg/ml 
1:2 0.5 ml of 125 pg/ml solution in 0.5 mls of zero 
standard 
62.5 pg/ml 
1:2 0.5 ml of 62.5 pg/ml solution in 0.5 mls of zero 
standard 
31.3 pg/ml (15 b+c) 
1:2 0.5 ml of 31.3 pg/ml solution in 0.5 mls of zero 
standard 
15.6 pg/ml (15c) 
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4.18.2 Results	  
Table	  3.21b:	  Experiment	  15	  raw	  data.	  Results	  displayed	  are	  the	  mean	  of	  duplicate	  (15c)	  









Synacthen	  Standard	  -­‐	  
1000	  
900.6	   960.8	   -­‐	  
Synacthen	  Standard	  -­‐	  500	   560.7	   530.6	   482.4	  
Synacthen	  Standard	  -­‐	  250	   240.2	   241.1	   230.1	  
Synacthen	  Standard	  -­‐	  125	   130.1	   129.8	   123.2	  
Synacthen	  Standard	  –	  
62.5	  
<	  min	   <	  min	   64.7	  
Synacthen	  Standard	  –	  
31.3	  
-­‐	   <	  min	   27.6	  
Synacthen	  Standard	  –	  
15.6	  
-­‐	   -­‐	   <	  min	  
Synacthen	  Standard	  -­‐	  0	   -­‐	   	   	  
	  
	  
Figure	   3.15:	   Validation	   experiment	   15a-­‐c:	   Scatter	   graph	   depicting	   the	   relationship	  
between	  observed	  and	  expected	  values	  when	  Synacthen	  standards	  were	  run	  on	  three	  
different	  occasions.	  Values	  less	  than	  the	  minimum	  standard	  are	  plotted	  as	  7	  pg/ml.	  a,	  b	  
and	   c	   denote	   the	   three	   experiments	   run	   on	   different	   days.	   The	   black	   line	   denotes	   the	  
perfect	  positive	  correlation.	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4.18.3 Interpretation 
The results of experiment 15 finally showed consistency, interpretability and 
repeatability indicating that the incubation of standards in a different buffer to 
the samples was the cause of the inconsistency of results. It was thought that 
with the use of Synacthen standards, made up with the kit zero standard, the RIA 
had been validated and was reliable enough to be used to analyse the volunteer 
samples from the NeSST2 study. However it is acknowledged that because the 
antibody is raised against ACTH and not Synacthen the calibration standards 
cannot be truly validated. 
The Synacthen standards, made up from the frozen high concentration stock 
(250,000 pg/ml), were divided into aliquots and frozen to allow standards made 
up from the same batch to be used for each assay when NeSST2 Study volunteer 
samples were analysed.  
 
4.19 Further Validation 
Ideally, to complete the assay validation work, an experiment would have been 
carried out in which the measurement of Synacthen in a biological matrix 
(blood/plasma) consisting of the zero diluent was demonstrated e.g. diluting 
spiked samples of ACTH-deplete EDTA plasma in zero calibrator. The Synacthen 
assay validation had used up considerable and unanticipated funds and thus, 
given the financial restrictions, a surrogate of clinical samples was used. This was 
considered a reasonable compromise as it had not been possible to validate the 
assay before analysis of the original NeSST clinical study samples and 
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interpretable	  results	  had	  been	  obtained.	  The	  analysis	  of	  the	  NeSST2	  clinical	  study	  
samples	  (vide	  infra	  chapter	  5),	  especially	  those	  diluted	  in	  zero	  diluent,	  presented	  
the	   opportunity	   to	   validate	   the	   assay	   in	   a	   biological	  matrix.	   The	   results	   of	   the	  
Synacthen	  standards	  run	  with	  each	  assay	  are	  tabulated	  below	  (table	  3.22).	  
	  
Table	  3.22:	  NeSST2	  Study	  Synacthen	  standards	  
	   Assay	  run	  
1	   2	   3	   4	   5	   6	   7	   8	   9	  
	  
500	  




250	   228.3	   237.2	   227.7	   204.0	   235.8	   234.5	   245.0	   196.9	   261.3	  
125	   132.4	   121.7	   130.6	   127.1	   125.6	   122.1	   115.2	   129.0	   123.1	  
62.5	   69.4	   64.9	   60.2	   72.9	   78.0	   91.0	   84.0	   56.5	   56.6	  
31.3	   36.6	   39.6	   32.2	   28.6	   24.1	   26.8	   45.1	   30.7	   39.3	  
15.6	   <	  min	   <	  min	   21.9	   18.8	   22.6	   24.1	   28.8	   25.9	   10.1	  
	  
	  
Figure	   3.16:	   Line	   graph	   depicting	   the	   relationship	   between	   observed	   and	   expected	  
values	   for	   the	   Synacthen	   standards	   run	   on	   9	   hACTH	   assays	   over	   9	   months.	   Each	  
coloured	   line	   depicts	   a	   different	   assay	   run.	   The	   black	   line	   denotes	   the	   perfect	   positive	  
correlation.	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The reproducibility over nine different assays run over nine months, the linearity 
and the close relationship to expected values were immensely reassuring. 
 
Despite the difficulties validating the Synacthen assay there had always been the 
sense, after processing the NeSST Study samples, that it reliably detected 
Synacthen in vivo. Further credence was given to this when similar results were 
obtained for the 1 mcg i.v formulation (the only dose to be repeated over the 
two studies) during the analysis of the NeSST2 Study when the Synacthen 
standards were employed (table 3.23).  
 
Table 3.23: Comparison of the mean, SD and range of peak plasma Synacthen 
obtained after 1 mcg i.v administration during the NeSST and NeSST2 Studies. Range in 
parenthesis. 
 NeSST Study1 NeSST2 Study 
Mean, SD and range of peak 
plasma Synacthen (pg/ml) 
222.7 +/- 87 
(103-360.8) 
258 +/- 102.6 
(92.2-393.4) 
 
4.20 Coefficient of Variations (CV) 
QCs enable assessment of inter-assay (batch-to-batch) variability. The kit ACTH 
QCs were used for experiments 1-14 and a table of the results is shown below 
(table 3.24). The low and high QCs obtained on the 12 assay runs using the 
hACTH RIA were excessively high reflecting the problems i.e. molecular instability 
and sensitivity to temperature, encountered when using this assay to detect and 
quantify Synacthen. Inter-assay CVs were calculated (ratio of the SD to the mean) 
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and displayed in table 3.23. Inter-assay CVs are always higher than intra-assay 
CVs and ideally inter-assay CVs of competitive RIA should not be significantly 






Table 3.24: Quality Control data for all experiments with mean, SD and CV for experiments 1-14 (those which utilised the hACTH RIA kit QCs). High values 
(>3SD) in red, low values (<3SD) in blue.  
 




1 2 3 4 5 6 7a 7b 7c 8 11 13 
Low 
QC 





150.7 122.1 80.5 124.8 84.5 122.8 120.0 123.7 120.0 125.5 83.4 88.9 122.2 
(22.2) 
19.8 
Low QC (SD) = 43 (28-58) high QC (3SD) = 121 (89.5-152.5) 
 5 Discussion 
 
It was not anticipated that the work validating a Synacthen assay would be so 
challenging, protracted or expensive. It was performed over more than two 
years, with significant periods of time elapsing between some experiments. On 
reflection this has, in parts, given a lack of cohesiveness and a progressive 
narrative to the work.  
 
RIAs have been largely superseded by sandwich format ACTH assays, which do 
not detect Synacthen. With no commercially available Synacthen assay and 
limited choice of ACTH assays using a method of detection suitable for Synacthen 
the only viable option was to attempt validation of an hACTH RIA. The MP 
Biomedicals RIA was thought to be the only assay available that met the 
specifications and the manufacturer quoted 100% cross-reactivity with 
Synacthen was mistakenly assumed to represent laboratory validation.  
 
It was demonstrated over a number of experiments that diluted Synacthen did 
not behave like ACTH standards despite controlling conditions to prevent 
degradation of Synacthen at room temperature, eliminating the matrix effect, 
acidifying buffers and investigating the influence of laboratory experience. In 
retrospect the different molecular weights of ACTH (4538 g/mol) and Synacthen 
(2932 g/mol) meant that using the standard curve derived from one molecule to 
measure the concentration of the other was unlikely to be successful. 
Researchers have been criticised for this before with authors reporting that the 
Charlotte Elder  08024835 PhD Thesis     
 213 
standard curves derived from ACTH(1-24) and ACTH(1-39) were not parallel and 
therefore counselling against using ACTH(1-39) standards to measure Synacthen 
(Grino, Darmon et al. 1999). In defence of this strategy the critiqued study 
authors reported they found the displacement curves to be almost identical at 
concentrations up to 125 pg/ml but at higher concentrations the ACTH(1-24) 
displaced the ACTH(1-39) tracer more than ACTH(1-39). This was attributed to its 
lower molecular weight, but the difference was found to be no greater than their 
molecular weights ratio (0.65) (Oelkers 1999).  
 
The major on-going concern with the assay is that there remains a disparity 
between the tracer (ACTH) and the standards/samples (Synacthen). This 
contravenes the basic premise of competitive RIA - that the antibody and 
samples should compete as identical molecules. As biological matter with 
different 3-dimensional configurations and molecular weights it is probable that 
Synacthen and the ACTH antibodies (antiserum) within the assay do not bind 
with the same affinity and therefore are not recognised on a one to one molar 
basis. Previously the antiserum from a similar RIA was found to cross-react with 
the Synacthen five times more readily than with ACTH(1-39) and the authors 
counsel caution when using a RIA designed for one peptide to measure another 
highly structurally similar peptide (Grino, Darmon et al. 1999). The only way to 
overcome this would be to manufacture a specific Synacthen antiserum and 
tracer, not felt to be feasible for this study. It was hoped that, whilst 
acknowledging binding would occur with different affinity, the two would relate 
in molar terms and therefore a reproducible and reliable relationship would be 
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demonstrated. It has been seen that, although ACTH antiserum is being used to 
detect Synacthen, the use of accurately made up Synacthen specific standards 
has meant a uniformity of samples and standards and yielded reliable and 
repeatable results with an interpretable curve from which to derive Synacthen 
values for the study.  
 
An assessment of assay variability was not performed as part of the experiments, 
in part due to lack of foresight and additionally the timescale over which the 
experiments took place. Ideally a test plasma volunteer sample should have been 
taken, divided into multiple aliquots, frozen and then one thawed and run with 
each assay allowing assessment of assay “drift”. This would have been superior 
to the kit QCs, and latterly the Synacthen standards, which were used as a 
surrogate to the   same volunteer sample tested on each assay run. 
 
One of the concerns throughout the validation attempts had been the possible 
variability of Synacthen in each vial, although this would not be a plausible 
explanation for the inconsistent results. The certificate of analysis provided by 
Alliance pharmaceuticals (Wiltshire, UK) stated that 95.0-105.0% of the declared 
content is present (as detected by HPLC). That equates to 237.5-262.5 mcg, a 
wide range of potential concentrations. This degree of variability may have 
exaggerated some of the inconsistencies seen when large dilutions were 
required. The Synacthen, marketed by Alliance (the sole UK distributor), is 
diagnostic grade material and is not designed nor intended for use as a 
calibrator, which would require much more accurate measurement of content. 
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The use of accurately made up frozen standards all from one batch (and a single 
Synacthen vial) for experiment 15 and analysis of all the NeSST2 study volunteer 
samples will have helped ameliorate possible inconsistency.  
 
The approximate measuring range of the assay is between 30 and 480 pg/ml, 
approximately from the top standard to the lowest limit of detection. The most 
sensitive measuring range (steepest part of the curve) lies between these values. 





The ACTH RIA with Synacthen standards, whilst accepting some compromise of 
scientific integrity, is felt to be “good enough”. Plasma Synacthen can be 
measured to allow relative, if not absolute, comparison between samples, 
enabling the adequate quantification of Synacthen for the pharmacokinetic 
modelling required of the study. Plasma Synacthen level is not a clinically useful 
measurement, cortisol is the clinical endpoint of interest in adrenal insufficiency, 
but this assay has been adequately validated for use as a research tool. 
  










The first clinical study 
in the development of 
a non-invasive Short 
Synacthen Test  
  




The NeSST study (Non-invasive Short Synacthen Test) formed part of a body of 
work looking to simplify the way children undergo assessment of their 
adrenocortical function, particularly in relation to detecting suppression in those 
with asthma on long term, high dose inhaled corticosteroids (ICS). The 
department in which this work was undertaken had previously explored 
alternative methods for assessing adrenal reserve and possible adrenal 
suppression in children with asthma.  
 
Cortisol can be readily measured in saliva (vide supra chapter 1, section 6.2). 
Previous work, conducted in 2007, validated a salivary cortisol enzyme 
immunoassay (Salimetrics, LLC, PA, USA) against plasma cortisol and conducted 
interference studies to ensure that ICS did not cross-react with the assay. This 
method was then used to compare fasting early morning cortisol in children with 
asthma (N=55) to a healthy cohort (N=152) to assess whether the technique 
could be used as a useful screening test for adrenal insufficiency (AI). Results 
showed that fasting morning cortisol levels were inversely related to the dose of 
ICS (r=0.36, p=0.007) such that the higher the dose of ICS, the lower the cortisol. 
While significantly more children on ICS had low levels of salivary cortisol (18.2% 
compared to 7.9%, (p=<0.05) at a salivary cortisol cut off of <2.0 nmol/L 
(approximates to a plasma cortisol of <150 nmol/L)) the sensitivity and specificity 
of the test were not sufficient to discriminate those who may have AI from the 
general population (Nickson, Wilson et al. 2008). 
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It was hypothesised that the sensitivity and specificity of fasting morning salivary 
cortisol testing for AI may be significantly enhanced by repeated sampling e.g. on 
three consecutive mornings or sampling according to the Cortisol Awakening 
Response (CAR), a sharp increase in cortisol, maximal 30 minutes after waking 
(Pruessner, Wolf et al. 1997). However, a recent study on 269 non-fasted school-
aged children on ICS has shown this not to be the case, although employing a 
cortisol cut off of <350 nmol/L in response to low-dose Synacthen shows promise 
(Blair, Lancaster et al. 2013).  
 
The standard, although not gold standard, diagnostic tool for AI is the Short 
Synacthen Test (SST) (Davies and Howlett 1996, Elder, Sachdev et al. 2012) and 
thus the next logical step in this programme of work was to devise a simpler 
version to enable testing on large numbers of children. A study to evaluate 
whether Synacthen can be administered nasally rather than intravenously, using 
salivary cortisol to measure to adrenal response, was devised.  
 
It is known that some absorption of Synacthen is possible via the nasal mucosa. 
The historical studies cited (vide supra chapter 1, section 5.3.1) examined the 
potential of nasally administered ACTH analogues as a replacement for depot i.m 
ACTH (which at that time was used as a regular therapy, as an alternative to 
corticosteroid treatment in a variety of inflammatory conditions). These studies 
looked at the use of i.n ACTH from the perspective of discovering an analogue 
with the pharmacological properties to allow its long-term use in chronic 
conditions. These are not the same properties required for the SST, where only a 
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single dose is needed. There are no studies to date looking at the use of nasal 
Synacthen either in the childhood population or as a one-off diagnostic test.  
 
A pharmacokinetic study in rats suggested that the bioavailability via the nasal 
route was approximately 4.4% of the i.v route (Wuthrich, Martenet et al. 1994). 
There are no other studies to date examining the pharmacokinetics of Synacthen 
delivery via this route. The previous research, though limited, has shown nasal 
Synacthen to be well tolerated and there have been no significant safety 
concerns reported. Whilst previous studies concluded that nasally administered 
ACTH was impractical for sustained therapeutic use, as a single dose, utilised for 




2 Aims and Objectives 
 
2.1 Aim: 
To develop a non-invasive alternative to the 1-microgram (low-dose) intravenous 
Short Synacthen Test (LDSST). 
 
2.2 Objectives: 
 To establish the first bioavailability and pharmacokinetic data of nasal 
Synacthen in humans. 
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 To compare the bioavailability of two different formulations of nasal 
Synacthen with the 1 mcg i.v SST. 
 To establish the inter-individual variability of cortisol response to nasal 
Synacthen in humans. 
 
 
3 Materials and Methods 
 
3.1 Study Design 
This was a pharmacological bioavailability study using an open label, triple arm, 
crossover design (figure 4.1). The crossover design, where between occasion 
variables are minimized (e.g. fasting or fed conditions, time of day, concomitant 
medication), is the recommended methodology for generating bioequivalence 
data (European Medicines Agency 2010). Expert advice (Dr Johnson, 
pharmacokinetic pharmacist and co-collaborator on NeSST Study) was that the 
study design be based on that recommended for bioequivalence studies, 
although this was a bioavailability study (vide infra definitions section 3.5.1). It 
was considered unnecessary to demonstrate that the two formulations (i.v and 
i.n) are the same (bioequivalence) but instead show that an adequate amount of 
Synacthen is absorbed to produce equivalence in the resultant cortisol response 
(bioavailability).  







Pre-treatment with dexamethasone (1mg x 2) 
14 paired blood and saliva samples (-1 to 180 minutes) taken 
25 mcg i.n 
Synacthen 
 



















Figure 4.1: Recruitment flow chart and volunteer pathway for NeSST Study 
 
In keeping with pharmacokinetic trials of this kind the subjects were neither 
randomized nor blinded and did not receive a placebo. It was a single-centre 




The participants for the study were healthy, male volunteers aged between 18 
and 64 years of age. European Medicines Agency (EMA) guidelines were followed 
and only adult, male volunteers were enrolled due to the possible adverse 
effects of the drug on a fetus or child and to reduce variability not attributable to 
the difference between routes of administration (European Medicines Agency 
2010, Guimaraes Morais and Lobato 2010). EMA guidance states that “this 
model, in vivo healthy volunteers, is regarded as adequate in most instances to 
detect formulation differences and to allow extrapolation of the results to 
populations for which the reference medicinal product is approved (the elderly, 
children, patients with renal or liver impairment, etc.)” (European Medicines 
Agency 2010). 
 
3.2.1 Number of subjects 
 
European Medicines Agency guidance was followed and 12 subjects were 
selected as the minimum number for a bioavailability study (European Medicines 
Agency 2010). It was not felt to be ethically or financially viable to recruit or test 
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more than 12 subjects. The intention was to replace withdrawn subjects, as their 
omission would jeopardise the statistical validity of the results. 
3.2.2 Inclusion criteria 
 
1. Aged between 18 and 64 years of age 
2. Male 
3. Body Mass Index (BMI) between 18.5 and 30 kg/m2 
4. Healthy (see exclusion criteria) 
5. Non-smoker 
 
3.2.3 Exclusion criteria 
 
1. Past or present history of an endocrinopathy 
2. Past or present history of asthma 
3. Past or present history of allergic rhinitis 
4. Past or present history of peptic ulcer disease/gastrointestinal 
bleed/significant dyspepsia 
5. Past history of intra-cranial or renal/adrenal pathology 
6. Presently on any medication 
7. Presently, or within the last 3 months, been prescribed any type of 
corticosteroid (oral, inhaled, nasal, rectal, i.v, i.m, intra-articular, intra-
ocular, topical)  
8. Ever been prescribed a prolonged course of oral corticosteroids (more 
than 1 month) 
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9. Previous adverse reaction (including mild hypersensitivity) to ACTH or 
Synacthen 
10. Previous severe allergic reaction or anaphylaxis 
11. Coryzal symptoms within the last week (and will be asked to report 
any new symptoms occurring within 24 hours of the test) 




All regulatory approvals (MHRA (Medicines and Healthcare products Regulatory 
Authority), REC (Research Ethics Committee) and R+D (Research and 
Development)) were in place before volunteer enrolment into the study. 
Recruitment was predominantly by word of mouth. The first volunteers were 
recruited when the study was discussed during a teaching session for medical 
students at Sheffield University. The students themselves then disseminated the 
participant information sheets (PIL) amongst friends, who contacted the principal 
investigator (PI, author). Ethical approval for the use of posters, emails and a 
short talk before lectures had been obtained but these methods were not 
required. In order to avoid costly translation services and the risk of volunteers 
misunderstanding important information only English speakers were recruited. 
 
A detailed PIL describing the background to and aims of the study, the 
methodology, inclusion and exclusion criteria, was given to those who expressed 
an interest in participating. A minimum time of 24 hours was stipulated before 
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enrolment to allow volunteers time to consider participation. Those who felt 
themselves to be eligible contacted the PI who discussed the study in more depth 
and answered queries during a telephone conversation. 
 
Informed consent was taken over the telephone and confirmed in writing at the 
first visit. The author performed all the recruitment and obtained consent from 
all the volunteers. Consent was additionally requested for subjects’ General 
Practitioner to be informed of their participation in the study. 
 
3.2.5 Subject payment 
 
Volunteers were informed that they would be paid £75 per three and a half hour 
visit for participation in the study (£225 in total for the three visits). There were 
no additional payments for travel expenses and lost earnings and this amount 
was felt to suitably recognise the time and dedication that participation in the 
study required. 
 
3.2.6 Subject data 
 
Basic demographic data was collected on all volunteers at visit one. This included 
age and ethnic group (performed by self selecting from a standard ethnic 
categories form used in SCH). Volunteers had their height (Harpenden 
Stadiometer, Holtain Ltd, Dyfed, UK) and weight (Marsden MS4202 Adult scales, 
Oxfordshire, UK) measured. This allowed calculation of body mass index (BMI) 
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and body surface area (BSA) to enable volume of distribution calculations for 
Synacthen.  
 
At each visit subjects were asked to report coryzal symptoms beginning within 24 
hours of the test (which may impact on nasal absorption due to changes in the 
mucosa) and this was additionally checked on all subsequent visits. 
Paired samples of blood and saliva were taken throughout each visit (14 samples 
over a three hour time period). These were analysed for plasma Synacthen and 
serum cortisol and salivary cortisol and cortisone levels.  
 
3.3 Subject visits 
Following recruitment, subjects were asked to attend the Children’s Clinical 
Research Facility (CCRF) at SCH on three occasions, each separated by a 
minimum of a fortnight. This allows for a sufficient washout period between 
administrations, at least 5-half lives of the drug, although one week is typical 
(European Medicines Agency 2010). When administering Synacthen on multiple 
occasions most researchers have left between two days and two weeks between 
visits (Dickstein, Shechner et al. 1991, Crowley, Hindmarsh et al. 1993, Bridges, 
Hindmarsh et al. 1998, Nye, Grice et al. 1999, Alia, Villabona et al. 2006), 
although no significant differences in adrenal responses were shown in one study 
when large ACTH doses were given two to five days apart (Leclercq, Bruno et al. 
1972).  
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Prior to each visit volunteers were asked to abstain from alcohol and recreational 
drugs for 24 hours and to take 1 mg of dexamethasone (500mcg tablets, 
Essential Generics, Surrey, UK) on retiring the night before the visit and a second 
1 mg dose after breakfast on the morning of the visit. There are no commercially 
available Synacthen assays, or any for research purposes, and therefore it was 
necessary to temporarily suppress the volunteers’ endogenous production of 
ACTH to enable use of an ACTH assay, with the inference that anything detected 
was Synacthen. The use of 1 mg dexamethasone the night before and in the 
morning on the day of the test will adequately suppress endogenous ACTH and 
cortisol production in almost all adults (Krieger, Allen et al. 1971).  
 
Each visit commenced between 08.30 and 09.30. Volunteers were not required 
to fast. On arrival the inclusion and exclusion criteria were checked, written 
informed consent taken and basic auxological measurements performed, as 
described above. An 18-gauge i.v cannula (Jelco, Smiths Medical International, 
Lancashire, UK) was sited with an i.v connector (Alaris Products, Rolle, 
Switzerland) and the volunteer was asked to rest, lying down, for 30 minutes to 
recover from the physiological stress of cannulation. Ten minutes before the first 
samples were taken the subject was asked to rinse their mouth thoroughly with 
water to minimise contamination that may compromise salivary cortisol assay 
performance. Additionally it was requested that they refrain from eating or 
drinking, other than water, during the visit. The volunteers were asked to remain 
supine for the duration of the test.  
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3.3.1 Subject safety 
 
Synacthen has a short half-life and is not known to cause any long-term adverse 
effects. Generally nasal drugs are well tolerated (Davis and Illum 2003) and there 
are no reports of major side effects following the administration of nasal ACTH 
analogues. Minor side effects include nasal irritation, although this has generally 
only been seen with prolonged use. 
 
Synacthen can rarely cause serious allergic reactions and is potentially 
anaphylactogenic. An emergency Standard Operating Procedure (SOP) (appendix 
3) was written and approved by a Paediatric Intensive Care consultant and a 
resuscitation officer. Medical and nursing staff working on the study, were asked 
to sign that they had read and understood the emergency SOP. An individualised 
resuscitation form was completed for each subject. Resuscitation equipment and 
laminated copies of the most current Adult Basic Life Support, Advanced Life 
Support and anaphylaxis algorithm (issued by the Resuscitation Council, 2010) 
and the emergency SOP were readily available. In addition staff carrying out the 
Synacthen administration and subsequent monitoring had undergone specific 
resuscitation training with a resuscitation officer and been certified as 
competent. In the event of a serious allergic reaction there was a 24-hour 
emergency paediatric team (including an anaesthetist) available.  
 
The dexamethasone taken by subjects prior to each visit, has potential side 
effects, mostly gastrointestinal. Precautions were taken to minimise this risk 
including the exclusion of volunteers with a history of dyspepsia, peptic ulcer 
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disease or a gastrointestinal bleed and advice to avoid taking the drug on an 
empty stomach was given (verbally, in PIL and detailed on the drug bottle label). 
In addition the letter sent to volunteers’ GPs warned of these potential side 
effects. Each subject was given a copy of the letter as a hand held record to 
present to medical services if they became unwell. They also had 24-hour contact 
details of the PI for advice. 
 
3.3.2 Synacthen administration 
 
After the rest period of 30 minutes blood and saliva samples were taken for basal 
ACTH and cortisol levels (-1 minute) and immediately afterwards the Synacthen 
(250mcg/ml, Alliance Pharmaceuticals Ltd, Wiltshire, UK) was administered. At 
the first visit this entailed 1 mcg of i.v Synacthen given as a bolus. This was made 
up using the SCH protocol for the routine clinical use of the LDSST, which 
instructs diluting 0.5 ml of 250 mcg/ml solution in 500 ml of 0.9% saline, mixing 
thoroughly (ten slow inversions) and then administering 4 ml of the solution to 
the subject.  
 
At the second visit 100 mcg of i.n Synacthen was administered by atomiser 
syringe (Mucosal atomizer device™, Wolfe Tory Medical Inc. Utah, USA). The 
Mucosal atomizer device™ (MAD) atomises liquids to 30-100 microns allowing 
rapid absorption into the bloodstream and cerebrospinal fluid (Wolfe Tory 
Medical Inc. 2009) (figure 4.2) and was recommended by paediatric pharmacists 
and felt to be appropriate by nasal drug experts when consulted. Two sprays of 
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0.1 ml Synacthen (250mcg/ml) were given up each nostril, thereby administering 
100 mcg. 
 
At the third visit 25mcg of i.n Synacthen was administered (a single dose of 0.1ml 
of 250mcg/ml solution atomised using MAD to one nostril). Doses were selected 
assuming a 4% bioavailability compared with the i.v route (Wuthrich, Martenet 
et al. 1994, Davis and Illum 2003). A dose of 25 mcg nasally would approximate 
to 1 mcg i.v. The dose of 100 mcg was selected as 4-5 mcg i.v is thought to 
produce a maximal physiological cortisol response (Oelkers, Boelke et al. 1988). 
 
 
Figure 4.2: Nasal administration of Synacthen with a Mucosal atomizer device™ (Wolfe 
Tory Medical Inc. Utah, USA) and 1 ml syringe attached. Kindly drawn on instruction of 
the author for inclusion in this thesis by Kelly-Marie Nelson, research healthcare 
assistant, SCH.  
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3.3.3 Blood and saliva sampling 
 
Paired blood and saliva samples were taken at -1, 5, 10, 15, 20, 30, 40, 50, 60, 75, 
90, 120, 150 and 180 minutes (where Synacthen administration was 0 minutes). 
Approximately 1.8 mls of venous blood was taken from the cannula at each 
sampling (a total of 25 mls per visit). Following each extraction the 5 ml discard 
volume was replaced to avoid excess blood loss over the course of the visits and 
the cannula was flushed with 0.9% saline to prevent blockage by blood clot 
formation. Heparin was not used on the advice of the hACTH assay 
manufacturers (MP Biomedicals, Santa Ana, CA, USA). 
 
3.3.3.1 Plasma Synacthen 
 
At each sampling 1 ml of blood was taken into an appropriately labelled EDTA 
container and the container gently inverted. The samples were immediately 
placed in an ice bath and centrifuged within 60 minutes (due to the short half life 
of ACTH/Synacthen in whole blood). To enable long-term storage at -800c, 
Trasylol (1000KIU/ml, Bayer Healthcare Pharma, Berkshire, UK) was added to the 
plasma as per assay manufacturer instructions. Trasylol is aprotinin, a bovine 
pancreatic trypsin inhibitor, which limits protein degradation of samples by the 
inhibition of trypsin and related proteolytic enzymes, and has been shown to 
slow the disappearance of both bioactive and immunoactive ACTH (Besser, Orth 
et al. 1971). All samples were stored in the -80c freezer in the CCRF at SCH. 
Samples were transported (five minute walk) and batch analysed in the 
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Department of Clinical Chemistry at the Royal Hallamshire Hospital, Sheffield, by 
the author, between November and December 2010).  
 
3.3.3.2 Serum Cortisol 
 
A serum separator tube was filled with 0.8 mls of blood and appropriately 
labelled. Following the completion of the subject visit the samples were 
centrifuged and separated and the residual serum stored at -800c in the freezer 
in CCRF until batch analysis in the department of Clinical Chemistry at SCH, 
between December 2010 and February 2011.  
 
3.3.3.3 Salivary cortisol and cortisone 
 
A minimum of 1 ml of saliva was collected at each time point using the drool 
technique (found to be the most effective technique in the department’s 
preliminary studies (Nickson, Wilson et al. 2008)), which involves individuals 
spitting or drooling down a straw into a specialised polypropylene collection tube 
(Salicaps, IBL international, Hamburg, Germany). Following collection of saliva all 
samples were inspected for any obvious blood contamination, had this been 
discovered these samples would have been discarded. The freshly collected 
samples were frozen at -800c and stored in the freezers in the CCRF until 
completion of all the visits. Salivary samples were sent frozen in a single transfer 
on dry ice to the Department of Biochemistry at University Hospital of South 
Manchester (UHSM), Wythenshawe, UK, for batch analysis in February 2011.  
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3.3.4 End of study questionnaire 
 
At the end of each volunteer’s involvement in the study they were asked to 
complete a five-question anonymous questionnaire (appendix 4) seeking their 
perception of the experience of participating in the study and the acceptability of 




3.4.1 Plasma Synacthen 
 
The sourcing, characteristics, method and problems validating the hACTH RIA 
used to detect plasma Synacthen have been extensively discussed in chapter 3. A 
standard curve was established with each assay. 
 
3.4.2 Serum Cortisol 
Serum samples were batch analysed in order to minimise variation, using the 
Abbott Architect chemiluminescent microparticle immunoassay method (Abbott 
Diagnostics Ltd, Berkshire UK). Abbott Diagnostics quoted functional sensitivity 
(with applied 95% confidence interval) as 28 nmol/L, a linear range of 28-1650 
nmol/L, and <10% total CV for serum samples in the ≥83 to ≤966 nmol/l range. 
Quoted limit of detection (LoD) is 22 nmol/L; typical daily Quality Control 
precision (CV) at the Sheffield Children’s Hospital was 2-3% at 100, 500 and 800 
nmol/l levels (personal communication, Matthew Jordinson, senior BMS, SCH). 
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Quoted cross-reactivity with dexamethasone was 0.0%.  
 
3.4.3 Salivary Cortisol 
 
Since the work done to validate a salivary cortisol enzyme immunoassay mass 
spectrometry analysis has rapidly evolved and is the preferred method for 
quantifying salivary steroids. Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) (Waters Xevo TQ MS, Kent, UK) was used. UHSM derived assay 
characteristics showed the assay to be linear up to 3393 nmol/L, with lower 
limits of quantitation of 0.75 nmol/L and intra- and inter assay imprecision of 
<8.9% over three levels of internal QC, with recovery and accuracy within 
acceptable limits. Additionally interference studies conducted within the 
laboratory at UHSM demonstrated high specificity (Jones, Owen et al. 2012). The 
cortisol assay was unaffected by the presence of dexamethasone. 
 
3.4.4 Salivary cortisone 
 
Significant amounts of cortisol are converted to the more inert cortisone in saliva 
and it is thought that cortisone may have a closer relationship with, and be a 
better marker of, serum free cortisol compared with salivary cortisol 
(Perogamvros, Keevil et al. 2010). Additionally it is thought that cortisone may be 
partly responsible for the interference observed with salivary cortisol 
immunoassays (Jones, Owen et al. 2012). At the time of the study this was a 
research tool only and required no additional saliva. Salivary cortisol and 
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cortisone were simultaneously analysed using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) (Waters Xevo TQ MS, Kent, UK). UHSM derived 
assay characteristics showed the assay to be linear up to 3676 nmol/L, with 
lower limits of quantitation of 0.50 nmol/L and intra- and inter assay imprecision 
of <6.5% over three levels of internal QC, with recovery and accuracy within 
acceptable limits (Jones, Owen et al. 2012). The cortisone assay was unaffected 
by the presence of dexamethasone. 
 
 
3.5 Statistical analysis 
The aim of the study was to determine the bioavailability of intranasal Synacthen 
and ascertain if equivalence (for the purposes of an adrenal suppression test) is 
possible via the nasal route. 
 
The generation of bioavailability and pharmacokinetic (PK) data from plasma 
Synacthen and serum cortisol values requires specialist knowledge, expertise and 
use of pharmacokinetic modelling software. This was provided by Dr Trevor 
Johnson (co-investigator, Principal Scientist for Systems biology at Simcyp 
Limited, Sheffield UK and honorary senior pharmacist at SCH).  
 
The analysis was performed using WinNonLin 6.1 (Pharsight, Missouri, USA). This 
is the industry standard for PK, pharmacodynamic (PD) and noncompartmental 
analysis.  
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3.5.1 Pharmacokinetic definitions 
The standard PK parameters to measure bioavailability, as recommended by the 
EMA are given below (Rowland and Tozer 1995, Guimaraes Morais and Lobato 
2010). 
 AUC(0-t) is the area under the concentration time curve from time zero 
until the last quantifiable time point i.e. 180 minutes. 
 AUC(0-) area under the concentration time curve from time zero until 
infinity. 
 Bioavailability (F) is concerned with both the amount of drug present in 
the systemic circulation and the rate of systemic absorption. 
Bioavailability is often measured by comparing administration via a non-
intravenous route with the i.v route. Relative or absolute bioavailability is 
dependent on the dose and the area under the concentration-time 
profiles (AUC) following administration via the route of interest and i.v 
route (figure 4.3). Two different formulations of the same drug may have 
the same bioavailability as measured by the AUC but one formulation 
may release drug more quickly compared to the other, resulting in a 
higher initial concentration (Cmax) at an earlier time (Tmax), therefore 
the formulations would not be bioequivalent. In this study bioequivalence 
is not necessary but enough of the intranasal dose must be absorbed and 
rapidly enough to produce an equivalent cortisol response to the 1 mcg 
i.v SST. 
 
Charlotte Elder  08024835 PhD Thesis     
 237 
  
     
     
  
      
       
Figure 4.3  : Relative Bioavailability equation where F = bioavailability, AUC = area 




 Cmax is the maximum plasma concentration achieved 
 Tmax  is the time to maximum plasma concentration 
 Pharmacodynamics (PD) - the effect of the drug on the body 
 Pharmacokinetics (PK) - the effect of the body on the drug 
 Terminal t½ - the time taken to halve the plasma concentration after 
achieving pseudo-equilibrium. If plasma absorption is not a limiting factor 
then terminal t½ essentially reflects plasma clearance and distribution. 
However if plasma absorption is a limiting factor then terminal t½ is a 
marker of the rate and degree of absorption. Terminal t½ is an important 
parameter in multiple dosing regimes as it determines the extent of drug 
accumulation.  
 
3.5.2 Pharmacokinetic data preparation  
 
Prior to analysis the concentration-time data for i.v and nasal Synacthen were 
visually inspected by plotting the individual profiles in Microsoft® Excel. Any 
baselines effects (from endogenous substances i.e. ACTH or an interfering 
substrate detected in the assay) should be removed from the PK profile prior to 
analysis and thus(BTS/SIGN)(BTS/SIGN)(BTS/SIGN)(BTS/SIGN)(BTS/SIGN) the -1 
minute Synacthen values were subtracted from all concentration time points. If 
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necessary the values were fixed after the concentration fell to zero, as PK 
analysis cannot compute negative numbers. All plasma concentrations reported 
as missing or below the lower limit of quantification were excluded from the 
analysis. Data was then arranged (subject, time, concentration, dose and route) 
for import into the pharmacokinetic (PK) software Phoenix WinNonLin 6.1 
(Pharsight, Missouri, USA). 
 
3.5.3 Pharmacokinetic data analysis 
 
The standard PK parameters for bioavailability, time to maximum plasma 
concentration (Tmax), maximum plasma concentration (Cmax), area under the 
concentration time curve from time zero until the last quantifiable time point 
(AUC0-t), area under the concentration time curve from time zero until infinity 
(AUC0-) and terminal half-life (terminal t½) were calculated for each individual 
using standard methods within the Phoenix WinNonLin 6.1 non compartmental 
analysis software. These are the standard PK parameters to measure 
bioequivalence as recommended by EMA (European Medicines Agency 2010, 
Guimaraes Morais and Lobato 2010) and have been adopted as best practice in 
the NeSST Study to assess the bioavailability of the intranasal doses and 
formulations of Synacthen. For calculating the terminal t½ a minimum of three of 
the last data points were used.  
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Descriptive statistics for the PK parameters were obtained for the i.v and i.n 
formulations prior to analysis. Bioavailability was calculated using the equation 
given in figure 4.4. 
  
     
     
  
      
      
 
 
Figure 4.4: Bioavailability equation for NeSST Study. F is bioavailability, AUCin and AUCiv 
are the AUC0-t for the intranasal and intravenous formulations respectively and Dosein 
and Doseiv are the doses for the two routes.   
 
Bioavailability of the i.n formulation to the i.v formulation were assessed on the 
basis of Cmax and AUC0-t (AUC0- was not used as the Synacthen was eliminated 
very rapidly with plasma concentrations being virtually zero by time t).  
 
The concentration-response data in terms of the Cmax for the Synacthen and 
cortisol data was collated manually in Microsoft® Excel. The concentration-
response data were analysed using a number of known models (Emax, sigmoidal 
Emax, linear and power function), models were fitted using non-linear 
regression. Weighted residuals were calculated to determine the difference 
between the observed and model predicted cortisol values at each Synacthen 
concentration, these were weighted based on the concentration of Synacthen to 
allow for potential analytical errors. The sum of the squares of the weighted 
residual values was calculated and the solver function in Excel used to fit model 
parameters to minimise this value. The best-fit model was determined using the 
Akaike information criteria (figure 4.5). All plasma concentrations reported as 
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missing or below the lower limit of quantification were excluded from the 
analysis.  
           (    )          
 
Figure 4.5: Akaike Information Criteria equation. Nobs is the number of observations, 
ln(WRSS) is the weighted residual sum of squares and Npar  is the number of parameters 
in the model. 
 
3.5.4 Non-PK data analysis 
 
In addition to the pharmacokinetic modelling mean cortisol and Synacthen at the 
various time points were compared by paired t-tests with a Bonferroni correction 
applied. The timing of the peak cortisol response, the dose-response relationship 
between nasal Synacthen and cortisol production and the inter-individual 




4.1 Recruitment data 
Full planned recruitment was achieved within five weeks, well within the three 
months allocated for the purpose. Due to the method of recruitment (word of 
mouth) it is unknown how many individuals were approached to participate in 
the study. All 12 of the healthy, adult males who contacted the PI, interested in 
enrolling, were eligible for inclusion (figure 4.1). When the study was fully 
recruited a further three interested candidates had their contact details recorded 
but only one was subsequently enrolled when an individual failed to attend his 
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first visit, became uncontactable, and after several weeks was deemed to have 
withdrawn. Another individual attended for his first visit and then failed to 
attend visits, despite multiple rearrangements. The data from his visit have been 
included in the analysis. No one was recruited in his place as it had become clear 
from the results that his further involvement would not alter the overall 
outcome and it was therefore deemed unethical.  
 
Table 4.1: NeSST Study recruitment data 








Number 13 1 12 11 11 
 
4.2 Demographic and anthropometric data 
Basic data were collected from all volunteers at the first visit: age, ethnic origin, 
height and weight (both measured), from which body mass index (BMI) and body 
surface area (BSA) were calculated. Table 4.2 summarises the 12 volunteers’ 
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Table 4.2: NeSST Study subjects’ demographic and anthropometric data 





Age (years) 12 19-44 24 7 
Height (m) 12 1.748-1.985 1.838 0.067 
Weight (kg) 12 63.6-89.8 77.5 6.8 
BMI (kg/m
2
) 12 20-29.4 23.1 2.2 
BSA (m
2
)* 12 1.8-2.22 2.0 0.1 
Ethnic origin 12 10 = white British, 2= white Irish 
* Dubois Formula: Body Surface area (m2) = 0.007184 × (height in cm) 0.725 × (weight in kg)0.425 
 
4.3 Data derived from patient specimen sampling 
Paired blood and saliva sampling was performed at 14 time points from -1 to 180 
minutes. If all samples on all volunteers had been successfully obtained there 
would have been 1428 data points, however 22 were missing (table 4.3). 
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Table 4.3: NeSST Study samples collected for each subject at each visit with missing 
data points and reasons given. "Complete” indicates all 14 samples of plasma 
Synacthen, serum cortisol and salivary cortisol/cortisone (N=42) were successfully 
collected. (Pl=plasma, S=Synacthen C=cortisol) 
Subject Number Visit 1 Visit 2 Visit 3 
1 Complete No serum C samples* No 5 min blood (S+C)
$ 
2 Complete Complete No 120 min pl S
$ 
3 Complete Complete Complete 
4 Complete Complete Complete 
5 No 5 min serum C
$ 
Did not attend visit Did not attend visit 
6 Complete Complete Complete 
7 Complete Complete Complete 
8 Complete Complete Complete 
9 Complete Complete Complete 
10 Complete 
No 50 min pl S
$ 
No 180 min salivary
£
  
No 20 min blood (S+C)
$ 
11 Complete Complete Complete 
12 Complete Complete Complete 
* Samples frozen prior to centrifugation and separation therefore haemolysed 
$ Problem with cannula bleeding back 
£ Research nurse forgot to ask for sample 
 
 
4.3.1 Proof of dexamethasone suppression 
 
The in vitro assay validation experiments detailed in chapter 2 were not 
complete when the NeSST Study Synacthen samples were analysed. In order to 
validate its use for measurement of Synacthen in study volunteers it was 
necessary to demonstrate that dexamethasone had successfully suppressed the 
subjects’ ACTH and corticosteroid production. This allowed the inference that 
any “ACTH” detected by the assay was Synacthen. Table 4.4 displays the plasma 
ACTH and cortisol for all volunteers at -1 minute (prior to Synacthen 
administration). 
 
Charlotte Elder  08024835 PhD Thesis     
 244 
Table 4.4: Plasma ACTH and serum cortisol values at -1 minute for 12 NeSST Study 
volunteers. ACTH in pg/ml, normal range <10pg/ml. Cortisol in nmol/L, normal range 
<50 nmol/L. High values shown in red. 
 Visit 1 (n=12) Visit 2 (n=11) Visit 3 (n=11) 
 ACTH Cortisol ACTH Cortisol ACTH Cortisol 
1 22.4 26.1 14.6 No sample 12.7 <22 
2 38.3 <22 39.4 <22 42.3 <22 
3 168.7 <22 184.1 <22 188 <22 
4 40.6 <22 42.1 <22 40.1 <22 
5 32.6 <22 No sample No sample No sample No sample 
6 52.9 25.1 45.3 <22 39.7 <22 
7 37.9 <22 33.7 44 37.3 22.8 
8 42.3 <22 44.2 <22 46.2 <22 
9 30.1 <22 30.4 26.1 28.2 <22 
10 56.5 33.2 58 24.3 45.9 <22 
11 25.1 52 35.7 93.8 36.6 124.8 
12 32.1 27.9 64.4 <22 31.5 24.5 
 
 
The low cortisol values in table 4.4 show that at all the visits, in all but one of the 
volunteers, adequate dexamethasone suppression was demonstrated. Subject 
11, on all three visits, had partially or unsuppressed cortisol values. He was 
reportedly healthy and did not have a Cushingoid habitus. It is likely that he was 
either non-adherent with the request to take dexamethasone or that he had 
another, undisclosed, exogenous source of corticosteroid. His data were 
excluded from the relevant analyses. For all volunteers the ACTH values were 
higher than would be expected suggesting lack of suppression. They show 
marked inter-individual variability but intra-individual consistency. The -1 minute 
samples were reanalysed using an immunochemiluminmetric (sandwich) ACTH 
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assay (Immulite 2000, Siemens Healthcare Diagnostics, Munich, Germany) and all 
had undetectable ACTH values (<5 IU/l).  
 
4.3.1.1 Potential interference with Trasylol 
 
The high baseline values raised the possibility of an interfering molecule. Two 
samples were tested with and without the addition of trasylol to assess whether 
its presence was affecting the results (table 4.5). The samples were treated the 
same in all other respects and were analysed at the same time on the same 
assay. 
 
Table 4.5: Plasma Synacthen results for paired samples with and without the addition 
of trasylol (aprotinin).  
Subject sample 
Plasma Synacthen 








(pg/ml and %) 
Subject 3 
1 mcg i.v Synacthen 
20 minute sample 
104.5 86.2 18.3 (17.5%) 
Subject 5 
1 mcg i.v Synacthen 
30 minute sample 
198.7 175.8 22.9 (11.5%) 
  
4.3.2 Comparison of intravenous and nasal administration routes 
 
The individual plasma Synacthen responses to each of the three doses of 
Synacthen are shown in figures 4.6a-c. High baseline and individual variation can 
be seen. It is clear that a single individual (subject 3, depicted in light green) had 
a significantly higher baseline in all three tests, compared with the other 
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subjects, and had greater overall variability. The mean plasma Synacthen (figure 
4.7a) and mean serum cortisol (figure 4.7b) over time following administration 
with each of the three doses of Synacthen is shown.  
 
  
 Figure 4.6a: Graph of the individual plasma Synacthen responses to i.v administration with 1 mcg Synacthen (baseline not subtracted). Each line 
depicts an individual study subject. 
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Figure	  4.6b:	  Graph	  of	  the	  individual	  plasma	  Synacthen	  responses	  to	  i.n	  administration	  with	  100	  mcg	  Synacthen	  (baseline	  not	  subtracted).	  
Each	  coloured	  line	  depicts	  a	  study	  subject.	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Figure 4.6c: Graph of the individual plasma Synacthen responses to i.n administration with 25 mcg Synacthen (baseline not subtracted). 





Figure	  4.7a:	  Graph	  of	  the	  mean	  rise	  of	  plasma	  Synacthen	  from	  baseline	  in	  subjects	  following	  administration	  with	  1	  mcg	  i.v,	  100	  mcg	  i.n	  and	  25	  
mcg	  i.n	  Synacthen.	  Standard	  deviations	  shown	  as	  error	  bars.	  




























Figure 4.7b: Graph of the mean rise of serum cortisol from a suppressed baseline in subjects following administration with 1 mcg i.v, 100 mcg i.n and 25 
mcg i.n Synacthen. Standard deviations shown as error bars. 
In order to compare the efficacy of the two routes the subjects’ mean plasma 
Synacthen and serum cortisol levels were compared at each time point (table 4.6 
summarises the data for all three tests and tables 4.7a-4.7f display the statistical 




 Table 4.6: Mean plasma Synacthen and serum cortisol at each time point for subjects undergoing the three NeSST study visits. SDs shown in parentheses. 
 1 mcg i.v visit 100 mcg i.n visit 25 mcg i.n visit 
 Synacthen pg/ml Cortisol nmol/L 
N = 11 
Synacthen pg/ml Cortisol nmol/L 
N = 10 
Synacthen pg/ml Cortisol nmol/L 
N = 10 
Mins N = 11 No S3* 
N = 10 
Minus baseline 
N = 11 
N = 10 No S3* 
N = 9 
Minus 
baseline 
N = 10 
N = 10 No S3* 
N = 9 
Minus 
baseline 
N = 10 
-1 50.4 (40.4) 38.6 (0.0) 0.0 (0.0) 23.6 (4.1) 55.6 (47.2) 41.3 (14.7) 0.0 (0.0) 32.0 (23.8) 51.2 (49.1) 36.0 (10.6) 0.0 (0.0) 30.9 (31.6) 
5 273.1 (101.8) 254.0 (215.5) 222.7 (87.0) 92.2 (57.2) 62.0 (45.7) 48.3 (14.5) 6.4 (4.9) 32.5 (25.7) 62.5 (54.5) 44.7 (11.2) 7.6 (7.4) 30.5 (30.0) 
10 112.0 (55.4) 95.9 (57.6) 61.6 (21.1) 226.9 (44.5) 63.9 (53.9) 47.7 (17.1) 8.6 (7.8) 56.4 (34.5) 57.3 (46.9) 42.9 (10.9) 6.2 (3.8) 31.4 (25.2) 
15 73.5 (42.8) 61.2 (22.6) 23.1 (13.5) 338.7 (52.0) 77.5 (59.2) 63.3 (41.1) 22.0 (28.6) 102.2 (55.0) 57.1 (48.3) 42.2 (11.8) 6.0 (4.9) 52.0 (41.6) 
20 62.2 (44.8) 49.1 (10.5) 11.8 (7.4) 359.0 (49.3) 69.1 (47.9) 56.1 (25.9) 13.5 (12.8) 142.1 (74.8) 54.5 (54.1) 36.7 (10.1) 4.1 (4.0) 50.7 (40.7) 
30 59.3 (44.5) 46.4 (7.9) 9.1 (6.8) 377.1 (46.9) 63.1 (48.9) 49.1 (21.7) 7.5 (9.6) 150.9 (73.7) 50.6 (43.5) 37.3 (12.0) 2.3 (3.0) 64.9 (55.9) 
40 53.6 (41.7) 41.5 (3.3) 3.5 (2.5) 337.0 (51.5) 62.7 (48.9) 48.8 (22.8) 7.1 (10.1) 128.9 (63.6) 54.8 (49.0) 40.1 (16.5) 5.4 (7.6) 52.7 (43.0) 
50  53.5 (41.0) 41.5 (3.3) 3.4 (3.0) 285.4 (55.7) 56.4 (53.2) 39.1 (11.9) 3.1 (3.5) 109.7 (57.7) 56.1 (50.1) 41.1 (17.6) 7.0 (8.2) 46.4 (33.1) 
60 49.9 (38.8) 38.6 (1.7) 1.5 (2.6) 253.5 (51.4) 62.9 (58.1) 45.8 (22.6) 6.0 (9.2) 94.7 (49.6) 58.5 (52.2) 43.4 (22.5) 9.3 (13.7) 42.9 (28.3) 
75 49.8 (38.2) 38.5 (1.7) 1.5 (2.5) 216.4 (49.7) 82.7 (110.1) 48.5 (21.7) 7.4 (8.5) 78.2 (32.0) 58.6 (50.8) 43.9 (21.6) 9.2 (13.9) 39.0 (23.9) 
90 48.2 (39.8)) 36.4 (0.9) 0.8 (1.4) 186.0 (51.4) 94.6 (163.7) 43.2 (17.6) 2.7 (3.4) 66.9 (36.6) 61.0 (66.7) 40.8 (21.2) 12.4 (19.0) 35.0 (19.6) 
120 50.2 (40.0) 38.7 (1.5) 1.4 (2.2) 142.9 (37.0) 60.4 (49.9) 46.4 (24.1) 6.3 (10.4) 52.4 (26.8) 62.7 (66.5) 41.1 (16.0) 11.6 (14.9) 30.1 (12.9) 
150 47.9 (42.3) 35.5 (0.3) 0.6 (1.2) 108.8 (27.3) 52.9 (48.9) 38.1 (14.7) 1.4 (2.3) 42.1 (19.1) 57.6 (67.8) 36.6 (13.6) 10.0 (19.1) 27.2 (8.7) 
180 46.9 (37.4) 36.0 (0.6) 0.5 (1.4) 81.8 (22.1) 52.4 (44.9) 38.7 (12.4) 1.0 (1.6) 33.7 (11.7) 57.4 (60.2) 38.7 (11.8) 8.9 (12.7) 24.8 (5.2) 
*No S3 – data with subject 3 removed (high baseline Synacthen in all three visits) 
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Table 4.7a: Mean, Standard deviation (SD), Standard error of the mean (SEM) and p value (paired t-test with Bonferroni correction) results of plasma 
Synacthen levels comparing 1 mcg i.v and 100 mcg i.n Synacthen at 14 time points (N=10). Statistical significance defined as p value <0.004 and denoted in 
red. 
Time (mins) 5 10 15 20 30 40 50 60 75 90 120 150 180 
Mean 
1 mcg i.v 232.0 61.3 22.2 11.8 10.0 3.8 4.2 1.7 1.2 0.9 1.5 0.6 0.6 
100 mcg i.n 6.4 8.6 22.0 13.5 7.5 7.1 3.1 6.0 7.4 2.7 6.3 1.4 1.0 
SD 
1 mcg i.v 85.8 22.2 13.8 7.8 6.4 2.4 2.7 2.7 2.5 1.5 2.3 1.2 1.5 
100 mcg i.n 4.9 7.8 28.6 12.8 9.6 10.1 3.5 9.2 8.5 3.4 10.4 2.1 1.6 
SEM 
1 mcg i.v 27.1 7.0 4.4 2.5 2.0 0.8 0.9 0.9 0.8 0.5 0.7 0.4 0.5 
100 mcg i.n 1.5 2.5 9.0 4.1 3.0 3.2 1.2 2.9 2.7 1.1 3.3 0.7 0.5 
P value <0.0001 <0.0001 NS (0.99) NS (0.78) NS (0.59) NS (0.38) NS (0.45) NS (0.23) NS (0.07) NS (0.20) NS (0.19) NS (0.34) NS (0.63) 
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Table 4.7b: Mean, Standard deviation (SD), Standard error of the mean (SEM) and p value (paired t-test with Bonferroni correction) results of plasma 
Synacthen levels comparing 1 mcg i.v and 25 mcg i.n Synacthen at 14 time points (N=10). Statistical significance defined as p value <0.004 and denoted in 
red. 
Time (mins) 5 10 15 20 30 40 50 60 75 90 120 150 180 
Mean 
1 mcg i.v 219.6 61.3 22.2 12.3 10.0 3.8 3.8 1.7 1.2 0.9 1.5 0.6 0.6 
25 mcg i.n 7.6 6.2 6.0 4.1 2.3 5.4 7.0 9.3 9.2 12.4 11.6 10.0 8.9 
SD 
1 mcg i.v 81.0 22.2 13.8 8.1 6.4 2.4 2.9 2.7 2.5 1.5 2.3 1.2 1.5 
25 mcg i.n 7.4 3.8 4.9 4.0 3.0 7.6 8.2 13.8 13.9 19.0 14.9 19.1 12.7 
SEM 
1 mcg i.v 27.0 7.0 4.4 2.7 2.0 0.8 0.9 0.9 0.8 0.5 0.7 0.4 0.5 
25 mcg i.n 2.5 1.2 1.6 1.3 1.0 2.4 2.6 4.4 4.4 6.0 4.7 6.0 4.0 
P value <0.0001 <0.0001 NS (0.009) NS (0.022) NS (0.020) NS (0.500) NS (0.292) NS (0.124) NS (0.101) NS (0.097) NS (0.067)  NS (0.138) NS (0.074) 
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Table 4.7c: Means, Standard deviations (SD), Standard error of the mean (SEM) and p values (paired t-test with Bonferroni correction) results of plasma 
Synacthen levels comparing 25 mcg and 100 mcg i.n Synacthen at 14 time points (N=10). Statistical significance defined as p value <0.004 and denoted in 
red.  
Time (mins) 5 10 15 20 30 40 50 60 75 90 120 150 180 
Mean 
25 mcg i.n 7.6 6.2 6.0 4.1 2.5 5.8 5.2 9.3 9.1 12.1 11.4 9.9 8.9 
100 mcg 
i.n 
6.5 8.6 22.0 13.4 7.2 9.5 6.2 8.5 9.8 5.5 8.8 4.4 4.0 
SD 
25 mcg i.n 7.4 3.8 4.9 4.0 2.9 7.3 4.7 13.1 13.2 18.1 14.2 18.1 12.0 
100 mcg 
i.n 
5.2 7.8 28.6 13.6 9.2 12.6 10.3 12.1 11.4 10.0 12.9 10.0 10.0 
SEM 
25 mcg i.n 2.7 1.2 1.6 1.3 0.9 2.2 1.5 3.9 4.0 5.4 4.3 5.5 3.6 
100 mcg 
i.n 
1.7 2.5 9.0 4.5 2.8 3.8 3.2 3.7 3.4 3.0 3.9 3.0 3.0 
P value NS (0.751) NS (0.458) NS (0.076) NS (0.052) NS (0.065) NS (0.351) NS (0.776) NS (0.891) NS (0.913) NS (0.317) NS (0.647) NS (0.387) NS (0.329) 
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Table 4.7d: Means, Standard deviations (SD), Standard error of the mean (SEM) and p values (paired t-test with Bonferroni correction) results comparing 
the serum cortisol response to 1 mcg i.v and 100 mcg i.n Synacthen at 14 time points (N=9). Statistical significance defined as p value <0.004 and denoted 
in red.  
Time (mins) 5 10 15 20 30 40 50 60 75 90 120 150 180 
Mean 
1 mcg i.v 85.5 227.0 335.5 350.1 369.0 335.2 285.6 254.4 217.6 187.4 145.8 112.5 83.8 
100 mcg 
i.n 
25.0 52.4 102.1 144.6 154.0 130.3 110.2 95.0 77.8 67.3 52.9 41.6 33.6 
SD 
1 mcg i.v 45.0 47.2 56.3 47.9 48.0 57.2 61.4 56.9 55.3 57.4 39.6 28.4 22.7 
100 mcg 
i.n 
6.4 34.9 70.5 93.1 96.1 90.5 80.8 69.2 53.2 48.1 32.4 23.8 15.2 
SEM 
1 mcg i.v 15.0 15.7 18.8 16.0 16.0 19.1 20.5 19.0 18.4 19.1 13.2 9.5 7.8 
100 mcg 
i.n 
2.1 11.6 23.5 31.0 32.0 30.2 26.9 23.1 17.7 16.0 10.8 7.9 5.1 
P value 0.005 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
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Table 4.7e: Means, Standard deviations (SD), Standard error of the mean (SEM) and p values (paired t-test with Bonferroni correction) results comparing 
the serum cortisol response to 1 mcg i.v and 25 mcg i.n Synacthen at 14 time points (N=10). Statistical significance defined as p value <0.004 and denoted 
in red. 
Time (mins) 5 10 15 20 30 40 50 60 75 90 120 150 180 
Mean 
1 mcg i.v 85.5 226.9 334.8 350.8 372.9 335.2 287.5 255.5 217.8 186.9 146.1 111.7 84.4 
25 mcg i.n 21.0 24.0 46.7 45.1 61.5 50.4 43.6 39.2 36.1 32.3 27.7 26.4 23.7 
SD 
1 mcg i.v 45.0 44.5 53.1 48.2 47.1 54.0 58.3 53.7 52.2 54.1 37.3 26.9 21.5 
25 mcg i.n 0.0 5.3 39.8 39.0 57.7 44.5 33.4 26.8 22.9 18.4 10.8 8.8 3.9 
SEM 
1 mcg i.v 15.0 14.1 16.8 16.1 14.9 17.1 18.4 17.0 16.5 17.1 11.8 8.5 6.8 
25 mcg i.n 0.0 1.7 12.6 13.0 18.2 14.1 10.6 8.5 7.3 5.8 3.4 2.8 1.2 
P value 0.003 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
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Table 4.7f: Means, Standard deviations (SD), Standard error of the mean (SEM) and p values (paired t-test with Bonferroni correction) results comparing 
the serum cortisol response to 25 mcg and 100 mcg i.n Synacthen at 14 time points (N=9). Statistical significance defined as p value <0.004 and denoted in 
red.  
Time (mins) 5 10 15 20 30 40 50 60 75 90 120 150 180 
Mean 
25 mcg i.n 21.0 24.3 49.5 48.2 66.0 53.6 46.1 41.2 37.7 33.5 28.4 27.0 24.0 
100 mcg i.n 25.0 52.4 102.1 128.7 154.0 130.3 110.2 95.0 77.8 67.3 52.9 41.6 33.6 
SD 
25 mcg i.n 0.0 5.5 41.1 40.5 59.3 46.0 34.5 27.6 23.7 19.1 11.2 9.1 4.0 
100 mcg i.n 6.4 34.9 70.5 85.4 96.1 90.5 80.8 69.2 53.1 48.1 32.4 23.8 15.2 
SEM 
25 mcg i.n 0.0 1.8 13.7 14.3 19.8 15.3 11.5 9.2 7.9 6.4 3.7 3.0 1.3 
100 mcg i.n 2.1 11.6 23.5 30.2 32.0 30.2 26.9 23.1 17.7 16.0 10.8 7.9 5.1 
P value 0.097 0.049 0.025 0.009 0.001 0.003 0.006 0.008  0.006 0.015 0.012 0.055  0.056 




The data demonstrate lower plasma Synacthen levels following nasal 
administration compared with the i.v route (more marked after the 25 mcg dose) 
with significant differences at 5 and 10 minutes in both nasal doses. There was 
no statistical difference between plasma Synacthen levels at any time point 
between the two nasal doses. The small rise in plasma Synacthen seen with 100 
mcg is delayed to 15 minutes post administration compared with that following 
the i.v dose. The standard deviations displayed in table 4.6 and error bars at the 
5 minute i.v peak in figure 4.7a indicate considerable inter-individual variability 
at most time points and for all three tests, some of this variation is explained by 
skewing caused by individual data. 
 
The cortisol responses from each of the three tests, shown in figure 4.7b, 
although present, are clearly reduced, in a dose-dependent manner, following 
nasal administration. The reduction in serum cortisol levels is highly statistically 
significant at all time points after 10 minutes when comparing 100 mcg i.n 
Synacthen and i.v and at all time points when comparing 25 mcg i.n to i.v. The 
cortisol response is significantly higher at 30 and 40 minutes when 100 mcg i.n 
Synacthen is administered compared to 25 mcg i.n. (tables 4.7d-f). 
 
4.3.3 Dose-response relationship of Synacthen and cortisol 
 
When looking at the dose of Synacthen that produces a maximal cortisol effect 
the relationship between peak plasma Synacthen, using the two different routes 
of administration, and peak serum cortisol was studied. Dr Johnson performed 
this analysis using a number of different models. The sigmoidal Emax gave the 




best-fit for the concentration-response data. The concentration of plasma 
Synacthen to produce half maximum response was calculated to be 44 pg/ml as 
10/11 Synacthen concentrations following a 1 mcg i.v dose were more than twice 
this concentration (88 pg/ml), indicating that for all the adult subjects studied a 1 
mcg dose will give a near maximal effect (figure 4.8). Correction of values for 
differences in body size (using BMI and BSA) and volume of distribution (Vd) did 
not impact on the relationship. 
 
Figure 4.8: NeSST Study individual peak plasma Synacthen plotted against peak serum 
cortisol following administration of three Synacthen doses  
 
4.3.4 Characteristics of the i.v low-dose Short Synacthen Test 
 
Performing a LDSST in 12 volunteers with 14 sampling times enabled an in-depth 
study of the test and its performance characteristics (table 4.8). On further 


























Plasma Synacthen pg/ml 
25mcg in 100 mcg in 1 mcg IV Model fit Linear (1 mcg IV)




minutes, the first sampling time after i.v injection, and returned to baseline by 20 
minutes in all volunteers (figure 4.6a). The mean peak plasma Synacthen level 
was 222.7 pg/ml (SD 87 pg/ml) (range 103.6 to 360.8 pg/ml).  
 
The Vd for Synacthen was very small and similar to typical blood volume. The 
clearance (CL) was intermediate, consequently the elimination half- life of the 
drug, calculated from 0.693*Vd/CL, was very short with a median value of only 
6.6 minutes. The related parameter ‘Mean Residence time’ (average time a 
molecule of Synacthen stays in the body) was also short at approximately 10 
minutes. 
 
Table 4.8: Summary of the PK (pharmacokinetic) parameters for 1 mcg i.v Synacthen 
PK Parameter Mean SD Median Range 
Clearance (ml/min) 675 313 680 324 - 1446 
Volume of 
distribution (ml) 
5275 2941 4680 2399 - 12050 
Cmax (pg/ml) 222.7 101 178 103.6 – 360.8 
Tmax (min) < 5 0 <5 - 
AUC0-t (min*pg/ml) 1640 811 1443 691 - 3082 
Mean Residence Time 
(min) 
10.98 4.3 9.81 6.7 – 20.8 
Elimination half-life 
(min) 
8.24 8.28 6.6 2.14 – 33.39 
 
The cortisol peak was seen to occur at different times: 18% (2/11) at 15 minutes, 
18% (2/11) at 20 minutes, 45% (5/11) at 30 minutes and 18% (2/11) at 40 
minutes. The mean peak cortisol was 383.8 (SD 48.7 nmol/l, range 314 to 450 
nmol/l), lower than would be expected. All the volunteers achieved an 




incremental rise from a suppressed baseline cortisol of more than 200 nmol/l 
(314-450 nmol/l) (table 4.9). 
 
Table 4.9: NeSST Study individual data displaying operating characteristics of i.v LDSST 














1 343.4 410 30 384 
2 186.2 314 15 314 
3 295.1 326 30 326 
4 169.6 389 30 389 
5 129.9 430 20 430 
6 164.8 383 20 358 
7 275.0 327 40 327 
8 252.6 450 15 450 
9 360.8 443 30 443 
10 168.7 426 40 393 




4.3.5 Pharmacokinetic data comparing i.v and i.n routes 
 
The data were analysed by the standard PK parameters for bioavailability and 
bioequivalence: Tmax, Cmax and AUC0-t.  The descriptive statistics for the i.v and 
i.n formulations and doses are shown in table 4.10.  
 
  




Table 4.10:  Summary statistics for bioavailability (F), Cmax and AUC0-t for the 25 mcg 
and 100 mcg nasal tests. 
100 mcg dose (n = 11) 
 AUC0-t Cmax Tmax F  F  
(Uncorrected for 
dose) 
Formulation nasal i.v nasal i.v nasal i.v   
Median 341 1443 14.9 178 17.5 5 0.00198 0.197 
Min 152 691 5.96 103 15 5 0.00067 0.0669 
Max 1237 3082 97 360 20 5 0.0179 1.78 
 
25 mcg dose (n = 11) 
 AUC0-t Cmax Tmax F  F  
(Uncorrected for 
dose) 
Formulation nasal i.v nasal i.v nasal i.v   
Median 148 1443 10.17 178 10 5 0.0023 0.0575 
Min 14 691 2.91 103.6 10 5 0.00043 0.0108 
Max 459 3082 18.6 360.8 10 5 0.0265 0.664 
 
 
The median absolute bioavailability of the 100 mcg intranasal dose was 
approximately 0.2% of the 1 mcg i.v dose but there was a great deal of variability 
(range 0.0007 to 0.179%), with one subject having a higher bioavailability with 
the nasal dose. The time to maximum concentration (Tmax) was longer for 
intranasal at 17.5 minutes compared to 5 minutes following i.v administration. 
The maximum concentration (Cmax) was approximately 8.3% of i.v (14.9 pg/ml 
compared with 178 pg/ml). The median Cmax ratio (nasal/i.v) was 0.088. 
 
The data following administration with 25 mcg intranasal Synacthen must be 
viewed with caution as so little of the drug was absorbed. The median absolute 
bioavailability was 0.24% compared with i.v (similar to that seen with 100 mcg). 




The Tmax was 10 minutes compared to 5 minutes i.v and the Cmax 5.7% of i.v 
(10.2 pg/ml compared with 178 pg/ml). The median Cmax ratio (nasal/i.v) was 
0.044. Results of the pair-wise comparisons of the nasal formulation at the two 
dose levels are shown in table 4.11. 
 
 
Table 4.11: Bioavailability assessment: point estimate and 90% confidence interval for 
ratio of geometric means for Cmax and AUC0-t 
 Cmax AUC0-t 
100 mcg nasal versus i.v 0.087 (0.04-0.176) 0.226 (0.120 – 0.423) 
25 mcg nasal versus i.v 0.044 (0.026 – 0.072) 0.065 (0.03 – 0.147) 
 
The bioavailability of intranasal Synacthen was very low and if the same criteria 
were used as for bioequivalence, with acceptance criteria for the confidence 
intervals set at 0.8 to 1.25 (standard for PK analysis), then the nasal formulation 
would fail with respect to both Cmax and AUC. 
 
 
4.4 Relationship between serum cortisol, salivary cortisol and 
salivary cortisone 
Part of the process of validation of a non-invasive LDSST entails the 
demonstration of a close and reliable relationship between serum and salivary 
cortisol. At each time point paired serum and saliva samples were taken to 
enable relational analysis. In total 459 paired samples were obtained. The scatter 
plot of their correlation is shown below (figure 4.9a).  
 





Figure 4.9a: Scatter plot of paired serum and salivary cortisol samples following 
Synacthen administration in the NeSST Study (salivary cortisol below the limit of assay 
detection displayed as 0.74 nmol/L and serum cortisol as 21 nmol/L). 
 
There was a disappointing lack of a convincing correlation between serum and 
salivary cortisol, some of which may have been attributable to the time delay in 
cortisol reaching the saliva and some due to the skewing effect of so many 
samples with undetectable salivary cortisol. Reanalysis was performed with any 
value below the limit of detection excluded and correlating the peak serum and 
peak salivary cortisol, to take into account their different timings (N=19) (figure 
4.9b). It shows a closer relationship, although that is based on many fewer data 
points. 
y = 0.6024e0.0049x 
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Figure 4.9b: Scatter plot of peak serum and peak salivary cortisol samples following 
Synacthen administration in the NeSST Study (salivary and serum cortisol below the 
limit of assay detection removed). 
 
A closer relationship has been described between serum cortisol and salivary 
cortisone (Perogamvros, Keevil et al. 2010). Figure 4.10a displays the correlation 
of paired samples and figure 4.10b shows the correlation enhanced, albeit with 
many fewer data points, by removal of values below the lower limit of detection 
and the peak serum cortisol value correlated against the peak salivary cortisone.  
 
y = 0.5428e0.0061x 
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Figure 4.10a: Scatter plot of paired serum cortisol and salivary cortisone samples 
following Synacthen administration in the NeSST Study (salivary cortisone below the 
limit of assay detection displayed as 0.4 nmol/L and serum cortisol as 21 nmol/L). 
 
 
Figure 4.10b: Scatter plot of peak serum cortisol and peak salivary cortisone samples 
following Synacthen administration in the NeSST Study (salivary cortisone and serum 
cortisol values below the limit of assay detection have been removed). 
y = 0.0554x + 0.8756 
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The correlation between salivary cortisol and salivary cortisone was also sought 
and 475 paired samples analysed (figure 4.11a). Once again analysis was 
performed with any value below the limit of detection excluded and the peak 
salivary cortisol and peak salivary cortisone correlated (N=19) (figure 4.11b).  
 
 
Figure 4.11a: Scatter plot of paired salivary cortisol and cortisone samples following 
Synacthen administration in the NeSST Study (salivary cortisone below the limit of assay 
detection displayed as 0.4 nmol/L and cortisol as 0.74 nmol/L). 
y = 0.1527x + 0.4397 

























Salivary Cortisone nmol/L 






Figure 4.11b: Scatter plot of peak salivary cortisol and peak salivary cortisone samples 
following Synacthen administration in the NeSST Study. 
 
The correlation between salivary cortisol and salivary cortisone was not as tight 
as predicted, although tightened by looking at the peaks, rather than paired 
samples. The relative timing of the peaks was then analysed. 
 
4.4.1 Salivary cortisol and salivary cortisone peak timings 
 
The timing of the peak serum cortisol following administration of Synacthen is 
likely to differ to that of peak salivary cortisol or cortisone. The timings of the 
salivary cortisol and cortisone peaks are displayed in table 4.12.  
y = 0.2528x - 0.7899 
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Table 4.12: Timings of the salivary cortisol and salivary cortisone peaks following 
administration with three different doses of Synacthen in the NeSST Study. 
 Salivary Cortisol Salivary Cortisone 
Minutes 1 mcg 100 mcg 25 mcg 1 mcg 100 mcg 25 mcg 
20 0 1 0 0 0 0 
30 7 0 0 1 0 0 
40 4 1 0 10 3 2 
50 1 0 0 1 3 2 
75 0 0 0 0 1 0 
No peak 0 9 11 0 4 7 
Total 12 11 11 12 11 11 
 
Following administration with 1 mcg Synacthen i.v the peak in salivary cortisol 
was seen in the majority at 30 minutes but with a third peaking at 40 minutes. 
Salivary cortisone peaked later and more reliably at 40 minutes. 
 
When examining the salivary responses to all three doses of Synacthen it was 
observed that cortisone is the more sensitive marker of adrenocortical response 
at lower concentrations compared with cortisol. Many of the nasal tests had 
salivary cortisol responses below the limit of assay detection but a measureable 
cortisone response was seen. A flat response was observed in salivary cortisol for 
all 25 mcg tests and 82% of 100 mcg tests. There was a lack of discernable 
salivary cortisone peak seen in a third of study subjects following 100 mcg and 
two thirds following 25 mcg nasal Synacthen.  
 
 




4.5 Study volunteer feedback 
The nasal administration of Synacthen via a mucosal atomizer device was 
straightforward and required no formal training. All volunteers, except one who 
did not attend after the first visit, completed an anonymous, five-question, 
questionnaire. All responses affirmed that volunteers had found the 
administration of nasal Synacthen easy and the salivary samples straightforward 
to produce. The results of the questionnaire are tabulated and the free text 
answers summarised in tables 4.13a-d below. 
 
Table 4.13a: Responses to question 1: How did you find having the nasal spray 
administered? 




8 2 1 0 0 0 11 
 
Only four comments were made “Far easier than any spray I have had before”, 
“No problem, “Very quick to administer” and “It’s a bit painful if the hard tip is 
pushed against the septum so maybe make sure it goes in straight and isn’t 
pushed at an angle”. 
 




Unpleasant Very unpleasant 
TOTAL 
9 2 0 0 11 
 




Four respondents commented on a vinegary smell/taste, due to the acetic acid, 
which forms a major constituent of the Synacthen preparation used. Those who 
commented said it was short-lived and not unduly unpleasant.  
 
Table 4.13c: Responses to question 3: Did you experience any unpleasant side effects 
from the nasal Synacthen? 





1 0 0 0 0 1 10 11 
 
Subjects were asked to “tick all that apply” and a single respondent entered the 
stinging and nasty taste. All others indicated that they had experienced no 
unpleasant side effects, although three commented on the vinegary taste. 
 
Table 4.13d: Responses to question 4: Overall how did you find the nasal Synacthen 
compared with the intravenous Synacthen? 
Much better Better 
Much the 
same 
Worse Much worse TOTAL 
1 5 4 1 0 11 
 
The respondent who answered “worse” qualified this by commenting “only 
slightly worse due to unpleasant vinegary smell”. Summarising a number of the 
respondents’ comments they felt that, although they did not find being 
cannulated unpleasant, they could see the nasal route being preferable for 
children or needle phobic adults. 




4.5.1 General comments  
 
Those who chose to comment complimented the running of the study. 
 
4.6 Safety 
There were no adverse events of any severity or type during the 34 visits.  
 
4.7 Summary of results  
 
The bioavailability achieved with 100 mcg and 25 mcg doses of nasal Synacthen 
were 0.2 and 0.24% respectively, compared to a 1 mcg i.v dose, this is more than 
16 times less than suggested by the study conducted in rats (Wuthrich, Martenet 
et al. 1994). The Cmax was 8.3% of i.v with 100 mcg and 5.7% with 25 mcg. The 
Tmax was 17.5 minutes with 100 mcg and 10 minutes with 25 mcg compared 
with 5 minutes (first time point measured after iv administration) after i.v. 
Equivalence, in terms of a reliable SST dosing regimen, was not achieved. There 
was considerable variation in the height and timing of the individual’s cortisol 




5.1 Proof of dexamethasone suppression 
The hACTH RIA employed uses a single epitope near the N terminus of the 
molecule (amino acid sequence 5-18) for detection and was quoted as cross-




reacting 100% with Synacthen. Single-site RIAs are sensitive but may lack 
specificity. It was this lack of specificity, which was exploited to allow detection 
of Synacthen but required endogenous ACTH to be suppressed. Dexamethasone, 
at a standard suppression dose of 1mg on two occasions prior to the test, was 
used for this purpose. 
 
Baseline (-1minute) ACTH and cortisol values were used to demonstrate 
adequate suppression. All but one of the volunteers (excluded from most 
analyses) had cortisol values of <50 nmol/L, the majority undetectable. In 
contrast to the cortisol, the ACTH values at -1 minute appeared unsuppressed for 
all volunteers. A number of factors have led to the supposition that there was 
assay interference by an unrelated yet structurally similar molecule. Both the 
ACTH (on the Immulite 2000 (Siemens) sandwich assay) and cortisol were shown 
to be adequately suppressed and thus the interfering molecule is likely to be 
unrelated to any HPA-axis molecule, due to its lack of suppression in the 
presence of dexamethasone. The values show remarkable intra-individual 
consistency but considerable inter-individual difference, implying interference 
with a molecule whose levels are person-specific, relatively constant within an 
individual but vary between individuals. Following administration of Synacthen 
the plasma values were seen to rise and then return to baseline by 20 minutes in 
all volunteers, allowing the inference that the interfering molecule was stable 
and unaffected by either dexamethasone or Synacthen.  
The presence of assay interference compromises the scientific integrity of the 
method employed to measure Synacthen. MP Biomedicals, the hACTH RIA 




manufacturer, was contacted and the data shared for their insights and advice. 
The information quoting 100% cross-reactivity with Synacthen, contained within 
the Directional Insert, was a supposition as the assay has never been tested 
against Synacthen. They had more than twenty-five years of experience with the 
same antibody but no records of similar problems and thus struggled to 
reproduce or explain the findings. They questioned whether the high baseline 
values might represent cross-reactivity with the dexamethasone and tested this 
reporting it not to be the case. 
 
The presence of trasylol was tested and demonstrated higher results in the non-
trasylol samples, although the values were not vastly different. Trasylol works to 
inhibit enzymatic degradation of Synacthen and as such one would expect that 
the samples with no added trasylol would contain less Synacthen. The difference 
in results is likely to represent assay variation rather than an inhibitory effect of 
trasylol. Only two samples were dual tested. Analysing more samples and those 
at -1 minute would have helped to more conclusively answer the question 
concerning assay interference. 
 
A meeting to review all the data was convened and the expert opinion sought 
was that, due to the relative stability of the molecule, if baseline values are 
subtracted from all subsequent time points, then the inference that any rise is 
due to Synacthen remains valid. 
 




One volunteer (subject 3) had much higher levels of ACTH detected compared 
with the other participants. There are two possible reasons for this; whatever is 
causing the assay interference is present in higher concentrations, or that he 
additionally has a heterophilic antibody (an endogenous antibody that binds 
assay antibodies) causing additional assay interference. As the ACTH antibody 
used in the assay is generated in rabbits it is possible that he has a heterophile 
antibody from previous rabbit exposure. His high ACTH levels skewed the data, 
causing non-parametric distribution and large standard deviations, and his data 
were excluded from analyses where relevant. 
 
5.2 Comparison of intravenous and nasal administration routes 
The plasma Synacthen levels attained following nasal administration were 
significantly reduced compared to the i.v route at both 5 and 10 minutes. The 
clearance of plasma Synacthen is very rapid and thus the large differences in 
plasma levels following the different routes of administration were not 
maintained over time. Despite differences in Cmax and AUC there was no 
statistical difference shown between the two nasal doses when Synacthen level 
was compared at each time point. This is likely to be due to poor nasal 
absorption of both doses.  
 
Some nasal absorption of Synacthen was achieved with both doses as evidenced 
by the resultant cortisol response. This was dose dependent with significantly 
higher serum cortisol levels attained with the 100 mcg nasal compared to 25 




mcg. Serum cortisol values were higher following i.v administration compared to 
both nasal formulations at all time points after 5 and 10 minutes for 25 mcg and 
100 mcg respectively.  
 
5.2.1 Bioavailability of nasal Synacthen 
The bioavailability of the nasal formulation was very low, less than 0.25% 
compared with the i.v formulation, as assessed by AUC corrected for dose 
differences. Despite minimal absorption of the 25 mcg dose the median relative 
bioavailabilities were very similar for the two nasal doses indicating that the very 
low absolute bioavailability is due to the drug not getting across the nasal 
mucosa rather than it being lost from the nose due to problems in administering 
the larger dose (e.g. dripping out).  
 
Synacthen is a relatively large, polar molecule - not ideal characteristics for 
effective nasal absorption. The doses selected for the study were based on a 
single murine study (Wuthrich, Martenet et al. 1994). Nasal anatomy is subject to 
considerable interspecies variability. The three turbinates found in the human 
nose are relatively simplistic compared to the murine nose. The more 
sophisticated cell types lining the more complex maxilloturbinates of the rodent 
nose allow more efficient and effective disposal of airborne particles and thus 
likely more effective absorption of Synacthen (Harkema, Carey et al. 2006).  
 




From the geometric means1 for the AUC0-t values at the two doses 0.226 (100 
mcg) and 0.065 (25 mcg) there appears to be a reasonably linear effect between 
dose and exposure. The inference from this is that nasal absorption of Synacthen 
is, at least in part, a dose dependent phenomenon and by increasing the dose 
the bioavailability of Synacthen may increase in a predictable manner. The 
current study indicates that with a 5-fold increase in dose (500 mcg) a similar 
absolute Synacthen exposure compared to the 1 mcg i.v dose may be achieved. 
The constraints of a tolerable nasal volume (0.2ml per nostril) did not allow for 
higher doses as there is only one suitable commercially available Synacthen 
product. 
 
Bioequivalence was not reached with either nasal dose. Cmax of 0.087 and AUC0-
t of 0.226 are far below the confidence intervals set at 0.8 to 1.25. In the context 
of this study the comparative bioavailability is the important comparative 
parameter. The results for bioequivalence were at this stage academic as it is not 
necessary to demonstrate bioequivalence between an i.n and i.v formulation but 
to show the i.n formulation is safe and as efficacious as the LDSST.  
 
5.3 Dose response relationship of Synacthen and cortisol 
Although the methodologies used in the study were to determine 
pharmacokinetic parameters the data have provided the opportunity to examine 
some features of the LDSST. The LDSST has emerged as a popular test of 
                                                 
1
 Geometric mean – an average calculated using the product of the values of interest (as opposed 
to the arithmetic mean which uses the sum) 




adrenocortical function, particularly within paediatric practice (Davies and 
Howlett 1996, Elder, Sachdev et al. 2012), yet there is paucity of data on the 
relationship between Synacthen and cortisol. There have been numerous studies 
describing the cortisol response to different doses of Synacthen yet, despite 
almost 50 years since the first description of the SST and its increasing 
popularity, few studies have focused on the relationship between 
ACTH/Synacthen and cortisol. Graphs depicting a straightforward causal 
relationship with ACTH rises followed by cortisol peaks appear in most 
endocrinology textbooks (Miller 2009) however it has been observed that 
cortisol can peak without a precedent ACTH rise and that even when the 
temporal relationship is clear, apparent proportionality may be lacking (Krieger, 
Allen et al. 1971). Whether these aberrations are attributable to inadequate 
assay sensitivity is unknown.  
 
A logarithmic dose-response relationship between Synacthen and cortisol 
following the administration of different doses of Synacthen has been described 
previously, yet neither study correlated peak plasma Synacthen with peak 
cortisol (Leclercq, Bruno et al. 1972, Krishnan, Miller et al. 1993). The most in-
depth relational study to date is a pharmacokinetic comparison of 250 mcg and 1 
mcg Synacthen in ten healthy adults. The authors reported that neither the peak 
plasma level nor the AUC for Synacthen significantly correlated with any of the 
characteristics of the cortisol response, including peak cortisol level, AUC for 
cortisol, timing of the peak or incremental rise from baseline (Alia, Villabona et 
al. 2006). The NeSST Study results indicate that the dose-response relationship 




was being masked in Alia et al’s study by the use of Synacthen doses that 
resulted in maximal cortisol responses and therefore lie on the flat part of the 
dose-response curve. This is seen by the lack of relationship with 1 mcg but with 
a dose-response relationship at the lower doses.  
 
Analysis of the NeSST Study data show that a plasma level of Synacthen of 
greater than 88 pg/ml, achieved with 1 mcg i.v LDSST, will result in near-maximal 
cortisol response. This is in keeping with two other studies in which the ACTH 
level required to near-maximally stimulate the adrenal gland has been quantified 
(Oelkers, Boelke et al. 1988, Darmon, Dadoun et al. 1999).  
 
5.4 Characteristics of the 1 mcg i.v LDSST  
5.4.1 Plasma Synacthen variability 
 
Further analysis of the 1 mcg i.v data demonstrated that, despite all volunteers 
having similar demographics and receiving the same dose of i.v Synacthen, made 
up by the same method and by the same individuals, there was considerable 
variability in plasma Synacthen values, a phenomenon noted previously with 
administration of low doses (Krishnan, Miller et al. 1993). The single epitope RIA 
used in this study, like others used previously, lacks specificity and may account 
for some of the variability (Graybeal and Fang 1985, Krishnan, Miller et al. 1993, 
Darmon, Dadoun et al. 1999, Alia, Villabona et al. 2006). Other potential 
confounders include dilution or mixing inconsistencies whilst making up of the 1 
mcg dose (Dickstein, Shechner et al. 1991), adsorptive losses of Synacthen on the 




plastic equipment (Murphy, Livesey et al. 1998, Wade, Baid et al. 2010) or the 
unidentified interfering molecule. As it is cortisol that is used as the primary 
endpoint in clinical practice the significance of the variation in Synacthen peaks is 
uncertain but may add weight to the call for commercial production of a 1 mcg 
Synacthen dose.  
 
It may be that the plasma Synacthen peak was missed following i.v 
administration by sampling at 5 minutes. With such rapid clearance it is likely 
that the real peak may lie between 1 and 3 minutes. 
 
5.4.2 Timing of serum cortisol peak 
 
The timing of the serum cortisol peak following 1 mcg i.v Synacthen varied and 
occurred at 30 minutes in 45% of study subjects. All experienced their peak 
between 15 and 40 minutes. Studies show the cortisol peak to occur between 15 
and 30 minutes (Crowley, Hindmarsh et al. 1991, Daidoh, Morita et al. 1995, Nye, 
Grice et al. 1999, Park, Park et al. 1999). The BSPED survey (vide supra chapter 2, 
section 1) revealed that all units sample at 0 and 30 minutes, 52% at 20 minutes 
and 69% at 60 minutes, with a number of additional sampling times (Elder, 
Sachdev et al. 2012). The NeSST Study data show that sampling at only 0, 20 and 
30 minutes would have missed a third of the peaks and a 60-minute sample 
would have been of no additional benefit being too late to detect any cortisol 
peaks. From our small adult cohort sampling times of 0, 15, 20, 30 and 40 
minutes would have identified all the cortisol peaks.  




5.4.3 Low peak serum cortisol 
 
The serum cortisol results were universally low in terms of diagnostic cut-off. 
Although controversial and subject to considerable variation in practice, most 
endocrinologists practicing in the UK look both at the incremental rise in serum 
cortisol from baseline, usually taking greater than 200 nmol/L as normal, and a 
peak cortisol of more than 500 nmol/L or 550 nmol/L (Lashansky, Saenger et al. 
1991, Miller 2009, Elder, Sachdev et al. 2012). All study subjects had a serum 
cortisol incremental rise of more than 200 nmol/L but none managed a peak of 
500 nmol/L. As all subjects were healthy it is thought that this may be due to a 
blunting effect of the dexamethasone. It is important to consider that the 
diagnostic cut-offs quoted in the literature are not from a supressed baseline and 
that the peak cortisol is a combination of baseline plus incremental rise and will 
therefore be lower when the baseline is artificially lowered. The effect of 
dexamethasone on the peak serum cortisol has been previously reported by 
some as having a potentiating effect (Landon, James et al. 1967, Leclercq, Bruno 
et al. 1972, Graybeal, Fang et al. 1985, Rosenfield, Helke et al. 1985, Crowley, 
Hindmarsh et al. 1991) and by others a blunting effect (Saito, Ichikawa et al. 
1979, Copinschi, Beyloos et al. 1983, Crowley, Hindmarsh et al. 1991, Dickstein, 
Shechner et al. 1991). It is unclear how dexamethasone interacts with the cells of 
the adrenal cortex and whether there is a direct inhibitory effect (Saito, Ichikawa 
et al. 1979) or not (Dardis and Miller 2003) as has been shown in rat models 
(Loose, Do et al. 1980). In order to investigate this further a study in which 
volunteers undergo the LDSST with dexamethasone suppression and without 
would need to be conducted.  




5.5 Relationship between serum cortisol, salivary cortisol and 
salivary cortisone 
Whilst acknowledging that it is unlikely a blood value will equate exactly with a 
tissue concentration and the serum and salivary assays will have different 
precision profiles, relational analysis (correlation) has been used, as by others 
previously, to assess whether the different measures agree and at different 
cortisol concentrations.   
 
The relationship observed between salivary cortisol and serum cortisol was 
exponential, as seen in previous studies, and is due to the Cortisol Binding 
Globulin (CBG) effect (Vining, McGinley et al. 1983, Perogamvros, Aarons et al. 
2011). At lower concentrations cortisol is bound by serum CBG, however at 
higher concentrations, when CBG is saturated, a more rapid increase in salivary 
concentration is seen. The change in curve slope “tipping point” appears to be at 
approximately 360nmol/L of serum cortisol, which is lower than the previously 
reported 500nmol/L (Perogamvros, Owen et al. 2009, Perogamvros, Owen et al. 
2010). A tighter and linear correlation was seen between salivary cortisone and 
serum cortisol, as would be expected because cortisone more closely reflects 
serum free cortisol and is unaffected by changes in CBG. The closest correlation 
has been shown to be between serum free cortisol and salivary cortisone but 
serum free cortisol is not routinely quantified because to do so is time-
consuming, cumbersome and expensive (Perogamvros, Keevil et al. 2010). The 
correlations achieved in this study are weaker than those quoted in the 




literature, despite being published by the same group who performed the 
salivary cortisol and cortisone analysis for NeSST. The reason for this discrepancy 
is unclear, however the relationship was tightened by correlating the serum and 
salivary peaks rather than the paired samples indicating that enzymatic 
conversion and absorption effects may have played a role.  
 
5.5.1 Salivary cortisol and salivary cortisone peaks  
 
Salivary cortisone was seen to be the more sensitive marker of adrenocortical 
response at lower values as peaks were detected when no salivary cortisol 
response was seen. Salivary cortisone has an approximately two-fold greater 
sensitivity, when measured by mass spectrometry, compared with salivary 
cortisol and the 11β-HSD-2 activity in saliva causes a 3-4-fold increase in 
cortisone over cortisol (personal communication, Professor Brian Keevil). 
Additionally the rate of enzymatic activity varies between individuals (personal 
communication, Professor Brian Keevil). In contrast serum cortisone has been 
found to decrease following ACTH administration suggesting that ACTH 
stimulates restoration of inactive cortisone to biologically active cortisol 
(Vogeser, Zachoval et al. 2001). Following the initial serum rise in cortisol, parotid 
gland 11β-HSD-2 activity may convert cortisol to cortisone and be partly 
responsible for the greater sensitivity. The timing of the peak salivary cortisol 
was seen between 30 and 40 minutes and between 40 and 50 minutes with 
salivary cortisone. The slightly later peak with cortisone is likely to be due to its 
enzymatic conversion from cortisol. 




5.6 Limitations and further work 
The PK data show that nasal Synacthen is absorbed in a dose-dependent manner. 
To improve the bioavailability an increase in the dose would likely increase the 
absolute amount of Synacthen available systemically. The relative bioavailability 
indicates that a 5-fold increase in dose (500 mcg) would be required to achieve 
the same exposure as a 1 mcg i.v dose. The Cmax value, when the dose was 
increased four-fold (25 mcg to 100 mcg), did not increase four-fold. This would, 
in normal circumstances, allay fears that increasing the dose to achieve 
bioequivalence would result in very high initial concentrations. Potential 
problems with toxicity when increasing the dose are not a concern in this study 
as Synacthen is routinely given in supraphysiological amounts (250 mcg i.v and a 
1 mg depot preparation) and is known to be safe. The scope for an increase in 
the dose of nasal Synacthen is limited by the currently available formulation (250 
mcg/ml vials only). Due to the restriction on volume for nasally administered 
drugs (0.2ml per nostril) equivalence in the adrenal stimulation with the LDSST 
could not be achieved just by increasing the volume five-fold, manufacturing a 
more concentrated formulation would be required. The addition of a nasal drug 




This study in 12 healthy, male adult volunteers has shown nasal Synacthen to be 
safe and easy to administer. Some systemic absorption was achieved as a 




resultant and dose-dependent cortisol response was seen however the 
Synacthen bioavailability was only 0.2% of that seen with i.v administration. 
When corrected for the increased dose given, it is postulated that a five-fold 
increase in the 100mcg dose is required to reach an acceptable bioavailability, 
however the considerable individual variability seen with nasal absorption is of 
concern.  
 
By studying the dose-response relationship of plasma Synacthen and serum 
cortisol at doses below 1 mcg a dose-response relationship between Synacthen 
and cortisol was demonstrated which supports evidence that 1 mcg Synacthen 
maximally stimulates the adrenal gland and give further credence to the use of 
the LDSST in clinical practice.  
 
  










The second clinical 
study in the 
development of a non-
invasive Short 
Synacthen Test  
  






The first clinical study (NeSST, chapter 4) showed nasal Synacthen to be easily 
administered and well tolerated but poorly absorbed and therefore exhibited 
low bioavailability. The estimated appropriate nasal dose to yield a similar 
cortisol response to the 1 mcg i.v dose was 500 mcg. The scope for a dose 
increase was limited by the available formulation of the Synacthen and tolerable 
nasal volume, 500 mcg would require 1 ml per nostril of 250 mcg/ml commercial 
preparation, far exceeding the recommended 0.2 ml per nostril (Personal 
communication, Archimedes Pharmaceuticals Ltd)(Wolfe and Braude 2010). 
Manufacture of a more concentrated formulation of Synacthen appropriate for 
nasal administration was therefore investigated. This offered the opportunity to 
further improve the absorption/bioavailability by the addition of a nasal drug 
enhancer, with the possibility of reducing the inter-individual variability in 
plasma Synacthen seen in the first NeSST Study (vide supra chapter 4, section 
5.4.1).  
 
Formulating a novel compound, performing appropriate stability testing, 
obtaining regulatory approvals and manufacturing clinical study grade product 
was a considerable undertaking. It required additional grant income and input 
from a number of different colleagues and commercial companies. This chapter 
details the process of manufacture of the new compound and the results of 
administering the novel IMP (Investigational Medicinal Product) to human 
subjects in a clinical study – the NeSST2 Study.  




The generic name tetracosactide, rather than Synacthen (proprietary name), is 
used to describe the active pharmaceutical ingredient in the newly formulated 
IMP. 
 
2 Aims and Objectives 
 
2.1 Aim: 
To investigate the use of a higher dose of nasal Synacthen (500 mcg) and the 
addition of a nasal drug enhancer in the development of a non-invasive 
alternative to the 1-microgram (low-dose) intravenous Short Synacthen Test 
(LDSST). 
2.2 Objectives: 
 To compare the bioavailabilities of three different nasal formulations 
of tetracosactide with the 1 mcg i.v SST. 
 To assess the effect of dose escalation on the absorption of nasal 
tetracosactide. 
 To assess the effect of a nasal drug enhancer, chitosan, on the 
absorption of nasal tetracosactide. 
 To establish the first bioavailability and pharmacokinetic data of nasal 
tetracosactide with chitosan in humans. 
 To establish the inter-individual variability of cortisol response to nasal 
tetracosactide with chitosan in humans. 
 




3 Materials and Methods 
 
The methodology employed in the NeSST2 Study was very similar to NeSST Study 
(vide supra chapter 4, section 3). The pre-study set-up and essential 
methodological differences are described below. 
 
3.1 Pre-study work on Investigational Medicinal Product 
Before recruitment or subject visits took place tetracosactide was sourced and 
imported; a nasal drug enhancer was selected and sourced; manufacturing was 
tendered and a manufacturer chosen; legal contracts were written; the novel 
combinations stability were tested; appropriate documentation was written; 
regulatory approvals (REC, MHRA and R+D) were gained and manufacture of the 
IMPs undertaken.  
 
Archimedes Development Ltd (linked with the Nottingham University School of 
Pharmacy) has expertise in nasal drug delivery. Meetings were held with their 
Director of Pharmaceutical Development and Vice President to share the NeSST 
Study results and garner advice about improving the absorption of nasal 
Synacthen, the viability of a nasal enhancer and what the process would involve. 
A number of enhancers were researched and then discussed. The majority of 
their experience is with chitosan and they were confident that its addition would 
significantly increase the bioavailability of nasal Synacthen. They estimated a 
bioavailability of 5-10% (an increase of 25-50 fold) based on experience with 
peptide molecules of comparable solubility, molecular weight, and polarity. It 




was also thought that chitosan would reduce the variability of nasal absorption 
seen in the first NeSST study.  
 
After having chosen to combine tetracosactide with chitosan quotes were 
requested from three NHS manufacturing pharmacies and Archimedes 
Development for the development and manufacturing work. Despite a number 
of enquires only Archimedes tendered and their quote was felt to be reasonable 
and thus they formulated the tetracosactide/chitosan nasal solutions (TNS), 
conducted stability testing and manufactured the clinical supplies. Archimedes 
Development Ltd performed all the necessary pre-clinical work, the information 
from which formed the basis of the Investigator’s Brochure, a detailed document 
submitted to the MHRA with comprehensive information about the IMP. 
 
The tetracosactide was sourced from Bachem (Bubendorf, Switzerland) and 
imported (after frantic negotiations during a medical student lecture on a Friday 
afternoon, when it was seized by HM Customs and Excise on entry to UK!). 
Archimedes Development Ltd supplied the Chitosan glutamate, manufactured 
under the trade name PROTASAN™ by FMC BioPolymer (NovaMatrix) Norway. Its 
use in the IMP required legal permissions from FMC Biopolymer (Philadelphia, 
USA) and involved lengthy negotiations and a tripartite agreement. The 
manufacture, packaging, quality control testing and batch release of the IMP 
formulations were conducted in accordance with current Good Manufacturing 
Practice at Archimedes Development Limited, Nottingham, UK. After more than 
18 months the new CTIMP (Clinical Trials of a Investigative Medicinal Product) 




study was successfully awarded REC, MHRA and R+D approval and the 
manufactured clinical supplies delivered to SCH. 
 
3.2 Study design  
The NeSST2 Study had a similar design to NeSST (vide supra chapter 4, section 
3.1); a pharmacological bioavailability study using an open label, quadruple arm, 
crossover design (figure 5.1), as recommended by EMA (European Medicines 
Agency 2010). In keeping with pharmacokinetic trials of this kind the subjects 
were not blinded and did not receive a placebo. In contrast to the NeSST Study 
the subjects received the first three formulations (1 mcg i.v, 100 mcg 
tetracosactide and chitosan and 500 mcg tetracosactide) in a randomised order 
and the fourth and final formulation (500 mcg tetracosactide and chitosan) only 
after interim analysis showed this to be required. Randomisation was felt to 
improve the scientific integrity of this bioavailability study and was performed by 
the Pharmacy department at SCH using an on-line programme 
(www.randomization.com). As before it was a single-centre study conducted 
from SCH, Sheffield, UK.  
 
3.3 Subjects and the visits  
In most respects the subjects and their visits were as they had been for the 
NeSST Study (chapter 4, section 3.2 and 3.3). The differences are detailed below 
and the recruitment and volunteer pathway shown in figure 5.1. 




 A routine MHRA inspection of the Research Department at SCH was 
undertaken in November 2010, during which the NeSST study was heavily 
scrutinised, as the only drug trial being conducted in and sponsored by 
the Trust. A concern was raised about informed consent being obtained 
after a drug (dexamethasone) had been administered. This was revised 
for the NeSST2 Study subjects, whereby written consent was obtained 
following enrolment but prior to visit 1 and before the dexamethasone 
was given. 
 After re-consulting the literature and the clearance data of both 
dexamethasone and tetracosactide the fortnight between visits was 
reduced to a single week. 
 Following peer-review of the NeSST Study results a suggestion was made 
to include a -14 minute sample in addition to the -1 minute sample 
before the tetracosactide is given. This was to confirm both the ACTH and 
cortisol were suppressed following dexamethasone administration.  
 The IMPs (TNS - Tetracosactide Nasal Solutions) and i.v comparator given 
at the visits are described below: 
o A low-dose SST, with 1 mcg i.v Synacthen (i.v comparator visit) 
o A nasal SST with 100 mcg of tetracosactide with chitosan to 
examine the effect of the addition of chitosan on nasal 
tetracosactide absorption and cortisol response (100 mcg had 
been given in the NeSST Study). 
o A 500 mcg nasal SST to examine the effect of the increased dose 
alone on nasal tetracosactide absorption and cortisol response. 




o If interim analysis indicated, a 500mcg tetracosactide with 
chitosan nasal SST to examine the cumulative effect of increased 
tetracosactide dose and the addition of a nasal drug enhancer on 
nasal tetracosactide absorption and cortisol response. 
 The plasma Synacthen samples were analysed in December 2011 and July 
2012 (final visit); the serum cortisol samples were processed between 
January and February 2012 and July 2012 and the salivary 








3.4 Tetracosactide Nasal Solution (TNS) 
The pharmacokinetic, metabolic, toxicological and clinical properties of 
tetracosactide following i.v injection are well known and are described in the 
Summary of Product Characteristics (Alliance Pharmaceuticals 2011). 
Tetracosactide nasal solution (TNS) has the same active pharmaceutical 
ingredient but with the addition of an excipient, chitosan, to aid absorption when 
administered nasally.  
 
Pharmacokinetic extrapolation using NeSST Study AUC data estimated that 500 
mcg of intranasal Synacthen would be required to give an equivalent response to 
the 1 mcg i.v LDSST. TNS is an aqueous solution containing either 0.5 mg/ml 
(providing 50 mcg tetracosactide) or 2.5 mg/ml (containing 250 mcg of 
tetracosactide) in the form of the acetate salt. In order to deliver 100 mcg and 
500 mcg one spray (of 0.1ml) per nostril (0.2 ml in total) was required. Two TNS 
solutions also contained chitosan glutamate (a cationic biopolymer which acts as 
a mucoadhesive/bioadhesive agent, (vide supra chapter 1, section 5.4.3). In 
addition, the three TNS solutions contained sodium chloride for tonicity 
adjustment, benzalkonium chloride as a preservative, and acetic acid and sodium 
acetate as a buffer to adjust/maintain pH.  
 
The TNS 0.5 mg/ml with chitosan, TNS 2.5 mg/ml, and TNS 2.5 mg/ml with 
chitosan solution were packaged as 0.5 ml aliquots in 2 ml glass vials and at the 




point of use, 0.1ml of the solution was withdrawn from the vial into a 1 ml 
syringe attached to a Mucosal Atomizer Device (Wolfe-Tory Medical, USA) 
(chapter 4, figure 4.2) to facilitate administration of 0.1 ml to each nostril. Each 
sealed vial was individually packaged in a labelled carton and stored refrigerated 
in the clinical trials refrigerator in the SCH pharmacy department.  
 
The 1 mcg i.v and 100 mcg nasal dose chosen for the study were below that of 
the i.v licensed dose, 250 mcg, and therefore toxic effects of Synacthen 
“overdose” were not anticipated. The 500 mcg nasal dose, although higher, 
when administered nasally was thought likely to yield much lower systemic levels 
of tetracosactide compared with the 250 mcg i.v dose. The 500 mcg dose with 
chitosan was only given because interim analysis revealed that systemic 
absorption with chitosan alone or with 500 mcg alone had produced an 
insufficient cortisol response in three of the volunteers. 
 
Tetracosactide is used as the acetate salt form in the existing injection product 
(Synacthen, Alliance Pharmaceuticals, UK). This salt form is reported to be 
sparingly soluble in water (approximately 10-30 mg/ml), however this solubility is 
sufficient to provide a solution suitable for intranasal administration. Two of the 
three TNS formulations contained chitosan (in the glutamate salt form). A 
chitosan glutamate concentration of 5 mg/ml was selected for the TNS 
formulations based on previous investigations and experience at Archimedes 
Development Limited (Nottingham, UK). 
 










Quantity per 0.5 ml 
TNS 




















2.7 mg 2.7 mg 2.7 mg 
Benzalkonium 
chloride 
Ph.Eur. Preservative 0.075 mg 0.075 mg 0.075 mg 
Acetic acid Ph.Eur. 
pH  
adjustment 







1.05 mg 1.05 mg 1.05 mg 
Water for 
injections 
Ph.Eur. Vehicle To 0.5 ml To 0.5 ml To 0.5 ml 
* Ph. Eur – European pharmacopoeia (monograph 0644, pages 3059-3060 of European Pharmacopoeia 2010, 7th Edition, 
Council of Europe, Strasbourg.) 




3.4.1 Physicochemical characteristics for Tetracosactide drug compound 
 
Molecular formula C136H210N40O31S (net) 
Molecular mass 2931.6 g/mol (monoisotopic mass, net) 
Salt form Acetate salt (between 4 and 8 moles of acetic acid 
may be present per mole of peptide) 
Physical form White to yellow powder 
Polymorphism Amorphous powder, as tetracosactide is isolated by 
lyophilisation. No crystalline or polymorphic forms 
are known. 
Appearance of solution Clear and colourless (1 mg/mL in water) 
 
  




3.4.2 Physiochemical characteristics of the chitosan used in the NeSST2 
Study 
 
Generic name:   Chitosan glutamate 
 
Chemical name: ß-(1→4)-linked 2-acetamido-2-dexoy-D-
glucopyranose and 2-amino-2-deoxy-D-
glucopyranose glutamate; ß-(1→4)-linked N-acetyl-
D-glucosamine and D-glucosamine glutamate 
Manufacturers name: PROTOSAN™ UP G 213 
CAS registry: 84563-76-8 
 
Molecular weight: The molecular weight (g/mol) of the monomer unit 
is 161 for D-glucosamine and 203 for N-acetyl-D-
glucosamine. Glutamate has a molecular weight of 
146. Typically, the molecular weight for PROTASAN 
UP G 213 is in the range 200000-600000 g/mol. 
Description: PROTASAN UP G 213 is a white or off-white powder 
that forms a clear, colourless to slightly yellowish 
solution when dissolved in water.  The solution may 
become thick, i.e. viscous depending upon the 
concentration of PROTASAN UP G 213 used. 
pH of aqueous solution:  The pH of an aqueous solution (1%) of PROTASAN 
UP G 213 is between 4 and 6. 
Solubility: Solubility of PROTASAN UP G 213 is a function of 
the concentration (g/l or mg/ml), ionic strength of 
the solution and the presence of buffering ions. 
 
3.4.3 Chitosan safety 
 
Chitosan glutamate has been tested for safety and toxicity in a number of animal 
species using different routes of administration. The preclinical data augment the 




considerable clinical data on intranasal chitosan in both human volunteers and 
patients. Nasal formulations containing chitosan, both in the form of solutions 
containing 5 mg/ml chitosan as well as powders, have been administered to over 
1000 people in clinical trials and in excess of 2900 doses have been administered. 
Collectively no safety or tolerability issues were identified in any study and these 
data do not identify any specific hazard that would preclude the use of chitosan 
in further clinical trials (personal communication, Peter Watts, Archimedes 
Development Ltd). 
 
3.5 Plasma Synacthen dilutions 
Dose escalation and the addition of chitosan resulted in a number of plasma 
Synacthen results above the limit of detection of the assay. When spun and 
separated the plasma had been split and frozen into two aliquots and thus the 
stored second aliquot samples were run following a 1:10 dilution in the MP 
Biomedicals zero standard. Twenty-five microlitres of plasma Synacthen sample 
were diluted in 225 microlitres of zero standard diluent and the results adjusted 
by multiplying by ten. 
 
3.6 Statistical analysis 
The PK and non-PK analyses were the same as those used in the NeSST Study 
(chapter 4, section 3.5): Cmax, Tmax, AUC, terminal half-life, mean residence 
time, bioavailability and clearance (for definitions see chapter 4, section 3.5.1). 




The addition of the -14 minute sample meant there were two possible baseline 
values to subtract from subsequent values when cleaning the data. Generally the 
-14 and -1 minute values were very similar. For consistency with the PK data 
analysis the -1 minute result was chosen as baseline unless it was at odds with 





4.1 Recruitment data 
Ten healthy, adult males who contacted the author, were eligible for inclusion 
and were duly enrolled and two were re-recruited from the first NeSST Study 
(figure 5.1). On discussion at later study visits, it became evident that two 
volunteers were experiencing mild dyspeptic symptoms soon after taking the 
dexamethasone, presumed to be a side effect. Both were excluded from any 
further visits (1 mcg and final visit for subject 11 and the final visit only for 
subject 1). No replacement subjects were recruited due to financial constraints 
(the i.v comparator visit would have had to be repeated). All other subjects 
participated in all four visits (table 5.2). Interim analysis was performed after 
subjects had completed three visits and supported continuation with 
administration of 500 mcg tetracosactide and chitosan to the remaining subjects.  
 




Table 5.2: NeSST2 Study recruitment data 
 Enrolled Attended 1 
mcg i.v visit  
Attended 100 
mcg + chitosan 
visit 
Attended 500 
mcg nasal visit  
Attended 500 
mcg + chitosan 
visit 
Number 12 11 12 12 10 
 
 
4.2 Demographic and anthropometric data 
Basic data were collected from all volunteers at the first visit: age, ethnic origin, 
height and weight, from which body mass index (BMI) and body surface area 
(BSA) were calculated. Table 5.3 summarises the 12 volunteers’ demographic 
and auxological data with ranges, means and standard deviations given.  
 
Table 5.3: NeSST2 Study subjects’ demographic and anthropometric data 





Age (years) 12 22-46 25 7 
Height (m) 12 1.760-2.060 1.816 0.085 
Weight (kg) 12 64.1-86.0 76.5 7.1 
BMI (kg/m
2
) 12 20.2-25.7 23.2 1.9 
BSA (m
2
)* 12 2.27-1.79 1.9 0.3 
Ethnic origin 
12 
10 = white British, 1 = black African, 1 = white other 
(American) 
* Dubois Formula: Body Surface area (m2) = 0.007184 × (height in cm) 0.725 × (weight in kg)0.425 
 
4.3 Data derived from patient specimen sampling 
Paired blood and saliva sampling was performed at 15 time points from -14 to 
180 minutes. If all samples on all volunteers had been successfully obtained 




there would have been 2160 data points, however 209 were missing, 135 
because the subjects were excluded from attending any further visits and 74 due 
to human error (table 5.4). The total number of plasma Synacthen samples 
analysed was 651, serum cortisol was 672 and salivary samples was 673. 
 
 




Table 5.4: Samples collected for each subject at each NeSST2 Study visit with missing data points and reasons given. "Complete” indicates all 15 samples 
of plasma Synacthen, serum cortisol and salivary cortisol/cortisone (N=45) were successfully collected. (pl S = plasma Synacthen, SerC=serum cortisol, 
Sal=salivary sample) 
Subject No 1 mcg i.v visit 100 mcg + chitosan visit 500 mcg nasal visit 500 mcg + chitosan visit 








3 Complete Complete Complete No -1 min pl S
& 
4 Complete Complete Complete Complete 
5 Complete
 
Complete Complete Complete 
6 
Complete 
No 40, 150, 180 min pl S + 
SerC* 
No 50 min sal
@ 
Complete No -14 min pl S
& 
7 Complete Complete No 10 min salivary
@ 
No -14-75 min pl S
% 
8 Complete Complete Complete Complete 
9 Complete Complete Complete Complete 
10 Complete Complete Complete Complete
 
11 - Complete Complete - 
12 Complete Complete Complete No 5,10,15,20,30,40 min pl S
£ 
* Problem with cannula bleeding back     
£ Nurse forgot to take samples 
& Problem during plasma centrifugation and plasma separation 
%  Lost samples 
@ Saliva sampling missed due to problem with blood sampling  





4.3.1 Proof of dexamethasone suppression  
 
The baseline plasma Synacthen samples were high in the NeSST Study. This was 
thought to be due to interference with an unrelated molecule (chapter 4, section 
5.1). Table 5.5 displays the baseline plasma ACTH and cortisol for all volunteers 
at -14 and -1 minute (prior to Synacthen administration). 
  




Table 5.5: Plasma ACTH and serum cortisol values at -14 and -1 minute for 12 NeSST2 
Study volunteers. Results for the 4 visits given for each volunteer (top left-hand box visit 
1, top right-hand visit 2, bottom left-hand box visit 3 and bottom right-hand visit 4). 
ACTH normal range <10pg/ml. Cortisol normal range <50 nmol/L. High values shown in 




Plasma ACTH (pg/ml) Serum Cortisol (nmol/L) 
-14 minute samples -1 minute samples -14 minute samples -1 minute samples 
1 - 87.9 86.7 87.4 48 <22 41.9 <22 
79.1 - 91.6 - 26.2 <22 22.5 - 
2 - 73.5 59 59 <22 23.2 <22 22.7 
54 174 68.3 298.9 22.4 78.4 <22 73.1 
3 91.7 >max 77.4 96.1 122.6 26.1 84.3 <22 
93 244.8 91.1 - <22 29.3 <22 23.3 
4 234.6 188 209.2 152.5 66.1 <22 39.9 <22 
162.5 367.8 171.1 468.4 <22 <22 <22 <22 
5 99.2 79.2 116.9 89.7 <22 <22 <22 <22 
131.6 166.3 131 171.1 <22 <22 <22 <22 
6 126.2  110.7 131.8 124.7 <22 <22 <22 <22 
128.5 - 117.5 281.3 <22 <22 <22 <22 
7 108.7 94.6 127.4 90.4 <22 <22 <22 <22 
97.3 - 120.2 - <22 28.8 <22 26.3 
8 324.3 123.9 160.7 96.5 33.4 382.8 33.1 374.9 
71.5 89.8 87.4 186.1 35.4 237.5 36.2 202.3 
9 65.1 57.6 58.6 58.2 <22 <22 <22 <22 
65.7 81.3 148.4 191.7 <22 <22 <22 <22 
10 124.2 145.6 122.9 143.4 32.4 31.7 29.8 23.7 
157.8 112.1 160.5 119.1 27.8 22.6 24.9 23.6 
11 274.7 257.8 212.5 239.5 <22 <22 <22 <22 
- - - - - - - - 
12 124.4 104.2 88.5 99.3 22.6 <22 <22 23.5 
115.7 113.4 114.4 107.5 25 <22 <22 23.8 
 
  




For all volunteers the baseline ACTH values were higher than would be expected 
but in the majority the low cortisol values in table 5.5 indicate that they had 
taken their dexamethasone and consequently suppressed their cortisol. In five 
visits of the 45 the cortisol prior to Synacthen administration (-14 and -1 minute 
samples) were either only partially suppressed or unsuppressed. None of the 
four volunteers had a Cushingoid habitus, they were all reportedly healthy and it 
is likely that they were either non-adherent with the request to take 
dexamethasone or had another, undisclosed, exogenous source of corticosteroid 
(although none had unsuppressed baselines at all visits).  
 Subject 2 had a slightly raised baseline cortisol (78.4, 73.1 nmol/L) at his 
final visit (500 mcg plus chitosan) but showed a good response to 
Synacthen and his data have been retained for analysis.  
 Subject 3, appears to have taken his dexamethasone just prior to his 100 
mcg plus chitosan visit – with baseline cortisols of 122.6 then 84.3 nmol/L 
and then displaying a fairly flat response to Synacthen; his data from this 
visit have been excluded from further analysis. 
 Subject 4, had a slightly elevated baseline cortisol (66.1 nmol/L) but by -1 
minute it is suppressed (39.9 nmol/L) at his 100 mcg plus chitosan visit, 
his data have been included for analysis. 
 Subject 8 appears not to have taken his dexamethasone before either his 
1 mcg i.v or his 500 mcg plus chitosan visits. His data from these visits has 
been excluded from relevant analyses.  
 




The plasma Synacthen values showed more intra-individual variability than in the 
NeSST Study and were universally high.  
 
 
4.3.2 Plasma Synacthen assay 
 
The Synacthen assay methodology had changed between the NeSST and NeSST2 
studies with the adoption of Synacthen standards made up using the zero 
standard from the RIA kit as a diluent. The results of the only repeated 
formulation, 1 mcg i.v, gave the opportunity to compare the workings of the 
assay. The mean plasma Synacthen values following 1 mcg i.v. Synacthen in both 
studies is shown in figure 5.2 (vide supra chapter 3, table 3.2.3). The high 
baseline, presumed due to an interfering molecule, is seen in both studies. The 
shape and height of the curves are similar with divergence after 90 minutes. 
There is overlap of error bars throughout.  
 
 





Figure 5.2: Mean Plasma Synacthen values following 1 mcg i.v. Synacthen in both 





4.3.3 Comparison of intravenous and nasal administration routes 
 
Following the nasal administration of 1 mcg i.v Synacthen, 100 mcg 
tetracosactide with chitosan and the 500 mcg tetracosactide nasal solutions 
interim analysis was performed. It was evident that there had been a poor 
response in some individuals and thus the decision was taken to proceed with 
the final visit and administer the 500 mcg tetracosactide and chitosan 
formulation. Individual plasma Synacthen levels and cortisol responses to the 
four different doses are displayed in figure 5.3. 







Figure 5.3: Individual study volunteers’ plasma Synacthen levels and serum cortisol responses 
to 1 mcg i.v Synacthen and three doses of nasal Synacthen (100 mcg with chitosan, 500 mcg 
and 500 mcg with chitosan).  
 





Figure 5.3 (continued): Individual study volunteers’ plasma Synacthen levels and serum 
cortisol responses to 1 mcg i.v Synacthen and three doses of nasal Synacthen (100 mcg 
with chitosan, 500 mcg and 500 mcg with chitosan).  
 
 





Figure 5.3 (continued): Individual study volunteers’ plasma Synacthen levels and serum cortisol 
responses to 1 mcg i.v Synacthen and three doses of nasal Synacthen (100 mcg with chitosan, 500 
mcg and 500 mcg with chitosan).  
 




The interim PK analysis demonstrated that, although the PK parameters of AUC 
and Cmax were similar between the 100 mcg plus chitosan nasal dose and the 1 
mcg i.v dose, there were a number of non-responders (subjects 3, 5 and 8), or 
those with a sub-optimal response (subject 2). In the majority of research 
volunteers the plasma Synacthen levels seemed higher following nasal 
administration with 500 mcg tetracosactide than after i.v and the cortisol 
response was higher, however once again there were non-responders (subjects 3 
and 11), or those with a sub-optimal response (subject 8). It was felt that 
administration of the 500 mcg tetracosactide with chitosan might overcome this 
individual variability. 
 
The individual plasma Synacthen responses to each of the four doses of 
Synacthen are shown in figures 5.4a-d. The y-axes scales are different on each 
graph due to the considerable variability of plasma levels following 
administration with different doses. High baselines and large individual variation 
can be seen. The individual cortisol responses to each of the four doses of 
Synacthen are shown in figures 5.5a-d and show greater variability with nasal 
administration, especially for the 100 mcg with chitosan and 500 mcg 
tetracosactide doses. The mean plasma Synacthen (figure 5.6a) and mean serum 
cortisol (figure 5.6b) over time following administration with each of the three 
doses of Synacthen are shown with standard deviations. 






Figure 5.4a: Graph of the individual plasma Synacthen responses to i.v administration with 1 mcg Synacthen in the NeSST2 Study (baseline not 
subtracted). Each coloured line depicts a study subject. 






Figure 5.4b: Graph of the individual plasma Synacthen responses to i.n administration with 500 mcg tetracosactide (baseline not subtracted). Each 
coloured line depicts a study subject. 






Figure 5.4c: Graph of the individual plasma Synacthen responses to i.n administration with 100 mcg tetracosactide + chitosan (baseline not subtracted). 
Each coloured line depicts a study subject.  





Figure 5.4d: Graph of the individual plasma Synacthen responses to i.n administration with 500 mcg tetracosactide + chitosan (baseline not subtracted). 
Each coloured line depicts a study subject.  





Figure 5.5a: Individual serum cortisol responses following i.v administration with 1 mcg Synacthen in the NeSST2 Study (N=10).   







Figure 5.5b: Individual serum cortisol responses following nasal administration with 500 mcg tetracosactide (N=12).   






Figure 5.5c: Individual serum cortisol responses following nasal administration with 100 mcg tetracosactide and chitosan (N=11).  





Figure 5.5d: Individual serum cortisol responses following nasal administration with 500 mcg tetracosactide and chitosan (N=9).   






Figure 5.6a: Graph of the mean rise of plasma Synacthen from a suppressed baseline in subjects following administration with 1 mcg i.v, 500 mcg 
tetracosactide i.n, 100 mcg tetracosactide + chitosan i.n and 500 mcg tetracosactide + chitosan i.n. Standard deviations shown as error bars. 






Figure 5.6b: Graph of the mean rise of serum cortisol from a suppressed baseline in subjects following administration with 1 mcg i.v, 500 mcg 
tetracosactide i.n, 100 mcg tetracosactide + chitosan i.n and 500 mcg tetracosactide + chitosan i.n. Standard deviations shown as error bars. Light blue line 
depicts a “normal” response on LDSST - 500 nmol/L 




The mean plasma Synacthen responses to the four different doses of 
Synacthen are heightened both by the increase in dose and the addition of 
chitosan. The resultant cortisol response was similarly affected by both dose 
and the addition of chitosan. The peak in plasma Synacthen following 
administration with 1 mcg i.v Synacthen is much lower compared with the 
nasal formulations however the cortisol peak is similar to those seen 
following 100 mcg with chitosan and 500 mcg nasal Synacthen.  
 
To assess whether chitosan improved the variability of Synacthen absorption 
the coefficient of variation has been calculated from the mean and standard 
deviations of the peak plasma Synacthen for the different doses, including 
those administered in the first NeSST Study. The Synacthen and cortisol 
peaks are compared in table 5.6. Baseline Synacthen (-1 minute) values have 
been subtracted from all subsequent data points. 
 
  




Table 5.6: Comparison of means, standard deviations (SD), ranges, coefficient of variation (CV) and timing of the peak for peak plasma Synacthen and 





Mean, SD, range & 
CV for plasma 
Synacthen peak in 
pg/ml 
Median with IQR and 
mode timing of the 





Mean, SD, range &  
CV for serum 
cortisol peak in 
nmol/L 
Median with IQR 
and mode timing of 
the cortisol peak in 
mins 



















































































The two 1 mcg i.v tests produced broadly similar plasma Synacthen responses 
(figure 5.2), both with a suppressed cortisol response. Considerable 
variability in plasma Synacthen levels with all formulations and serum cortisol 
response following nasal administration are demonstrated by the large 
ranges and SDs and can be seen in figures 5.4a-d, 5.5a-d and by the large 
error bars in figure 5.6a and b. The calculation of CVs gives a measure of 
variability and is considerably smaller for the i.v dose than the nasal 
formulations. When chitosan is added to 100 mcg tetracosactide it reduces 
the variability of peak plasma Synacthen values (CV falls from 187.8% to 
52.6%) however with the 500 mcg tetracosactide dose the addition of 
chitosan appears to worsen variability (80.1% to 107.5%). The addition of 
chitosan reduced the variability of peak serum cortisol at both doses (100 
mcg 59.2% to 47.8% and 500 mcg from 45.6% to 20.6%). The timing of the 
cortisol peak is seen to vary more after nasal Synacthen than following i.v 
administration.  
 
The cortisol response to the higher dose of nasal Synacthen given in the first 
NeSST Study (100 mcg), the combined mean of the two 1 mcg i.v tests from 
both studies and the three nasal doses from the NeSST2 Study are displayed 
in figure 5.7 for a visual comparison of the effect of increase dose and 
addition of a nasal drug enhancer. The cortisol responses are further 
compared for the four NeSST2 Study doses in table 5.7 by paired t-test with 
Bonferroni correction. 





Figure 5.7: Mean rise of serum cortisol from a suppressed baseline in subjects following Synacthen administration with 1 mcg i.v (data from 
NeSST and NeSST2), 100 mcg i.n (NeSST), 100 mcg tetracosactide + chitosan i.n, 500 mcg tetracosactide i.n and 500 mcg tetracosactide + 
chitosan i.n. Standard deviations not shown for clarity. Light blue line depicts a “normal” response on LDSST - 500 nmol/L. 




Table 5.7: Paired t-test with Bonferroni correction results comparing the mean cortisol responses at 13 different time points of the four tests. Statistical 
significance defined as p value <0.004 and denoted in red.  
Tests compared 
Sampling time (minutes) 
5 10 15 20 30 40 50 60 75 90 120 150 180 
1) 1 mcg i.v  
2) 500 mcg tetracosactide + 
chitosan 
0.057 0.057 0.323 0.574 0.001 0.002 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
1) 1 mcg i.v  
2) 100 mcg tetracosactide + 
chitosan 
0.006 <0.0001 0.04 <0.0001 0.74 0.284 0.971 0.820 0.949 0.849 0.990 0.817 0.617 
1) 1 mcg i.v 
2) 500 mcg tetracosactide  
0.002 0.001 0.048 0.132 0.666 0.432 0.036 0.011 0.009 0.008 0.010 0.028 0.010 
1) 500 mcg i.n tetracosactide  
2) 500 mcg tetracosactide + 
chitosan 
0.061 0.004 0.103 0.061 0.052 0.07 0.046 0.016 0.007 0.011 0.027 0.026 0.025 
 1) 100 mcg  
tetracosactide + chitosan  
2) 500 mcg tetracosactide + 
chitosan 
0.081 0.001 0.019 0.030 0.005 0.014 0.004 0.004 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 




The 500 mcg tetracosactide and chitosan nasal formulation resulted in 
significantly higher cortisol response at all time points after 30 minutes 
compared with the 1 mcg i.v preparation. The 100 mcg tetracosactide and 
chitosan formulation resulted in statistically lower cortisol values at 10 and 20 
minutes when compared to 1 mcg i.v but otherwise there was no statistically 
significant difference between the two. The comparison between 500 mcg 
tetracosactide and the i.v preparation showed statistically significantly higher 
serum cortisol at 5 and 10 minutes only. The addition of chitosan to 500 mcg 
tetracosatide appeared, when examining the increase in serum cortisol seen in 
the graph (figure 5.7), to enhance the cortisol response considerably, however 
the difference is not statistically significant at any of the time points. This is likely 
due to large error bars and small subject numbers. An increase in dose from 100 
mcg to 500 mcg increased the cortisol response significantly at 10 minutes and 
then all time points after 75 minutes. As some of the differences were thought to 
be due to the different patterns of absorption between the formulations the 
mean peak cortisol for the tests were compared (table 5.8). 
 Table 5.8: Paired t-test results comparing the mean peak cortisol responses of the four formulations. Statistical significance defined as p value <0.05 and 
denoted in red.  
 
 Tests compared 
1) 1 mcg i.v 
2) 100 mcg 
tetracosactide + 
chitosan 
1) 1 mcg i.v 
2) 500 mcg 
tetracosactide 
1) 1 mcg i.v 
2) 500 mcg 
tetracosactide + 
chitosan 
1) 100 mcg i.n 
tetracosactide + 
chitosan 
2) 500 mcg 
tetracosactide + 
chitosan 
1) 500 mcg i.n 
tetracosactide 
2) 500 mcg 
tetracosactide + 
chitosan 
1) 500 mcg i.n 
tetracosactide 




0.333 0.904 <0.0001 0.001 0.007 0.604 
 The difference between mean peak cortisol response when administering 1 mcg 
i.v Synacthen and nasal 500 mcg tetracosactide or 100 mcg tetracosactide plus 
chitosan or those two nasal formulations were not statistically different, 
however 500 mcg tetracosactide and chitosan leads to statistically significantly 
higher peak cortisol than both other nasal formulations and 1 mcg i.v.  
 
4.3.4 Pharmacokinetic data comparing i.v and i.n routes 
 
A summary of the PK analysis is displayed in table 5.9, which includes data from 
the first NeSST study for comparison. The AUC data for the different 
formulations have been compared using Box and Whisker plots (figure 5.8). The 
clearance (CL) and volume of distribution (Vd) data are included for 
completeness sakes but are difficult to interpret due to probably assay 














 Table 5.9: Plasma Synacthen PK data for NeSST and NeSST2 studies. (All data are median values plus range) 
 
 
NeSST & NeSST2 NeSST Study NeSST2 Study 
Dose 1 mcg iv 
 
25 mcg in 
 
 
100 mcg in 
 
100 mcg i.n with 
chitosan 
 
500 mcg i.n 
 
500 mcg i.n with 
chitosan 




10 10 8 10 7 
AUC 0- (min/pg/ml) 1442  
(691-3082)* 148.4  




(1041 – 20937) 
16191  
(1285 – 47411) 
20371  
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289013  
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(ml) 
 1703027  
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Figure	  5.8:	  Box	  and	  Whisker	  plot	  of	  plasma	  Synacthen	  Area	  Under	  the	  Curve	  for	  different	  doses	  of	  Synacthen	  
administered	  in	  NeSST	  and	  NeSST2	  Studies 
 As observed during interim analysis, the 100 mcg tetracosactide with chitosan 
intranasal dose had the closest relevant PK parameters (AUC, Cmax) to the 1 mg 
i.v dose, although not for all the study volunteers. The bioavailability was 
markedly increased following the NeSST2 study doses compared with those 
given in the NeSST Study.  
 
The median absolute bioavailability of the 100 mcg with chitosan intranasal dose 
was approximately 0.72% (range 0.36 to 5.1%) of the 1 mcg i.v dose. The 
bioavailability with 500 mcg tetracosactide showed the greatest variability, 
1.25% (0.08-5.1%) and the highest bioavailability was achieved with the 500 mcg 
tetracosactide and chitosan formulation, 1.9% (0.52-4.8%). The time to 
maximum concentration (Tmax) was longer for intranasal formulations, 10-12.5 
minutes, compared with five minutes following i.v administration and was 
longest with the 500 mcg tetracosactide and chitosan preparation (12.5 
compared to 10 minutes). The maximum concentration (Cmax) was 
approximately 53.9% following 100 mcg with chitosan, 303.8% after 500 mcg 
tetracosactide and 407.3% following 500 mcg tetracosactide with chitosan, much 
greater than those seen with the nasal doses given in the NeSST Study.  
 
The bioavailability of the 100 mcg Synacthen intranasal dose increased by 3.65-
fold following formulation with chitosan, although the populations were not the 
same as the results are combined from the NeSST and NeSST2 studies. The 
bioavailability of the 500mcg intranasal dose was higher than anticipated 




without the addition of chitosan and the addition of the nasal enhancer only 
increased the bioavailability by 1.5-fold.   
Mean residence time (MRT) measures the time that molecules of Synacthen 
remain in the body after injection/nasal ingestion to elimination and therefore, 
as one would expect, the MRT was longer for the nasal formulations than for the 
i.v preparation. At both 100 and 500 mcg the MRT was reduced following the 
addition of chitosan, but dose escalation appeared not to influence it. Similarly 
the elimination (or terminal) half-life of plasma Synacthen was shorter following 
the addition of chitosan to both the 100 and 500 mcg doses. It was almost the 
same for the i.v and 500 mcg tetracosactide with chitosan formulations. Despite 
a shorter half-life, the cortisol response appeared more prolonged with the 
higher nasal doses. 
 
Following both the 100 mcg tetracosactide with chitosan and the 500 mcg 
tetracosactide doses individuals showed a similar cortisol response to the 1 mcg 
i.v test but consistency was lacking. As expected there was more variability in the 
data following intranasal administration compared with i.v. 
 
4.4 Relationship between serum cortisol, salivary cortisol and 
salivary cortisone  
 
The relational analysis of the NeSST Study salivary samples, both to each other 
and the paired serum sample revealed a correlation, but not as tight as had been 
anticipated. The data from the NeSST2 Study were analysed in the same way 




(figures 5.9a-c). The NeSST Study and NeSST2 Study data were combined to give 
approximately 1150 paired samples. These data are not displayed here as the 
trends are very similar and the NeSST study values serve to add numerous 
samples below the lower limit of assay detection. Tighter relationships than 
previously were seen between serum and salivary cortisol (figure 5.9a), salivary 








Figure 5.9a: Scatterplot of paired serum and salivary cortisol samples following 
administration with 4 formulations of Synacthen in the NeSST2 Study (salivary cortisol 
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A clear exponential, or biphasic response is seen between salivary and serum 
cortisol. A tight linear relationship between salivary cortisol and cortisone is 




Figure 5.9b: Scatterplot of paired salivary cortisol and cortisone samples following 
administration with 4 formulations of Synacthen in the NeSST2 Study (salivary cortisol 




y = 2.8326x + 6.4156 
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Figure 5.9c: Scatterplot of paired serum cortisol and salivary cortisone samples 
following administration with 4 doses of Synacthen in the NeSST2 Study (serum cortisol 




4.4.1 Salivary cortisol and salivary cortisone peaks and timings 
 
The relationship between the timing of the serum cortisol peak and the peaks in 
salivary cortisol and cortisone following administration with 500 mcg 
tetracosactide and chitosan were examined in a number of ways to determine 




y = 0.1145x - 4.012 
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Table 5.10: Times of peak serum cortisol, salivary cortisol and salivary cortisone 
following nasal administration with 500 mcg tetracosactide and chitosan (N=9). Mode 







Peak cortisol/cortisone times in minutes 
Serum cortisol Salivary cortisol Salivary cortisone 
Subject 1 75 75 75 
Subject 2 40 50 60 
Subject 3 75 75 75 
Subject 4 60 75 60 
Subject 5 90 120 120 
Subject 6 90 90 90 
Subject 7 90 90 90 
Subject 8 60 75 75 
Subject 9 90 90 120 
Mode 
90 75 75 
Median 
(IQR) 






Figure 5.10: Mean serum cortisol, salivary cortisol and salivary cortisone responses over time following nasal administration with 500 mcg tetracosactide 
with chitosan (N=9). 




When viewing the graph of mean cortisol response to 500 mcg tetracosactide 
and chitosan (figure 5.10) the peak times for peak salivary cortisol and cortisone 
appear to occur slightly later, at 75 minutes, compared to the 60 minute peak 
seen when measuring the response in serum. However the modal peak time 
occurs at 90 minutes when measuring serum cortisol and earlier at 75 minutes 




4.5 Study volunteer feedback 
The study volunteers were asked to complete a 5-question anonymous questionnaire 
after the third visit. A summary of the responses is given below (tables 5.11a-d) and 
comparisons to the responses given to the same questions in the NeSST Study (figures 
5.11a-d). 
Table 5.11a: Responses to qu 1: How did you find having the nasal spray administered? 




5 4 3 0 0 0 12 
 
The following comments were made “very vinegary” “somewhat unpleasant”, 
“difficult not to sneeze afterwards but overall it was fine” “less uncomfortable 
when nurse administers compared to when held the nasal device myself”, “smelt 
a tad like vinegar but no irritation or reaction”, “a fair amount went down the 
back of my throat”.  
 




The responses were compared to those given by the NeSST Study volunteers 
(figure 5.11a) and show, despite the drug being given using the same atomiser 
devise NeSST2 study volunteers did not find it as easy. This may have been borne 
out of confusion in the question wording as many appeared to be answering 
about the nasal Synacthen rather than the method of administration. 
 
Figure 5.11a: Volunteer responses from the NeSST Study and NeSST2 Study when 
asked “How did you find having the nasal spray administered?” 
 
 




Unpleasant Very unpleasant 
TOTAL 
3 8 1 0 12 
 
Comments: “Fine”, “strong vinegary smell, makes your eyes water and makes 





















sneeze once”, “slight sting but only lasted a second or two”, “induced a sneezing 
fit the second time”. 
 
Again the responses were compared to those given in the NeSST Study (figure 
5.11b) and show that, whilst the majority in the NeSST Study found nasal 
Synacthen administration to be of no problem, most found it to be slightly 
unpleasant NeSST2 Study. 
 
 
Figure 5.11b: Volunteer responses from the NeSST Study and NeSST2 Study when 
asked “How did you find receiving the nasal Synacthen?” 
 
Table 5.11c: Responses to question 3: Did you experience any unpleasant side effects 
from the nasal Synacthen? 



























Subjects were asked to “tick all that apply” and a number ticked several 
responses, whilst three experienced no unpleasant side effects. 
 
The comparison with the NeSST Study responses (figure 5.11c) show more 
volunteers complaining of sneezing, nasal irritation and stinging compared to the 
majority who had complained of no unpleasant side effects in the NeSST Study. 
 
Figure 5.11c: Volunteer responses from the NeSST Study and NeSST2 Study when asked 
“Did you experience any unpleasant side effects from the nasal Synacthen?” 
 
 
Table 5.11d: Responses to question 4: Overall how did you find the nasal Synacthen 
compared with the intravenous Synacthen? 
Much better Better 
Much the 
same 
Worse Much worse TOTAL 


















Free text comments: A number (N=5) of respondents felt that whilst neither 
method was unpleasant nasal administration is preferable to avoid cannulation 
“…if people struggle with cannulas/needles nasal would be a much more 
preferable option”. Others felt there was no preferable option.  
The two study comparison (figure 5.11d) revealed more of a spread of responses 
for NeSST2 volunteers with more feeling nasal Synacthen was preferable to i.v 
but more also thinking it was inferior. 
  
Figure 5.11d: Volunteer responses from the NeSST Study and NeSST2 Study when 




No adverse events attributable to the administration of 
Synacthen/tetracosactide were recorded for the NeSST2 Study. On two occasions 




















dexamethasone self-administration. Both subjects were excluded from further 
study.  
 
4.7 Summary of results  
 
Although variable, both the 500 mcg tetracosactide and the 100 mcg 
tetracosactide with chitosan formulations showed a good and comparable 
cortisol response to the 1 mcg i.v dose in some individuals. A dose escalation to 
500 mcg tetracosactide and chitosan, giving much higher plasma Synacthen 
Cmax and AUC, was required to achieve a cortisol response of over 500 nmol/L in 
all volunteers. This was not achieved with the 1 mcg i.v dose. The bioavailabilities 
calculated for the 100 mcg tetracosactide with chitosan, 500 mcg tetracosactide 
and 500 mcg tetracosactide and chitosan respectively were 0.72%, 1.25% and 
1.9%, considerably higher than seen with the doses given in the NeSST Study. As 
expected the Tmax was longer with the nasal formulations and more variable 
than with the i.v dose. The nasal formulations were less well tolerated with more 






There was disappointingly a smaller data set for the 500 mcg tetracosactide with 
chitosan dose compared to the other three formulations due lost samples, 




nursing errors, volunteers excluded for presumed non-adherence to the pre-test 
dexamethasone and those unable to continue due to dyspeptic symptoms. 
 
5.1 Synacthen assay and proof of dexamethasone suppression 
As observed in the NeSST Study the baseline results (-14 and -1 minute samples) 
were universally high, although HPA-axis suppression was shown by the low 
baseline cortisol results in the majority of volunteers. For a more extensive 
discussion see chapter 4, section 5.1.  In contrast to the NeSST Study, the intra-
individual consistency of the high plasma Synacthen baseline results is not so 
striking. The trend of rise from and fall back to baseline observed in both studies 
following Synacthen administration, seen most clearly after i.v administration, 
gives credence to the theory of an unrelated and stable interfering molecule, 
unaffected by either dexamethasone or Synacthen, and remains the most 
plausible explanation.  
 
In the 2 years between analysis of the NeSST and NeSST2 Study samples the 
hACTH RIA was validated for quantifying Synacthen, albeit with significant flaws 
(vide supra chapter 3). The Synacthen standards used in NeSST2 sample analysis, 
made from the RIA kit zero standard, and used to derive the standard curve from 
which the volunteer samples were calculated, improved the scientific integrity of 
the Synacthen sample analysis. However the different assay standards employed 
need to be taken into consideration when making direct comparisons between 
NeSST and NeSST2 Study data. 





The reliability of the assay to give similar results when measuring the same 
sample on different occasions, inter-assay precision, has not been demonstrated. 
It was only in retrospect that the author recognised the missed opportunity to 
test inter-assay precision. All plasma Synacthen samples were split following 
separation and frozen and therefore a selection of the remaining frozen samples 
could have been rerun on the assay during the analysis of diluted high samples 
and the results compared to the first analysis. The Synacthen standards, which 
were from one batch, have acted as a surrogate for inter-assay precision and 
were very similar to one another (figure 3.16). 
Overall the results following the administration of 1 mcg i.v Synacthen, the only 
dose to be performed in both NeSST studies, were similar, a surrogate marker of 
Synacthen test and assay reliability. However in both studies considerable 
individual plasma Synacthen variability was seen possibly reflecting inherent 
biological variability. Mean plasma Synacthen was seen to rise towards the end 
of the testing time in the NeSST2 Study only and the error bars were much 
larger, this was due to two individuals with aberrant high results at the end of 
testing, possibly due to human error and a mix up of samples (figure 5.2a). The 
acknowledged flaws in the assay: variability in Synacthen responses to the same 
dose of tetracosactide, even the i.v formulation, and unresolved issue of the high 
baseline values, have resulted in plasma Synacthen results that must be viewed 
with some caution. Trends and general comparisons are valid however over 
interpretation and direct comparisons, are not.  
 




5.2 Comparison of intravenous and nasal administration routes 
Despite the individual variability observed in both plasma Synacthen (all 
formulations) and serum cortisol results, particularly seen with nasal 
formulations, it is clear that both dose escalation and the addition of the nasal 
drug enhancer, chitosan, increased plasma Synacthen levels, and therefore the 
resultant cortisol response, following nasal administration. 
 
Statistical analysis comparing the difference in mean serum cortisol of the 
formulations at each time point revealed that cortisol rises earlier and therefore 
was significantly different, when Synacthen was given i.v. However the 
differences were not significant when comparing i.v with the 500 mcg 
tetracosactide plus chitosan dose, presumably because the additive effect of the 
high dose and the nasal drug enhancer caused an early high rise in plasma 
Synacthen levels, not dissimilar to that seen with i.v Synacthen. Both 
formulations of the 500 mcg tetracosactide elicited a good cortisol response but 
exhibited a slower clearance time and prolonged raised serum cortisol. This may 
be due to slower with nasal formulations and more prolonged absorption (due to 
reduced mucociliary clearance) when chitosan is added. This may lead to 
prolonged adrenocortical stimulation or reflect supraphysiological stimulation 
with upregulation of glucocorticoid synthesis (Alia, Villabona et al. 2006).  
 
There was no significant difference in the peak cortisol when comparing the 1 
mcg i.v test to both the 100 mcg tetracosactide with chitosan and the 500 mcg 
tetracosactide doses, indicating clinical parity between the formulations. 




However when individual’s data are studied both tests, in particular the 100 mcg 
tetracosactide with chitosan, included non-responders and thus the reliability of 
the formulation was questioned. The 500 mcg tetracosactide with chitosan 
produced a significantly higher cortisol peak than all three of the other 
formulations, with all subjects reaching above 500 nmol/L peak cortisol, despite 
their suppressed baseline, and thus “passing” their LDSST.  
 
5.2.1 Pharmacokinetic data: the effects of dose escalation and the 
addition of chitosan 
 
The bioavailability of the 100 mcg (NeSST Study data) and 500 mcg doses were 
improved by the addition of chitosan but the effect was less pronounced for the 
500 mcg dose. The bioavailability of the 100 mcg intranasal dose increased by 
3.65-fold following formulation with chitosan, however it must be noted that, as 
this required combining NeSST and NeSST2 data, neither the populations nor the 
assay methodology are the same. The five-fold dose increase between the two 
studies improved the bioavailability considerably and, perhaps surprisingly, the 
addition of chitosan to the 500 mcg dose only increased the bioavailability by 
1.5-fold. The dose escalation had a greater effect on absorption of nasal 
Synacthen shown by the better bioavailability of the 500 mcg dose without 
chitosan compared to the 100 mcg dose plus chitosan.   
 
The bioavailability of both doses of nasal Synacthen in the NeSST Study was 
approximately 0.2%. The expectation therefore was that the bioavailability seen 




with the 500 mcg tetracosactide dose in the NeSST2 study would be similar, 
however it was 1.3%, 6.5-fold higher and was 3.4-fold lower than in the murine 
study (Wuthrich, Martenet et al. 1994). If the result is a true reflection of the 
relative bioavailabilities it may be that the high concentration alone results in 
improved absorption lessening the effect of the enhancer i.e. a dose effect 
causing a larger concentration gradient and consequent saturation of an efflux 
mechanism. Whether Synacthen is a substrate for the known drug efflux 
transorter (P-gp) present in the nasal mucosa is unknown (Kandimalla and 
Donovan 2005). Additional contributing factors may be the difference in the 
assay methodology, the inherent assay variability or the difference in the 
populations being compared. Alternatively the tetracosactide may be subject to 
pre-absorption losses e.g. peptidase activity in the nasal cavity, which would 
have a relatively greater effect on the lower dose and thus explain the higher 
bioavailability seen with the 500 mcg tetracosactide dose.  
 
It was hoped that the addition of chitosan to tetracosactide would not only 
enhance absorption but would improve variability. When comparing the CVs for 
the different nasal formulations chitosan reduced the variability of mean peak 
serum cortisol in both the 100 and 500 mcg doses. When considering clinical 
practice and the applicability of a non-invasive SST it is peak serum cortisol 
variability that can yield borderline cases and false positives and negatives. The 
addition of chitosan and the reduction of variability are important, however 
neither formulation had a CV as low as seen with i.v administration.  
 




The reduction in mean residence time observed with the addition of chitosan is 
likely to be the result of more rapid absorption, as would be expected with an 
enhancer which aids paracellular transport across the nasal mucosa. There is no 
clear relationship between terminal half-life and dose escalation. When the dose 
is increased from 100 mcg to 500 mcg the half-life reduces, possibly a reflection 
of saturation of the elimination pathway, yet the results for equivalent doses 
with the addition of chitosan confound this theory. One would expect a longer 
half-life with chitosan, as more is absorbed and faster, resulting in higher plasma 
concentrations to be eliminated. The prolongation of the cortisol response at 
higher doses may be explained by the greater Synacthen concentrations 
achieved with the higher doses remaining above the minimum concentration 
that evokes a cortisol response.  
 
5.3 Relationship between serum cortisol, salivary cortisol and 
salivary cortisone 
An exponential or biphasic relationship was observed between serum and 
salivary cortisol when paired samples were compared, as previously reported 
(Vining, McGinley et al. 1983; Gozansky, Lynn et al. 2005; Perogamvros, Owen et 
al. 2010). The non-linearity is due to the presence of Cortisol Binding Globulin 
(CBG), binding serum free cortisol at low concentrations but becoming saturated 
at higher concentrations allowing free cortisol to become available for 
absorption into the saliva. When paired samples of salivary cortisol and salivary 
cortisone were plotted a linear relationship was seen, as in the NeSST Study, but 




with a considerably tighter correlation. This is also true for the relationship seen 
when serum cortisol and salivary cortisone were correlated. The serum cortisol 
and salivary cortisol/cortisone analyses were carried out in NHS clinical chemistry 
laboratories, on assays which remained the same between the two studies, and 
thus the tighter relationships observed in the NeSST2 paired samples are likely to 
be due to a greater spread of values, with many more samples of higher values, 
and fewer outliers.  
 
Although individual variance in CBG is unlikely to have affected the results in this 
healthy, adult, male population it has been reported previously (Dhillo, Kong et 
al. 2002). It is possible that the tighter correlation observed in NeSST2 is due to 
the higher values, where CBG is less of a concern in contrast to low cortisol levels 
where it is not always straightforward to delineate what is free and what is 
bound (personal communication, ML).  
Cortisone is emerging as the preferred salivary marker of adrenocortical function 
and the data from the NeSST and NeSST2 studies support this. Cortisone is more 
sensitive at the lower end of both the physiological and the assay range, due to 
the effect of 11β-HSD-2 causing it to have a 3-4 fold higher concentration than 
cortisol. This sensitivity makes it better suited to the detection of adrenal 
insufficiency (Arafah, Nishiyama et al. 2007, Perogamvros, Owen et al. 2010, 
Blair, Lancaster et al. 2013) and it has a close and linear relationship with serum 
cortisol removing interference from CBG variance (Perogamvros, Owen et al. 
2009). If the slope of the correlation curve, when plotting paired serum cortisol 
and salivary cortisone data from the NeSST2 Study, is used a correction factor of 




0.115 would need to be employed e.g. 57.5 nmol/L salivary cortisone equates to 
500 nmol/L serum cortisol. 
 
5.3.1 Sampling times 
 
The mean, mode and median time for the salivary cortisol and cortisone peak to 
occur following administration with 500 mcg tetracosactide with chitosan was 75 
minutes. Serum cortisol was more variable with the mean peak occurring at 60, 
the median at 75 and the mode at 90 minutes. Sampling times of 60, 75 and 90 
minutes for serum or salivary cortisol would have caught 8/9 of the peaks in this 
cohort of healthy male adults. Additional sampling at 120 minutes would have 
increased the capture for salivary cortisone peaks from 7/9 to 9/9. 
 
5.4 Side effects 
Although the distribution of responses was different, there was no discernable 
difference in volunteers’ comparison of nasal and intravenous administration. 
The vinegary smell and taste was noted in the feedback from both studies and 
was due to the acetic acid present in all formulations. Volunteers in the NeSST2 
Study were more likely to find nasal Synacthen administration “slightly 
unpleasant”, complain of nasal irritation, sneezing and stinging, compared with 
the NeSST participants. This may have been due to the increased concentration 
of tetracosactide or have been side effects attributable to the chitosan. The 
questionnaire was given out after the completion of three visits, as it was not 
known whether interim analysis would support the testing of a further dose. 




Unfortunately the questions did not differentiate between visits and therefore it 
is not clear whether the nasal symptoms are related to the chitosan, the 
increased concentration or another, unknown factor. In one questionnaire the 
volunteer detailed the test in which they had experienced the nasal symptoms 
(100mcg with chitosan). Chitosan has been found in extensive studies to be non-
toxic and is very well tolerated (Davis and Illum 2003). 
 
5.5 Limitations and further work 
The number of research participants in the final analysis, especially in the 
500 mcg tetracosactide with chitosan group, was disappointing and below 
the 12 anticipated. Had the non-adherence to the dexamethasone been 
anticipated it may have been possible to organise for a baseline cortisol to be 
taken for immediate analysis and the visit abandoned if it been high. The 
laboratory where the serum cortisol samples were analysed (SCH) was only 
set up to batch analyse research samples a maximum of once per day. 
Additionally the timing this extra step would have required was not feasible. 
 
In order to determine the differential effect of chitosan the desired 
methodology is to give the different formulations to the same individuals, who 
act as their own internal control. When comparing the 100 mcg doses both 
NeSST and NeSST2 data were used, and the studies involved different individuals. 
When comparing the two 500 mcg doses numbers were limited due the 




exclusions made. The fact that the comparative analysis has been performed on 
different individuals or on small numbers limit the conclusions that can be drawn. 
 
Despite our healthy male cohort of study volunteers, variations in CBG levels may 
have been present. It has previously been shown, in a mixed cohort of healthy 
adults, that CBG levels vary significantly between and within individuals and 
enough to affect the results of a SST (Dhillo, Kong et al. 2002). A more in depth 
study of the relationship between serum and salivary cortisol may have been 
possible with correction for the CBG variable. However it is not usually necessary 
to correct for CBG, particularly in a healthy, male population and congenital CBG 
deficiency is very rare.  
 
The manufacture of a novel drug also offers the opportunity for a formulation 
with a more pleasant flavouring and odour to negate the vinegary taste and 
smell produced from the acetic acid which recipients would fine more palatable. 
 
5.6  Conclusion 
The results of the NeSST2 Study show that increasing the dose and adding the 
nasal drug enhancer, chitosan, both improve nasal Synacthen absorption and 
therefore the height of the cortisol response, making it similar to that seen with 
1 mcg i.v, albeit individually variable. The cumulative effect of the five-fold dose 
escalation and the addition of chitosan resulted in plasma Synacthen levels and 
cortisol responses higher than seen with 1 mcg i.v, all volunteers “passing” the 
LDSST. The chitosan additionally reduced the variability of peak serum cortisol. A 




bioavailability of 1.9% was achieved with 500 mcg tetracosactide with chitosan, 
almost ten-fold that seen with 100 mcg nasal Synacthen in the NeSST Study, but 
below the 5-10% predicted by Archimedes Drug Development Ltd and 
equivalence was not achieved. Despite the lower than expected bioavailability 
and difficulty interpreting the PK data due to low numbers and “noise” created 
by the assay, the cortisol responses (in particular the 500 mcg tetracosactide 
with chitosan formulation) were good and, as cortisol is the primary endpoint in 
clinical practice, reflect success in the first step in the development of a non-
invasive SST.  
  



















The first five chapters of this thesis present the background to the development 
of a non-invasive Short Synacthen Test, some small studies looking at local and 
national practice, the validation of a Synacthen assay and the two clinical studies 
undertaken. The material presented is discussed in detail within each chapter. 
This final chapter serves as a summary of the work achieved so far and a 
discussion of further work required in the development of a non-invasive SST and 
its utility in research to help delineate the children prescribed ICS who are most 
at risk of adrenal suppression. 
 
1 What has been learnt from the NeSST and NeSST2 
Studies? 
 
1.1 Validation of a Synacthen assay 
In order to generate comparative pharmacokinetic data it was necessary to 
measure plasma Synacthen levels following the administration of the different 
formulations and doses of Synacthen. There were considerable and 
unanticipated difficulties in the validation of the method and there continue to 
be concerns regarding flaws in the assay.  
 
Serial dilution experiments failed to produce consistent and interpretable results 
until Synacthen standards were made up using a single vial of Synacthen and the 
zero standard from the hACTH RIA kit. Although this enabled validation of the 
assay it still contravenes the basic premise of competitive RIA, whereby the 




antibody and sample compete for binding as identical molecules. Despite this, 
the Synacthen standards have yielded reliable and repeatable results with an 
interpretable curve from which to derive Synacthen values for the study. Plasma 
Synacthen levels showed considerable variability between individuals, which may 
in part be the assay, but is likely to reflect biological variance.   
 
The other concern, which remains unresolved, is the lack of a suppressed 
baseline plasma Synacthen for all research subjects, despite other evidence of 
adequate dexamethasone suppression. The most likely explanation is assay 
interference by an unrelated yet structurally similar molecule, however the intra-
individual consistency was not seen as clearly in the NeSST2 Study as in the 
NeSST Study. It was felt, after discussion with laboratory colleagues, that if 
baseline values were subtracted from all subsequent time points, then the rise 
seen after Synacthen administration was likely to be due to the administered 
Synacthen rather than changed levels of interference and this was the 
methodology adopted throughout the studies.  
 
Quantifying plasma Synacthen levels is a research tool and does not have a role 
in clinical medicine. Cortisol is the clinical endpoint of interest in adrenal 
insufficiency and, as the measurement of plasma Synacthen is time-consuming, 
expensive and remains unreliable, future studies are likely to focus on cortisol 
measurement only. Future studies with glucocorticoids as the sole endpoint 
would enable volunteers not to undergo dexamethasone suppression. This is 
likely to reduce the number of volunteers excluded for both side effects and non-




adherence to medication. Additionally it would remove the blunting effect on the 
glucocorticoid response.  
 
1.2 Bioavailability and pharmacokinetics of nasal Synacthen 
Synacthen is a relatively large, polar molecule and not is ideally suited to nasal 
administration. Although poorly absorbed, some bioactive Synacthen was 
achieved with both the 25 mcg and 100 mcg doses in the NeSST Study, as 
evidenced by the resultant cortisol response. The responses of both plasma 
Synacthen and serum cortisol were dose dependent, with significantly higher 
serum cortisol levels attained with i.v compared to nasal and with the 100 mcg 
nasal compared to 25 mcg doses. The bioavailability of both doses of nasal 
Synacthen in the NeSST Study were very low, approximately 0.2%. The results 
were disappointing but showed a proof of concept – nasal Synacthen could be 
absorbed and was well tolerated. 
 
Both dose escalation and the addition of a nasal drug enhancer were trialed in 
the NeSST2 Study and both enhanced the bioavailability and cortisol response. 
The bioavailabilities calculated for the 100 mcg tetracosactide with chitosan, 500 
mcg tetracosactide and 500 mcg tetracosactide and chitosan respectively were 
0.72%, 1.25% and 1.9%. Although variable, both the 500 mcg tetracosactide and 
the 100 mcg tetracosactide with chitosan formulations showed a good and 
comparable cortisol response to the 1 mcg i.v dose in most research subjects. 
The combination of 500 mcg tetracosactide with chitosan, gave a much higher 




plasma Synacthen Cmax and AUC, and was the only formulation, including i.v, 
with which all volunteers achieved a cortisol response of over 500 nmol/L. Dose 
escalation improved the absorption of nasal Synacthen more than the addition of 
chitosan, and together there was a cumulative effect. The addition of chitosan 
improved the variability of the cortisol response. 
 
1.3 Salivary cortisol and cortisone 
The relationship observed between salivary and serum cortisol, in both studies, 
was exponential. This is expected and is due to the Cortisol Binding Globulin 
(CBG) effect. Salivary cortisone is less affected by CBG, reflecting serum free 
cortisol and therefore a tight and linear correlation was seen between salivary 
cortisone and serum cortisol. The correlations achieved in the NeSST Study were 
weaker than expected and improved in the NeSST2 Study, with no change in 
methodology and was attributed to having more data points in the upper ranges. 
Salivary cortisone was the more sensitive marker of adrenocortical response at 




2 Further work – NeSST3 and beyond 
 
A validated non-invasive SST would enable large-scale research in healthy 
children of different ages, both sexes and different pubertal stages to establish 
normative data, currently unviable due to the invasive nature of the test. These 




data could be used to compare the adrenocortical responses of children with 
asthma on different doses of ICS to ultimately enable stratification of patients 
into risk groups with their adrenal monitoring tailored to their risk; negating 
unnecessary investigation of low-risk patients and allowing close monitoring for 
high-risk individuals.  
 
The following future research stream is proposed: 
 
 NeSST3 Study: Perform three non-invasive LDSSTs (500 mcg 
tetracosactide plus chitosan) in the same individuals (N=6) to establish 
the intra-individual variability. 
 NeSST4 Study: Perform non-invasive LDSST, with 1 mcg i.v comparator, in 
20 children of both sexes and varying ages in order to establish that the 
chosen dose, peak cortisol response, bioavailability and pharmacokinetics 
are similar in the paediatric population compared with adult males. The 
PK data would require measurement of Synacthen, which needs further 
consideration before being undertaken. 
 NeSST5 Study: In order to interpret the findings of the SST in children with 
possible adrenal insufficiency one must know the response in normal, 
healthy children. Approximately ten male and ten female subjects in each 
of the following age bands: 6 months-2 years, 3-5 years, 6-8 years, 9-11 
and 12-15 years will undergo a non-invasive SST to establish the first 
normative data for the LDSST in the paediatric population. The effects of 
age, sex and pubertal status should be studied as previously pubertal 




stage and age have been shown to impact on salivary cortisol 
concentration (Tornhage 2002) and cortisol response to Synacthen 
(Lashansky, Saenger et al. 1991, Blair, Lancaster et al. 2013).  
 NeSST6 Study: Having established normative data, studies in children on 
ICS can be undertaken to investigate what dose may potentially cause 
adrenal suppression and the role of age, sex and pubertal stage. A recent 
study has shown sex but not age to impact on likelihood of an abnormal 
response to LDSST in children on ICS and age and sex to impact on peak 
cortisol levels (Blair, Lancaster et al. 2013). Children of both sexes, 
different ages (6 months – 15 years) and on varying doses of ICS will 
undergo a non-invasive SST, although the number required will be 
determined once normative data from NeSST5 Study have been analysed 
as means and standard deviations are required for power calculations. 
 
Additional research within the above stated streams: 
 The 500 mcg tetracosactide plus chitosan dose yields higher serum 
cortisol results compared to 1 mcg i.v and therefore may be higher than 
the dose required to maximally stimulate the adrenal gland. The exact 
dose of Synacthen required for maximal stimulation is a controversial 
area (chapter 1, section 4.4) and likely to shown some biological 
variability between individuals. Assessing patients with known adrenal 
insufficiency with the non-invasive test and calculating the sensitivity and 
specificity of the test would be important step in its validation. 
 




 The plasma Synacthen levels in both the NeSST and NeSST2 studies show 
considerable individual variability. Some of this biological variability may 
be due to genetic variance of HPA-axis receptors, e.g. CRH and 
glucocorticoid. Variation in CRHR1 (CRH receptor 1) has been shown to 
significantly contribute to the degree of improvement in lung function 
with ICS. (Tantisira, Lake et al. 2004). Future studies should consider the 
inclusion of genotyping as this may allow individual responses to 
Synacthen to be analysed and future prediction of dose responsiveness to 
be anticipated.  
 
 
3 Recommended non-invasive LDSST. 
 
This work supports further work validating a nasal alternative to the i.v LDSST. It 
demonstrates that Synacthen can be absorbed nasally in the amounts necessary 
to produce a reassuring cortisol response in healthy adult males. Further 
validation in non-dexamethasone suppressed adults, children and non-healthy 
populations is required. Although found to be palatable and safe in the adult 
volunteers investigated here, larger-scale safety studies would need to be 
conducted. From the results presented in this thesis further work to validate a 
non-invasive low-dose Short Synacthen Test, performed with nasally 
administered 500 mcg tetracosactide plus chitosan and salivary cortisone 
sampling at 60, 75 and 90 minutes would be recommended, with the diagnosis of 




adrenal insufficiency taken as a peak cortisone of less than 57.5 nmol/L (or lower 
using a correction factor of 0.115).  
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Taking the kernel of an idea and first transforming it into a scientifically valid 
research protocol; then negotiating the project through the necessary regulatory 
approvals; evolving it from paper to reality and having to right all the 
assumptions made was challenging. To then have that rewarded with 
disappointing results was a considerable set back and required reworking of the 
project, the timescales, additional funding and further regulatory approvals to be 
sought. However satisfying collaborative relationships were forged and a novel 
formulation developed which yielded much more satisfying results. The overall 
process was at times disheartening, frustrating and lonely, however there were 
moments of great joy and satisfaction. Without the support of many people the 
former emotions may have eclipsed the latter.  
 
None of this would have been possible without the idea, support and supervision 
of Dr Neil Wright. He has always made time for me, given me the freedom and 
autonomy to direct the project and provided an excellent meta-perspective 
when required. Dr Jerry Wales has been a wise and experienced second 
supervisor answering queries and returning drafts with unnerving speed. 
Professor Nick Bishop has provided thoughtful general academic supervision 
over the five years and has been unfailingly supportive. 
 
The project was in essence a pharmacokinetic study and thus Trevor Johnson, 
the PK expert and final collaborator on the NeSST Studies, has been a vital 
component. He has been endlessly patient with my enquires and been generous 
with his time and experience.  
 
The laboratory staff at the endocrine lab (Royal Hallamshire Hospital) helped me 
source and validate a method for measuring Synacthen. Had we known what a 
torrid journey it would be we might never have embarked on it. Martin Loxley 
gave up his time and expertise helping in analysing results and planning further 




validation experiments, whilst teaching me about RIA and analytical chemistry. 
Vikki Moyse and the other staff in the lab were endlessly helpful. Dr Kevin Page 
generously gave up time to consider the flaws and advice on the assay 
methodology and later read and comment on my assay validation chapter.  
 
Without funding the studies would never have taken place. We received two 
grants from The Children’s Hospital Charity for which we are very grateful. 
Without the volunteers for the NeSST and NeSST2 studies, who generously gave 
up their time and were accommodating and reliable, there would have been 
nothing to analyse and write about. 
 
This body of work required the help, advice, support and collaboration of many 
people. Both NeSST and NeSST2 studies required a lot of work in set up, 
individuals in R+D (in particular Chris Small and Wendy Swann), pharmacy (in 
particular John Bane, Christina Cooper and Jayne Clements), finance (Stephanie 
Bell), the Clinical Research Facility nursing staff (in particular Chris Cutler, Alison 
Barber and James Bull) and SCH clinical chemistry staff (in particular Matthew 
Jordinson, Jane Dalley, Emelia Bethell and Philip Craddock) were all key in this 
process. 
 
The input from collaborators has been essential. Brian Keevil and his team at 
University Hospital South Manchester advised on and then analysed our salivary 
samples. Peter Watts and Alan Smith from Archimedes Pharmaceuticals in 
Nottingham have been incredibly efficient and helpful in advising, tendering, 
assisting with information for the Investigator’s Brochure and then 
manufacturing our nasal drug formulations.  
 
In order to have adequate time to complete the studies, analyse samples, data 
and write this thesis I required an extension to my clinical lectureship, which was 
conceived of and then championed by Neil Wright and Nick Bishop and 
supported by Simon Clark. I am doubtful as to whether I would ever have 
completed the work without the additional time created by their faith in me.  





The small projects looking at local and national guidance detailed in chapter 2 
where conducted under my supervision by Drs Pooja Sachdev, Taffy Makaya, 
Emmy McCowen, Razia Petkar and Bindu Avatapalle. 
 
The introduction chapter of this thesis has been helped by Sarah Massey and the 
SCH library staff who have helped sourcing journal papers, Rebecca Scoble at 
Alliance Pharmaceuticals for the information on Synacthen and the artistic 
talents of Steve Jones (research assistant at Sheffield Children’s Hospital (SCH)) 
and Kelly-Marie Nelson (research healthcare assistant at SCH), who has helped 
enormously with the figures.  
 
Finally to my partner and daughters, who kept me going when I needed it, gave 
me vital distraction to stop it becoming all-consuming and have been 
unswervingly supportive.  
 
This project and thesis would not have been possible without all these people 
and numerous others who have contributed in their way, so a big and very 
heartfelt thank you to them all. 
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British Society of Paediatric Endocrinology and Diabetes SST survey 
         
 
April 2009 
Dear Paediatric Endocrinology Colleague, 
 
We are currently surveying all British paediatric endocrinology departments about 
their use of the Short Synacthen Test (SST). We are interested in looking at how 
many of us now use the low dose SST, how the low dose is prepared and whether 
there is much variation in what we consider a normal result. The questionnaire 
should only take you a few minutes.  
 
We have approached all BSPED members but only require one reply per 
department. 
We would be grateful if you would email it or post it back to the address given 
below. 
 
Thank you in advance for your help. 
 
 
Charlotte Elder, Pooja Sachdev and Neil Wright – Sheffield Children’s Hospital. 
 
e-mail:   C.J.Elder@sheffield.ac.uk 
 
Postal address: Dr C Elder,  
Clinical Research Fellow, 
 Academic Unit of Child Health,  
Stephenson Wing,  
Sheffield Children’s Hospital,  
Western Bank,  
Sheffield S10 2TH.









2. Does your centre carry out Short Synacthen Tests? Please circle as 
appropriate 
Yes     No 
If you have answered “no” please return the questionnaire at this point, you do not 
need to fill in any further answers. If “yes” please continue. Thank you. 
 
3.    What dose of Synacthen does your department use? Please circle answer. 
 
low dose (1mcg)  standard dose (250mcg)  another dose  
 
If you have answered “another dose” please state the dose 
…………………. 
 
4. If you use a dose less than 250mcg please describe how this is made up: 











5. At what times do you take your cortisol samples? Please circle all appropriate 
0 min    10 min             20 min  30 min  60 min   
other (please specify) 
………………………………………………………………… 
6. What cut off for normal do you use?
a. Peak cortisol (please circle as appropriate) 
 
>500nmol/l >550nmol/l >580nmol/l other (please 
specify)………………… 
 
b. Rise from baseline (please circle as appropriate) 
 
>200nmol/l  Other (please 
specify)…………………………………
 
c. For a normal result do you require (please circle tick appropriate box) 
i. Only peak cortisol     
ii.  Only rise from baseline    
iii.  Both peak and rise from baseline   
iv. Either peak or baseline but not both  
 5. Are you aware of the recommendations introduced in 2005 by the Committee 
on the Safety Medicines (CSM) that children on high dose inhaled corticosteroids 
(HDICS) should carry a steroid alert card and have Short Synacthen Tests 
performed? 
Yes    No 
 
6. Have you noted an increase in the number of SSTs requested in your hospital 
since these recommendations were introduced in 2005? 
   Yes    No 
 
7. Have you detected adrenal suppression in children on HDICS (but with no 
other obvious cause)? If “yes” please give the number of cases. 
Yes    No 
 
  






Survey of GP knowledge of adrenal suppress ion and inhaled 
corticosteroids 
 
Dear GP/asthma nurse, 
 
Adrenal suppression in children on inhaled corticosteroids (ICS) is an area of 
emerging interest in paediatrics. However which children are at particular risk is 
unknown and how much of a part steroid dose, age and gender play is yet to be 
discovered. A large study looking to answer these questions is underway at 
Sheffield Children’s Hospital and as part of this we are trying to gather related 
data. 
 
One of our areas of interest is the children on high dose ICS managed in primary 
care. To this end we are conducting a survey of Sheffield GPs examining their 
awareness of adrenal suppression, prescribing practices and referral patterns. We 
would be most grateful if you could fill in this very short anonymous 
questionnaire regarding your own clinical practice when managing these children. 
It should take no longer than a few minutes. Additionally we hope you are happy 
for your Practice Manager to supply information regarding the number of 
asthmatic children in your practice and the proportion prescribed high-dose 
inhaled corticosteroids. We will endeavor to send you a copy of the survey results 
when it is completed. 
 
Please return the questionnaire to us at your earliest convenience in the stamped 
addressed envelope provided.  
If you have any questions about this work or require further information please do 
not hesitate to contact me on the following email. (Dr Razia Petkar: 
raziapetkar@gmail.com) 
 








Dr Razia Petkar – Paediatric StR 4, Sheffield Children’s Hospital 
Dr Charlotte Elder – Clinical Research Fellow in Paediatrics, University of 
Sheffield 
Dr Neil Wright – Consultant Paediatric Endocrinologist, Sheffield Children’s 
Hospital 
High dose inhaled corticosteroids in asthmatic children managed in primary 
care: 
Thank you for taking the time to fill out this anonymous questionnaire. It should 
take no more than a few minutes to complete.  
 
1) Are you a (please tick most appropriate answer using boxes provided) 
  GP Partner          
  GP Other   
   Asthma Nurse   
   Nurse (other)   
 
2) Do you have a designated asthma lead at your practice? 
Yes    
No    
   Other (please specify) 
………………………………………………………….. 
 
3) Is there a policy in your practice for referring asthmatic children to secondary 
care? 
Yes    
No    





4) If referring to secondary care, would you tend to refer to a: 
General Paediatrician?   
Respiratory Paediatrician?  





5) If referring to secondary care, what is most likely to prompt the referral?  
(Please rank your answers from 1= most likely reason to refer, 2 = next most 
likely reason and rank all those that apply to your referral practice) 




Increasing dose of inhaled steroids  Rank No 
………. 
Poor compliance    Rank No 
………. 
Persistent poor control   Rank No 
………. 
Patient requiring multiple treatments  Rank No 
………. 
Concern re medication side effects  Rank No 
………. 
Young age of patient    Rank No 
………. 
Multiple admissions    Rank No 
………. 
Parental pressure to refer   Rank No 
………. 






6) Are you aware of the association between high dose inhaled corticosteroids and 
adrenal suppression?          
Yes    
No    
 
7) How often do you monitor height of children on high dose inhaled steroids? 
Annually   
Opportunistically  
Never    






8) What dosage guidance do you use, if any, when prescribing inhaled 
corticosteroids to children? 
  BNF for children     
  Committee on safety of medicines/DH   
  NHS National Prescribing Centre   
  British Thoracic Society/SIGN    
  None of these      
  Other (please specify) 
…………………………………………………………………. 




   
9) What is the maximum dose of Budesonide you would prescribe a patient of 6 
years of age? 
200 micrograms b.d    
400 micrograms b.d  
800 micrograms b.d  
Other (please specify)…………………………………. 
10) What is the maximum dose of Beclomethasone dipropionate you would 
prescribe a patient of <2 years of age?  
100 micrograms b.d  
200 micrograms b.d  
400 micrograms b.d  
Other (please specify) ………………………………….. 
11) What is the maximum dose of Fluticasone propionate you would prescribe a 
patient aged 5 years? 
100 micrograms b.d  
200 micrograms b.d  
   400 micrograms b.d  
   Other (please specify) ………………………………….. 
  





The Practice Manager 
 
 
A group of paediatricians at Sheffield Children’s Hospital are studying children 
who are prescribed steroid inhalers as part of their asthma treatment. There is 
increasing concern that some of these children may not be able to mount an 
adequate stress response due to the steroid medication in their inhalers (adrenal 
suppression). As part of a large program of work in this area the endocrinology 
department at SCH are conducting a survey of local GPs to find out more about 
their awareness of this subject, their prescribing practices and referral patterns.  
We would be most grateful if you could spare the time to inform us of the 
following things:  
i) The total number of children with a diagnosis of asthma at your 
surgery (0-15 years i.e. not anyone after their 16th birthday) 
ii) The numbers prescribed steroid inhalers stratified into the age group 
categories given in the table below. 
 
We have also enclosed an anonymous questionnaire: one for a GP (whom eve you 
feel is most appropriate) and one for your practice nurse/asthma nurse (whom ever 
has the greatest role in your asthma service). We would be most grateful if you 
could distribute them, with the stamped addressed envelopes provided, and ask 
that they are returned to us. These questionnaires will only take your staff a few 
minutes to complete.  
If you have any questions about this work please do not hesitate to contact us on 
the following email. 
(Dr Razia Petkar: raziapetkar@gmail.com) 
 





Dr Razia Petkar – Paediatric StR 4, Sheffield Children’s Hospital 
Dr Charlotte Elder – Clinical Research Fellow in Paediatrics, University of 
Sheffield 
Dr Neil Wright – Consultant Paediatric Endocrinologist, Sheffield Children’s 
Hosp 
 












< 5 years of age 
      
     5-11 years of age 
      
      12-16 years of age 
 
 
Total number of children with asthma 
registered at this GP practice 
 
   
 
Beclomethasone dipropionate  
Children on 400mcg twice daily (800mcg 
total daily dose) 
   






MANY THANKS FOR YOUR TIME AND EFFORT 







Fluticasone propionate  
Children on 200mcg twice daily (400mcg 
total daily dose) 
   
 
Budesonide  
Children on 400mcg twice daily (800mcg 
total daily dose) 
   
 
Mometasone furoate 
Children on >800mcg daily 
   





Emergency Standard Operating Procedure 
 
NeSST STUDY 
EMERGENCY Standard Operating 
Procedure for: 
  
SEVERE ALLERGIC REACTION 
 ANAPHYLAXIS 
 AND CARDIAC ARREST 
  
IN ADULTS AND CHILDREN 
 
Guidelines as per Resuscitation Council (UK) 
2008 





- Read and familiarise yourself with this guidance 
- Always be prepared 
- Do not administer Synacthen until you: 
 Have completed the accompanying resuscitation form 
 Know they do not have a history of severe 
allergic reaction/anaphylaxis/previous allergy to Synacthen 
 Know how to access and use the resuscitation equipment 
- If your subject becomes unwell follow this guidance 
- If in doubt CALL FOR HELP: 
If CHILD: 
 Hospital Resuscitation Team call: Dial 2222 – stating 
“Paediatric resuscitation team to Clinical Research Facility, 
via surgical ward 3” 
If ADULT: 
 Hospital Resuscitation Team call: Dial 2222 – stating “Adult 
cardiac arrest, paediatric resuscitation team to Clinical 
Research Facility, via surgical 3”. 
  If you then ring back on “0” switchboard will additionally 
connect you to 999. 
This guideline should be left in the room with the subject at all 
times  




Volunteer end of study questionnaires (NeSST and NeSST2 studies)  
 
END OF NeSST STUDY QUESTIONNAIRE 
 
Thanks again for taking part in the NeSST Study, we really appreciate 
it. As a last request we’d be grateful if you could spend a few minutes 
filling in this anonymous questionnaire about how you have found the 
study.  
 
1. How did you find having the nasal spray administered? (please 
tick most appropriate answer) 
Very easy    
Easy     
OK     
A little tricky   
Difficult    









2. How did you find receiving the nasal Synacthen? (please tick 
most appropriate answer) 
No problem    
Slightly unpleasant  




Unpleasant    







3. Did you experience any unpleasant side effects from the nasal 
Synacthen? 
(Please tick ALL that apply) 
  Stinging     Soreness  
  
  Irritation     Itching  
  
Sneezing     Nasty taste in mouth
  
 





4. Overall how did you find the nasal Synacthen compared with 
the intravenous Synacthen (please tick the box of the most 
appropriate answer): 
Much better    
Better     




Much the same   
Worse    
Much worse    






5. Do you have any general comments or suggestions about the 
conduct of the NeSST Study (e.g. recruitment, information 








Many thanks again – NeSST Study Team 
  




END OF NeSST2 STUDY QUESTIONNAIRE 
 
Thanks again for taking part in the NeSST2 Study, we really 
appreciate it. As a last request we’d be grateful if you could spend a 
few minutes filling in this anonymous questionnaire about how you 
have found the study.  
 
 
1. How did you find having the nasal spray administered? (please tick most 
appropriate answer) 
Very easy    
Easy     
OK     
A little tricky    
Difficult    










2. How did you find receiving the nasal Synacthen? (please tick most 
appropriate answer) 
No problem    
Slightly unpleasant   
Unpleasant    













3. Did you experience any unpleasant side effects from the nasal Synacthen? 
(Please tick ALL that apply) 
  Stinging     Soreness  
  
  Irritation     Itching   
  
Sneezing     Nasty taste in mouth 
  
 





4. Overall how did you find the nasal Synacthen compared with the 
intravenous Synacthen (please tick the box of the most appropriate 
answer): 
Much better    
Better     
Much the same   
Worse     
Much worse    
Please explain why: 









5. Do you have any general comments or suggestions about the conduct of 





If you are willing for your comments to be published 
anonymously please sign and date below: 
Print name:      Date: 
Signature: 
Many thanks again – NeSST2 Study Team 
 
 
